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1 Introduction
1.1 Cancer
The  term  cancer  refers  to  a  group  of  diseases  which  is  characterised  by  the 
uncontrolled proliferation and spread of dysregulated cells. A wide variety of risk 
factors  can  result  in  the  occurrence  of  cancer.  These  can  be  grouped  in  external 
factors like tobacco, chemicals, radiation, and infectious agents, and internal factors 
like  mutations,  hormones,  and  immune  conditions.  These  causal  factors  may act 
together or in sequence to initiate or promote carcinogenesis.
Cancer is treated with surgery, radiation, chemotherapy, hormone therapy, stem cell 
transplantation, biological therapy, and/or targeted therapy, depending on the type, 
physical form, and location of malignant cells.
In 2008, the 5-year relative survival rate for all cancers diagnosed between 1996 and 
2003 was 66% (American Cancer Society, 2008).
With more than 1,430,000 new cancer cases and more than 1,500 cancer deaths per 
day which had been expected to occur in 2008 in the US, cancer is the second most 
common cause of death in the US, exceeded only by heart diseases. The National 
Institutes of Health estimated overall costs for cancer in 2007 at $219.2 billion, taking 
into  consideration  direct  medical  costs  as  well  as  indirect  costs  due  to  loss  of 
productivity (American Cancer Society, 2008).
1.2 Acute myeloid leukaemia
Acute myeloid leukaemia (AML) is the most common form of acute leukaemia in 
adults and is estimated to have affected 13,290 people and account for 8,820 deaths in 
2008 in  the  United  States  (American  Cancer  Society,  2008).  It  is  a  heterogeneous 
group of malignancies having in common the overproliferation of haematopoietic 
stem cells and their failure to differentiate, leading to uncontrolled accumulation of 
myeloblasts in bone marrow and blood (Stone et al., 2004).
In  order  to  distinguish  its  different  forms,  AML  was  first  classified  based  on 
morphological  findings  in  1976  and  in  a  revised  form  in  1985  by  the  French-
American-British (FAB) Cooperative Group (Bennett et al., 1976 & 1985).  However, 
with  scientific  progress,  especially  chromosomal  and  genetic  abnormalities  were 
revealed and recognised as important in selecting treatment strategies (Grimwade et  
al., 1998). Therefore the World Health Organization (WHO) revised and expanded 
the  FAB  classification,  taking  into  consideration  morphological,  immunological, 
cytogenetic, genetic, and clinical features (Vardiman et al., 2002).
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The US National Cancer Institute lists the classification as follows (National Cancer 
Institute, 2007):
• AML with characteristic genetic abnormalities.
• AML with t(8; 21)(q22;q22); (AML/ETO).
• AML with inv(16)(p13q22) or t(16;16)(p13; q22); (CBFβ/MYH11).
• Acute  promyelocytic  leukemia  (AML  with  t(15;17)(q22;  q12); 
(PML/RARα) and variants) (FAB classification M3).
• AML with 11q23 (MLL) abnormalities.
• AML with an FLT3 mutation (not in the WHO classification scheme). 
• AML with multilineage dysplasia. 
• AML and MDS, therapy related. 
• Alkylating agent-related AML and MDS.
• Topoisomerase II inhibitor-related AML.
• AML not otherwise categorized. 
• Acute  myeloblastic  leukemia,  minimally  differentiated  (FAB 
Classification M0).
• Acute  myeloblastic  leukemia  without  maturation  (FAB Classification 
M1).
• Acute myeloblastic leukemia with maturation (FAB Classification M2).
• Acute myelomonocytic leukemia (AMML) (FAB Classification M4).
• Acute  monoblastic  leukemia  and  acute  monocytic  leukemia  (FAB 
classifications M5a and M5b).
• Acute erythroid leukemias (FAB classifications M6a and M6b).
• Acute megakaryoblastic leukemia (FAB Classification M7).
• AML/transient myeloproliferative disorder in Down syndrome.
• Acute basophilic leukemia.
• Acute panmyelosis with myelofibrosis.
• Myeloid sarcoma.
• Acute leukemias of ambiguous lineage. 
In  general,  treatment  strategies  for  AML  comprise  two  phases.  First,  induction 
chemotherapy eradicates all haematopoietic precursor cells from the bone marrow, 
allowing  repopulation  of  the  blood  with  normal  cells.  After  remission,  a  second 
therapeutic phase is applied to remove residual cells that are likely to account for a 
relapse.  Current  approved  post-remission  therapeutic  strategies  include  intensive 
consolidation  chemotherapy,  high-dose  chemotherapy  with  or  without  radiation 
therapy, low-dose maintenance therapy, and autologous or allogenic haematopoietic 
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stem cell transplantation (Tallman et al., 2005; National Cancer Institute, 2007). For 
both induction and post-remission therapy, the risks and benefits of the therapeutic 
approach  have  to  be  evaluated  and  stratified  according  to  the  patient’s  age  and 
general  condition,  disease  progression  and  blast  percentage,  previous  history  of 
myelodysplastic  syndromes,  cytogenetic  aberrations  of  leukaemic  cells,  the 
expression of  proteins that confer multi-drug resistance or that  are pivotal  to the 
regulation of cell proliferation and survival, and last but not least patient preference 
(Tallman et al., 2005; National Cancer Institute, 2007).
In  contrast  to  the  majority  of  therapies  described  above,  which  are  directed  at 
haematopoietic cells in general and thus can cause severe side effects, the specific 
targeting and elimination of malignant cells only is to be preferred.
This can be achieved by targeting cell-surface specific receptors either by monoclonal 
antibodies, natural ligands, or cytokines, or by conjugations of these proteins with 
either chemotherapeutic drugs, radioactive particles, or toxins.
1.3 Immunotoxins
Following the notion of Paul Ehrlich, who developed the concept of a chemical that 
binds to and specifically kills microbes or tumour cells already in the beginning of 
the 20th century (reviewed in Gensini et al., 2007; Strebhardt & Ullrich, 2008), it took 
until the 1970s for the first antibody-toxin conjugates to be produced and tested (e.g. 
Moolten & Cooperband, 1970; Ghose et al., 1972; Thorpe et al., 1978). For this, murine 
antibodies or Fab fragments were coupled chemically to chemotherapeutic drugs or 
to  native protein-based toxins such as the bacterial  toxins  Pseudomonas  aeruginosa  
exotoxin  A (ETA) and diphtheria toxin (DT) or the plant toxin Ricin (Ghose  et al., 
1972; Vitetta et al., 1983; Pastan et al., 2006).
An  important  step  in  the  history  of  immunotoxins  was  the  development  of  the 
hybridoma technology by Georges Köhler and César Milstein for the production of 
monoclonal  antibodies  (mAbs)  (Kohler  &  Milstein,  1975).  Nevertheless, 
heterogeneous composition, poor stability, in case of solid tumours bad penetration 
abilities  due  to  the  big  size  of  the  fusion  protein  (Pastan,  2003),  and the  lack of 
specificity  due  to  the  native  toxin  binding  domains  turned  out  to  be  the  major 
drawbacks of the first generations of immunotoxins (Pastan et al., 2006). 
As soon as the structure and funtional domains of the toxins had been elucidated, the 
native cell binding domains were removed (e.g. Blythman et al., 1981), and only the 
catalytic  and translocation  domains  were  retained  and  coupled  to  the  respective 
binding unit. Despite that, unspecific binding to endothelial cells was often observed, 
leading to damage of these cells resulting in vascular leak syndrome (VLS), which is 
characterised by leakage of fluid from the circulation into the tissues, edema, a fall in 
serum proteins, hypotension, and, at worst, vascular collapse (Vitetta, 2000).
Introduction 11
The problem of  heterogenity  was not  completely  solved  until  recombinant  DNA 
technology could be used for the construction of immunotoxins. In addition, it was 
easily possible to reduce the size of the antibody to a single chain format, in which 
the variable domains of the heavy and light chain of an antibody are linked to each 
other e.g. by a (Gly4Ser)3 linker (Huston et al., 1988). Furthermore, as an alternative to 
antibodies or their derivatives,  natural ligands (e.g. Barth et  al.,  1999; Huhn et al., 
2001) and cytokines (e.g. Frankel et al., 2002) have been used. Another alternative as 
binding structure,  which again requires  chemical  coupling to  the toxin,  are  RNA 
aptamers (Chu et al., 2006).
Also the toxic domains were varied in the course of time. Especially various plant-
derived  toxins  were  recruited  for  use  in  immunotoxins  (Bolognesi et  al.,  1992). 
However, as toxic domains of plant as well as of bacterial origin always imply the 
risk  of  evoking  an  undesired  immune  response  against  the  administered 
immunotoxin, human toxins like the RNAse A family members angiogenin (Newton 
et  al.,  1996)  and pancreatic  RNAse 1  (Psarras et  al.,  1998),  or  the  serine  protease 
Granzyme B (1.5) moved into the focus of interest.
1.3.1 Immunotoxins against AML
In the past, primary AML cells and/or AML-derived or -related cell lines have been 
successfully  targeted  via  the  receptors  for  IL-3  (Feuring-Buske et  al.,  2002),  IL-4 
(Vallera et al., 2000), IL-6 (Rozemuller et al., 1996), GM-CSF (Perentesis et al., 1997), 
and  CD33  (van  der  Velden et  al.,  2001).  Among  these  immunoconjugates  is 
gemtuzumab ozogamicin (Mylotarg), an anti-CD33 antibody chemically coupled to 
the organic bacterial drug calicheamicin, which was approved by the FDA in 2000 
(Bross et al., 2001). Apart from denileukin diftitox (Ontak), which is a fusion protein 
between IL-2 and diphtheria toxin (DT) approved for the treatment cutaneous T-cell 
lymphoma in 1999, Mylotarg is the only immunotoxin which has been approved by 
the FDA up to now. However, severe haematological and hepatotoxic side effects 
caused  at  least  in  part  by  insufficient  targeting  have  limited  its  therapeutic 
application (van der Velden et al., 2001; Rajvanshi et al., 2002), and finally the FDA 
decided to withdraw Mylotarg from the market in 2010 (Tuma, 2010).
Side  effects  similar  to  those  of  Mylotarg  have  been  reported  for  DT388-GM-CSF 
(Westcott et al., 2004).
Another immunotoxin, HuM195/rGel, which is a humanised anti-CD33 single chain 
antibody recombinantly fused to the plant toxin gelonin (McGraw et  al.,  1994),  is 
currently under investigation in a clinical phase 1 trial (http://clinicaltrials.gov). As 
this drug targets the same antigen as Mylotarg, similar drawbacks can be expected.
Another target antigen, which was chosen to be the focus of this work, is CD64, the 
high affinity receptor for IgG (described in detail  in chapter  1.4).  This receptor is 
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known to be overexpressed on AML subtypes M4 and M5 but not restricted to these 
subtypes  (Ball et  al.,  1989).  For  several  reasons,  CD64  can  be  considered  to  be 
favourable as target antigen. First, a main function of CD64 is internalisation. In case 
of the immunoconjugates targeting CD33 (Bross et al., 2001), which is a cell adhesion 
molecule, or receptors such as interleukin-3 receptor (Feuring-Buske et al., 2002) and 
granulocyte-macrophage colony-stimulating factor receptor (Perentesis  et  al.,  1997; 
Frankel et al., 2002), which are signal transduction receptors, presumably only a small 
portion  of  the  administered  immunotoxin  becomes  internalised,  whereas  CD64 
internalises very efficiently (Guyre et al., 2001). Furthermore, the expression pattern 
of the receptor is limited, and normal, nonactivated CD64-expressing cells are not 
affected by immunoconjugates (Thepen et al., 2000; Zhong et al., 2001; van Roon et al., 
2003). Therefore, CD64 can be considered as beneficial for the targeted delivery of 
cytotoxic or immunomodulating drugs.
Furthermore, the humanised CD64-specific monoclonal antibody H22 (Graziano  et  
al.,  1995), which has also been converted to a single-chain format (de Kruif  et  al., 
2000), and its derivatives have been used in a variety of applications including as 
fusion  proteins  with  antibodies  (Curnow,  1997;  Sundarapandiyan  et  al.,  2001; 
Borchmann et al., 2002) and toxic components such as calicheamicin (van Roon et al., 
2005), ETA' (Tur et al., 2003) and Ricin A (Thepen et al., 2000; Zhong et al., 2001; van 
Roon et al., 2003; van Vuuren et al., 2006). Both Ricin A and ETA' fusions to H22 have 
been used as therapeutic agents against AML cells (Zhong et al., 2001; Tur et al., 2003).
1.3.2 Optimisation of immunotoxins
In order to maximise efficacy and safety of a given immunotoxin, different strategies 
have been pursued in the past. First, the fusion proteins were  reduced in size by 
utilisation of antibody fragments instead of full-size antibodies and also by replacing 
native bacterial  or plant toxins with only their  catalytical subunits  (1.3).  This size 
reduction  resulted  in improved  penetration  of  solid  tumours  (Pastan,  2003). 
Furthermore,  as  recombinant DNA technology replaced the chemical coupling of 
immunotoxin domains, homogenous and much more stable protein populations with 
retained cytotoxicity were obtained (drawbacks of chemically coupled immunotoxins 
summarised by Frankel, 1988). Concerning stability, the introduction of a  disulfide 
bond between heavy and light chain of a single chain antibody (scFv) proved to be 
advantageous (Brinkmann et al., 1993). Later on, also site-specific  PEGylation was 
shown to increase serum stability and plasma half-life. Furthermore, a reduction of 
systemic animal toxicity and immunogenicity was reported (Tsutsumi et al., 2000). 
However, PEGylation does not seem to be suitable for all immunotoxins, as complete 
inactivation after PEGylation was reported as well (Onda et al., 2008).
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Immunogenicity  is  a  general  problem  when  proteins  of  non-human  origin  are 
applied  to  humans.  Especially  in  the  treatment  of  solid  tumours,  neutralising 
antibodies  can  lead  to  rapid  clearance  of  the  immunotoxin  and  prevent 
readministration after the first treatment cycle (Hassan et al., 2007). In patients with 
haematopoietic  malignancies,  neutralising  antibody formation  is  present  but  low, 
probably  because  the  immune  system  of  these  patients  is  impaired  by  prior 
chemotherapy and/or by the nature of their disease (Pastan, 2003).  An interesting 
strategy  to  minimise  immune responses  towards  an  immunotoxin  is  the  rational 
deletion of B and T cell epitopes, as was reported by Onda et al. for B cell epitopes 
in  2008, and for T cell epitopes by Cantor  et al. during the approval phase of this 
thesis  in  2011.  Nevertheless,  immunogenicity  can  be  completely  circumvented  if 
human or humanised binding moieties and human toxins are used.
After having chosen a target antigen with a high density as exclusive as possible, a 
binding unit with high and specific affinity should be found. Especially in terms of 
internalisation  rate,  it  might  make  sense  to  crosslink  target  receptors  and  thus 
increase  internalisation (Swanson & Hoppe,  2004).  This  could  be  achieved by  an 
increase of the valency of the binding unit (Guillemard et al., 2005), which is feasible 
also with the scFv antibody format (Kelly et al., 2008).
However, having internalised into an endosome does not yet bring the toxin to its 
cytosolic  target,  i.e.  an  endosomal  release  by  membrane  transfer  is  necessarily 
required.  Whereas  DT  and  ETA  naturally  possess  a  translocation  domain 
accomplishing this, for human toxins such domains have not been found so far. An 
alternative to the strategy applied by Zhao et al., who fused the translocation domain 
of ETA to Granzyme B (Zhao  et al., 2004c), is to use a  membrane transfer peptide 
(MTP) in fusion to the protein of interest. Synonyms for these kind of peptides are 
Trojan peptides, protein transduction domains or cell-penetrating peptides (Derossi 
et al., 1998; Fuchs  et al., 2005; Stewart  et al., 2008). ScFv fusion proteins harbouring 
MTPs e.g. from the human immunodeficiency virus TAT protein (Frankel & Pabo, 
1988; Green & Loewenstein,  1988) or the  Drosophila  homoeoprotein (Derossi et al., 
1994)  proved  to  reach  their  targets  more  efficiently  than  the  unconjugated 
counterparts  (Nakajima et  al.,  2004;  Avignolo et  al.,  2008).  However,  a  potential 
problem with the use of MTPs might contingently be unspecific action if the MTP 
comes freely in contact with any cell membrane. Therefore, Keller et al. designed a so-
called molecular adapter separating binding and toxic unit of their immunotoxin, in 
which  a  MTP  is  flanked  by  an  endosomably  cleavable  peptide  (ECP)  and  a 
cytosolically cleavable peptide (CCP) (Keller et al., 2001). Only if the ECP is cleaved 
off in the endosomes after receptor-mediated internalisation, the MTP is exposed to 
exert its function. Upon entering cytosol, the CCP is cleaved to release the toxin from 
the  MTP.  Especially  for  toxins  such  as  Granzyme B  or  angiogenin  for  which  an 
unimpaired  N-terminus  is  crucial  (Harper  et  al.,  1988;  Edwards  et  al.,  1999),  this 
approach facilitates the display of the full cytotoxic potential.
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Using a MTP derived from the PreS2-domain of hepatitis-B virus surface antigen 
(Oess & Hildt, 2000), the adapter concept was verified by the same group in 2003 
(Heisler et al., 2003).
An additional  benefit  of  an adapter  sequence  is  that  it  obviates  potential  sterical 
hindrance of the toxin and the binding unit.
Finally,  the efficacy of  the toxin might be increased by amino acid modifications 
either  directly  enhancing  cytotoxicity  or  indirectly  enhancing cytotoxicity  by  the 
elimination of  potential  inhibitor sites  (as  shown for angiogenin by Harper et  al., 
1988; Leland et al., 1998).
1.4 CD64
The 72-kDa glycoprotein CD64 belongs to the family of Fc receptors, i.e. receptors 
that  recognise  the  constant  part  of  the  heavy  chain  of  an  antibody  (Fc  region). 
Members of  this  receptor  family are found on most  cells  of  the immune system. 
Specific Fc receptors have been described for all classes of immunoglobulins, i.e. for 
IgA (FcαR), IgD (FcδR), IgE (FcεR), IgG (FcγR), and IgM (FcμR) (Fridman, 1989).
The Fc receptors for IgG (FcγR) comprise three different types, differing in receptor 
structure, affinity for IgG, and cell distribution (Ravetch & Kinet, 1991; van de Winkel 
& Anderson, 1991):  CD64 (FcγRI), CD32 (FcγRII), and CD16 (FcγRIII).
CD64 (FcγRI) is the only IgG receptor that binds monomeric IgG with high affinity 
(Anderson et al., 1986). It is expressed on cells of the myeloid lineage, i.e. monocytes, 
macrophages and dendritic cells. These cells can be activated by several cytokines 
that upregulate CD64, including IFN-γ, which plays a crucial role in inflammatory 
responses and causes a 5- to 10-fold increase of CD64 expression as well as enhanced 
receptor  activity  (Fanger et  al.,  1989).  CD64  mediates  endocytosis/phagocytosis, 
antibody-dependent  cellular  cytotoxicity,  and  the  production  of  cytokines  and 
superoxide  (van  de  Winkel  &  Anderson,  1991).  It  also  influences  the  severity  of 
various  inflammatory  diseases  such  as  rheumatoid  arthritis  (Wijngaarden et  al., 
2003),  allergic asthma (Viksman et  al.,  2002)  and atopic dermatitis  (Kiekens et  al., 
2000).
Previous studies focusing on the targeting of dysregulated CD64+ cells in cutaneous 
inflammation  and  arthritis  have  shown  that  anti-CD64  immunotoxin  treatment 
successfully eliminated CD64+ activated macrophages, but left resting macrophages 
with low CD64 expression unaffected (Thepen et al., 2000; van Vuuren et al., 2006). 
The key element here is not the degree of CD64 expression, but rather the state of 
activation  of  these  cells  (cf.  chapter  4.8).  As  mentioned  before,  anti-CD64 
immunofusions with Ricin A as well as with Pseudomonas exotoxin A (ETA’) proved 
to be potent triggers of apoptosis in CD64+ AML cells (Zhong et al., 2001; Tur et al., 
2003).  However,  protein  domains  of  non-human  origin  can  provoke  undesirable 
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immune responses, which might prevent repeated administration in the clinic.  To 
circumvent this from the start, the human toxin Granzyme B was chosen as the toxic 
moiety of an anti-CD64 immunotoxin in this thesis.
1.5 Granzyme B
The  serine  protease  Granzyme  B  (32  kDa  with  glycosylation)  is  an  essential 
component of the granules released by cytotoxic T cells and natural killer (NK) cells 
(Krahenbuhl et al., 1988; Clement et al., 1990) and, in mice, was recently detected also 
in skin-associated mast cells (Pardo et al., 2007). In cytotoxic T cells and NK cells, the 
co-secreted protein perforin delivers a macromolecular complex of Granzyme B and 
a chondroitin sulfate proteoglycan (serglycin) to the cytosol of target cells (Froelich et  
al.,  1996b;  Metkar  et  al.,  2002),  however,  the mechanism of  the perforin-mediated 
transfer  has  been  discussed  intensely  throughout  the  years  (e.g.  Liu et  al.,  1995; 
Froelich et  al.,  1996b;  Metkar  et  al.,  2002;  Voskoboinik & Trapani,  2006;  Pipkin & 
Lieberman,  2007).  Recent  work  again  supports  the  original  notion  of  perforin 
monomers assembling into pores through which the granzymes can enter (Kurschus 
et al., 2008).
Having entered the cytosol of a target cell, Granzyme B induces apoptosis via several 
different  ways.  Known substrates  of  Granzyme B  include  the  caspase  zymogens 
procaspase-3,  -6,  -7,  -8,  -9,  and  -10  (reviewed  in  Talanian et  al.,  1997;  Trapani  & 
Sutton, 2003a), among which both procaspase-3 (Metkar et al., 2003) and procaspase-
10 (Talanian et al., 1997) were described as the first and foremost to be processed. 
Granzyme  B  also  cleaves  several  caspase  substrates  such  as  poly(ADP-ribose) 
polymerase (PARP) (Froelich et  al.,  1996),  nuclear  matrix  antigen (NuMA),  DNA-
dependent  protein  kinase  (DNA-PK)  (Andrade et  al.,  1998),  DFF45/inhibitor  of 
caspase-activated deoxyribonuclease (ICAD) (Thomas et al., 2000),  Bid (Barry et al., 
2000; Sutton et al., 2000), and also the ζ chain of the T cell receptor (Wieckowski et al., 
2002).  Furthermore,  Granzyme  B  was  reported  to  cleave  extracellular  cartilage 
proteoglycan  (Froelich et  al.,  1993;  Ronday et  al.,  2001)  and  neuronal  glutamate 
receptor (GluR3B) (Gahring et al., 2001) as well as extracellular matrix proteins such 
as vitronectin, fibronectin, and laminin, which might lead to programmed cell death 
due to loss of anchorage (anoikis) (Buzza et al., 2005). Taken together, Granzyme B 
provides  multiple  routes  to  initiate  apoptosis  (reviewed  in  Talanian et  al.,  1997; 
Trapani & Sutton, 2003a; Bots & Medema, 2006a), which is advantageous if any way 
of apoptosis induction is blocked inside the target cell. Consequently, Granzyme B 
has been used successfully for the generation of several immunotoxins (Liu et  al., 
2003a; Liu et al., 2003b; Kurschus et al., 2004; Zhao et al., 2004c; Dalken et al., 2006; 
Wang et  al.,  2007),  among which a  genetic  immunotoxin approach  has  also  been 
realised (Zhang et al., 2003; Wang et al., 2007; Zhang et al., 2008).
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For full activity of Granzyme B, a free N-terminus was described as crucial (Edwards 
et al., 1999). This is also reflected by its synthesis as a zymogen, of which a dipeptide 
has to be cleaved off to yield active Granzyme B (Kam et al., 2000).
1.6 Recombinant expression of therapeutic proteins
The advent of  recombinant  DNA technology has revolutionised the strategies  for 
production of therapeutics and vaccines required for the treatment of many diseases. 
Currently more than 125 recombinant proteins are approved in the United States or 
the European Union (Rader,  2008),  covering a  market  of  56  billion US$ per  year 
(Dutton  &  Scharer,  2007).  Furthermore,  more  than  1800  recombinant  drugs  or 
vaccines are being or have been investigated in clinical trials, of which 452 currently 
are in the patient recruitment phase (http://clinicaltrials.gov, status: July 2010, search 
term: recombinant). A further expand of the market can be anticipated.
Depending on the characteristics of and requirements for the protein of interest, an 
appropriate  expression system has  to  be  chosen,  taking into  consideration  codon 
usage of the host, yield, proper folding and post-translational modifications of the 
target protein, ease of downstream processing, scale-up options, and safety, all with 
regard to time and cost efficiency. In an industrial scale, GMP compliance is a major 
requirement as well.
Currently, the most important expression systems for the commercial production of 
recombinant protein are microbial and mammalian bioreactor systems (Thiel, 2004).
For  all  expression  systems,  the  production  of  the  recombinant  protein  might  be 
enhanced by codon optimisation of the encoding gene, i.e. codons rarely used in a 
specific host organism are replaced by frequently used codons. This service is offered 
by several companies in the course of gene synthesis and will be used in this thesis as 
well.
1.6.1 Microbial expression
Bacteria, among which  E. coli is now as ever the most widely employed host, have 
become popular as expression hosts due to their fast growth and high volumetric 
productivity, ease of handling, and inexpensive media. However, several limitations 
of bacterial systems might favour the use of an alternative expression system. On one 
hand, most prokaryotes are not able to carry out post-translational modifications like 
glycosylation or formation of disulfide bridges in their cytoplasm. On the other hand, 
recombinant  protein  often  tends  to  aggregate  and  form  inclusion  bodies  in  the 
cytoplasm,  of  which the protein  can be only  partly  recovered through time-  and 
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labour-intensive solubilisation in denaturing agents followed by careful renaturation. 
Furthermore, cell lysis to recover the cytoplasmic proteins also results in the release 
of endotoxins, which must be removed specially from the final product (Rai & Padh, 
2001).
One possible approach to circumvent some of the problems mentioned above is to 
direct  the  protein  to  the  periplasmic  space  for  example  by using the  pelB leader 
sequence (Lei et al., 1987). In this compartment, the formation of disulfide bonds is 
possible (Wulfing & Pluckthun, 1994), and a lower amount of proteases compared to 
the  cytoplasm  allows  to  recover  the  protein  with  less  proteolytic  degradation 
(Talmadge & Gilbert, 1982). Moreover, presence of chaperones leads to stabilisation 
of the recombinant protein (Wulfing & Pluckthun, 1994). The periplasmic expression 
procedure was developed further by applying an osmotic stress protocol (Barth et al., 
2000), which was applied during this work as well.
A vector system suitable for periplasmic expression is pET26b from Novagen.  The 
pelB leader sequence directs the expressed protein into the periplasm. An N-terminal 
hexa-histidine tag facilitates the purification and detection of the expressed protein.
Other microorganisms used for expression of recombinant proteins include yeasts 
such as Saccharomyces cerevisiae,  Pichia pastoris  and Hansenula polymorpha (Boer et al., 
2007) as well as filamentous fungi like e.g. Aspergillus niger (Gerngross, 2004) or the 
single-celled slime mold  Dictyostelium discoideum  (Arya et al., 2008). As eukaryotes, 
these organisms are all capable of N- and O-linked glycosylation, however, terminal 
sugar residues differ from their human counterparts and thus can have an impact on 
functionality and/or immunogenicity. The same problem is given for baculovirus- or 
plasmid vector-driven expression in insect cells (Rai & Padh, 2001).
1.6.2 Mammalian expression
In  contrast  to  the  difficulties  given  with  glycosylation  in  microbial  or  insect  cell 
systems, mammalian expression offers all kinds of post-translational modifications 
from the start. Still, differences in glycosylation pattern were reported for rodent and 
human cells (Rai & Padh, 2001), e.g. for chinese hamster ovary (CHO) and human 
embryonic kidney (HEK293) cells (van den Nieuwenhof et al., 2000). Even the use of 
a single human cell line was reported to contingently produce altered glycosylation 
profiles due to culture conditions or the transfection event itself (Rai & Padh, 2001; 
Gerngross,  2004;  Twyman et  al.,  2005;  GE  Healthcare,  2006).  However,  as 
glycosylation  is  most  authentic  in  mammalian  cells,  60-70%  of  all  recombinant 
protein pharmaceuticals are produced in mammalian cells. Whereas in the past, and 
in lab scales up to now, fetal  calf  serum is used as default  additive to propagate 
mammalian cells, most industrial cell culture processes are executed in serum-free 
media today (Wurm, 2004). Besides the optimisation of media, the culture format is 
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another  possibility  to  enhance  the  production  of  recombinant  protein.  Especially 
fermentation bioreactors, whether run in batch or perfusion modes, provide a good 
means of reaching higher cell densities and improved oxygen supply. For adherent 
cells, it is possible to either adapt them to suspension culture or to grow them on 
microcarrier beads.
For the mammalian expression carried out during this thesis,  the human cell  line 
HEK293T was focused upon as the main production system. This cell line is a highly 
transfectable derivative of the HEK293 cell line constitutively expressing the simian 
virus  40  (SV40)  large  T  antigen,  allowing  for  high  replication  rates  of  plasmids 
carrying  the  SV40  origin  of  replication.  The  pSecTag2-based  pMS  vector  system 
(Stocker et al.,  2003) offers  this feature.  Furthermore,  the Ig  kappa  leader  sequence 
directs the secretion of the expressed protein into the culture supernatant, and an N-
terminal hexa-histidine tag facilitates IMAC purification and immunoblot detection. 
In addition, an internal ribosome entry site (IRES) and an egfp  gene downstream of 
the gene of interest allow the bicistronic co-expression of eGFP, and thus provide an 
easy  way  of  monitoring  successful  transfection  and  expression  of  the  protein  of 
interest.
Another derivative of HEK293 cells is the commercially available cell line FlpIn293 
(Invitrogen). The Flp-In system allows stable integration of the gene of interest at a 
specific genomic location featuring a Flp recombination target (FRT) sequence. The 
expression plasmid pcDNA5/FRT also harbours this sequence, and by cotransfection 
with pOG44, which encodes Flp recombinase,  a homologous recombination event 
leads  to  target  gene  integration  into  the  host.  With  this  approach,  the  problems 
associated with random insertion of the transgene, which seems to be also observed 
with supercoiled plasmid DNA without any recombination sequences (Wurm, 2004), 
can be overcome.
In contrast to the advantages mentioned above, the major drawback of mammalian 
cell  culture is  the height of production costs.  Furthermore,  traditional methods of 
clone  selection  are  time  consuming  and  laborious,  and  methods  are  too  low-
throughput to screen the volume of cells required to give a reasonable probability of 
finding a high-producing clone (Browne & Al-Rubeai,  2007).  Other disadvantages 
include the limited capacity for scale-up and the risk of contamination with human 
pathogens (Twyman et al., 2005).
Although expression in transgenic animals or hens'  eggs is  promising in terms of 
yield,  the  breeding  and  maintenance  of  those  animals  is  very  time-  and  cost-
intensive, and the regulatory framework is restrictive (Twyman et al., 2005). Thus, 
transgenic  animals  as  expression  systems  are  economically  not  acceptable  for 
facilities of non-industrial background.
Introduction 19
1.6.3 Plant expression
Another option for the expression of recombinant proteins are plant-based systems. 
Plants allow for cost-effective production of recombinant proteins with the option to 
increase  production  to  an  agricultural  scale  while  eliminating  risks  of  product 
contamination  with  endotoxins  or  human  pathogens  (Fischer et  al.,  2004).  Since 
human  serum  albumin  has  been  produced  in  plants  and  plant  cells  as  the  first 
protein  for  potential  therapeutic  use  (Sijmons  et  al.,  1990),  a  wide  variety  of 
therapeutic proteins has been produced in crop plants like tobacco, lettuce, alfalfa, 
maize,  rice,  wheat,  barley,  potato  and many others  (reviewed in  Ma  et  al.,  2003; 
Fischer  et al.,  2004; Twyman et al.,  2005). However,  so far only one immunotoxin, 
composed of the ribosome-inactivating protein bryodin genetically fused to a murine 
anti-CD40 single chain antibody, has been produced in plants (Francisco et al., 1997). 
As  bryodin  is  a  plant-derived  toxin,  the  successful  expression  of  a  humanised 
immunotoxin in plants would be a novel achievement.
Other plant expression systems, which have not yet come to widespread commercial 
use or are still in the pipeline of initial development, include dandelion (Dirk Prüfer, 
personal communication), the moss Physcomitrella patens (Decker & Reski, 2004), the 
unicellular  green  alga  Chlamydomonas  reinhardtii  (Franklin  &  Mayfield,  2004),  or 
duckweed of the genera Lemna (Gasdaska et al., 2003) or Wolffia  (Kruse  et al., 2002). 
The best characterised and most frequently used expression host, however, is tobacco 
(Nicotiana tabacum). Its high biomass yield and rapid scalability were considered to 
make tobacco very suitable for commercial molecular farming (Fischer  et al., 2004). 
Despite that, as with other plant systems, the non-authentic glycosylation pattern, the 
often low target protein yields, and the high content of secondary metabolites such as 
phenolic  compounds,  which  must  be  removed  completely  during  downstream 
processing,  have  prevented  the  routine  approval  of  plant-derived 
biopharmaceuticals for use in clinical trials (Fischer  et al., 2004). Nevertheless plant 
expression is an emerging field with a promising future perspective.
As with bacterial or mammalian expression systems, one way to optimise expression 
in plants is to vary the targeting of the protein of interest. Apart from the promoter-
driven exclusive expression in a defined tissue or organ, as was for example reported 
for  expression  in  seeds  or  seed  compartments  (reviewed  by  Stoger  et  al.,  2005), 
targeting to intra- or extracellular compartments like apoplast, ER or chloroplasts can 
be achieved by appropriate signal peptide sequences (Daniell et al., 1990; Denecke et  
al.,  1992;  Voss et  al.,  1995).  Furthermore,  the  factors  that  determine  the  optimal 
extraction of the target protein from the plant have a direct influence on the initial 
choice of expression strategy, and  therefore must be considered already at an early 
stage (Hassan et al., 2008). In terms of yield, for full size antibodies as well as single 
chain Fv fragments expressed in tobacco, the secretory pathway, i.e. targeting to the 
apoplast,  has  been  shown  to  be  more  suitable  for  expression  than  the  cytosol 
(Zimmermann et  al.,  1998;  Schillberg et  al.,  1999).  However,  with  its  oxidising 
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environment,  abundance of molecular  chaperones and absence of many proteases 
(Twyman et al., 2005), the endoplasmic reticulum (ER) is even more promising for the 
accumulation of a recombinant protein. Indeed, yields of recombinant proteins have 
been observed to be up to ten times higher when the protein is targeted to the ER and 
retarded there by a KDEL signal (Schillberg et al., 2002). Furthermore, as plant and 
mammalian glycosylation only differs in the late Golgi apparatus, the plant-specific 
glycosylation and, with this, potential immunogenicity is circumvented by retention 
in the ER (Gomord et al., 2004).
Another  compartment  suitable  for  recombinant  protein  expression  are  the 
chloroplasts.  To  date,  23  vaccine  antigens,  among them vaccines  against  anthrax 
disease,  pestilence,  malaria,  and  cholera,  have  been  expressed  in  chloroplasts 
(Davoodi-Semiromi et al., 2009). In general, there are two possible ways to achieve 
accumulation of recombinant protein in chloroplasts: transformation of the plastome 
by particle bombardment using a vector facilitating homologous recombination on 
the one hand (Verma & Daniell, 2007), and genome transformation with a transgene 
harbouring a signal sequence which mediates the post-translational import of the 
protein into the chloroplasts on the other hand. Following the latter concept,  two 
recent  works  using  the  pTRA  vector  system  (derivatives  of  pPAM,  GenBank 
accession number AY027531) demonstrated that  chloroplast  expression of  vaccine 
candidates  even  surpassed ER expression  in  terms of  yield (Maclean et  al.,  2007; 
Meyers et al., 2008).
Taken  together,  the  pTRA  vector  system  is  well  established  for  expression  of 
recombinant  protein  in  apoplast,  ER  and  chloroplasts  (e.g.  Schinkel et  al.,  2005; 
Meyers et al., 2008) and will be used in this thesis as well.
1.7 Aim of the thesis
Dysregulated myeloid cells expressing the high affinity receptor for IgG, CD64, were 
shown to play a major role in as different diseases as acute myeloid leukaemia (AML 
M4 and M5), rheumatoid arthritis, atopic dermatitis and allergic asthma. In the past, 
immunotoxins comprised of the CD64-targeting single chain antibody H22 and the 
toxins  Pseudomonas exotoxin A or the plant-derived ricin A proved efficient in the 
elimination of  disease-specific  CD64+ cells  in  vitro and  in  vivo.  However,  as  non-
human  protein  domains  are  known  to  elicit  undesired  immune  responses,  a 
replacement  of  the non-human toxin with a human toxin is  the easiest  option to 
highly reduce the risk of anti-immunotoxin responses.
Therefore, a novel H22-based immunotoxin with the human protein Granzyme B as 
toxic moiety was the main focus of this thesis. However, as it cannot be expected that 
all tumour cells are equally susceptible to different toxins, a test system to address 
this issue should be established first. For this, a eukaryotic plasmid vector allowing 
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cytosolic  expression  of  Granzyme  B  should  be  cloned.  In  case  CD64+ U937  cells 
transfected with this vector underwent cell death, i.e. Granzyme B as potent cytotoxic 
agent as well as U937 cells as appropriate model system were confirmed, cloning and 
expression  of  the  immunotoxin  Gb-H22(scFv)  should  be  realised.  Different 
expression systems were evaluated to identify the most efficient production system.
Following production, an appropriate downstream procedure to yield pure and fully 
active protein had to be established and optimised.
Finally,  the  protein  should  be  functionally  characterised  in  vitro in  terms  of  its 
binding, proteolytic and cytotoxic/apoptosis-inducing properties.
As a final additional branch of this thesis, structural variations of Gb-H22(scFv) with 
the aim to increase cytotoxicity were designed. As for all immunotoxins lacking a 
natural  translocation  domain,  an  improvement  of  translocation  by  introducing  a 
peptide sequence mediating membrane transfer is highly desirable. Previous studies 
have shown the usefulness of an adapter sequence comprised of  an endosomably 
cleavable  peptide  (ECP),  a  membrane transfer  peptide  (MTP),  and a  cytosolically 
cleavable peptide (CCP) to release the toxin. An increase in cytotoxicity compared to 
the same constructs without adapter was documented. However, from these findings 
it  could  not  be  concluded  whether  the  increase  in  cytotoxicity  was  due  to  an 
improved membrane transfer, or just an effect of toxin release, or in the best case a 
combination  of  both.  In  order  to  clarify  this,  minimal  adapter  variants  of  Gb-
H22(scFv) featuring MTP or CCP alone, or a combination of both, were prepared and 
characterised.
The work scheme of this thesis is summarized in a flow chart in Fig. 3.1.
Introduction 22
Fig. 3.1: Work scheme of this PhD thesis.
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals and consumables
If not otherwise stated, chemicals in analytical grade quality and consumables were 
supplied by Roth (Karlsruhe, Germany).
2.1.2 Buffers and media
Buffers and their stock solutions were prepared according to standard procedures 
using MilliQ water (twofold deionised).  If not noted otherwise,  the pH value was 
adjusted using aequeous HCl or NaOH. If necessary and possible,  solutions were 
sterilised by autoclaving for 20 min at 121°C and 2 bar. Heat-sensitive components, 
such  as  antibiotics,  were  prepared  as  stock  solutions,  filter-sterilised  (pore  size 
0.2 μm) and added to the medium/buffer after cooling below 60°C.
Where  appropriate,  antibiotics  were  used  in  the  following  final  concentrations: 
ampicillin  100 µg/ml,  chloramphenicol  30  µg/ml,  kanamycin  50  µg/ml  (E.  coli)  or 
25 µg/ml  (A.  tumefaciens),  rifampicin  25  µg/ml,  carbenicillin  50  µg/ml,  penicillin 
100 U/ml, streptomycin 100 µg/ml, zeocin 100 µg/ml. For FlpIn293 cells, the optimal 
hygromycin B concentration was determined experimentally (3.2.2.6).
Tab.  2.1 lists  the  buffers  used and their  composition,  Tab.  2.2 presents  the broth 
media and their composition.
Tab. 2.1: Standard  buffer  compositions.  Buffers  marked  with  *  were  filter-sterilised  and  stored 
at 4°C.
Buffer Composition Concentration
10x PBS (pH 7.4) NaCl 
KCl 
Na2HPO4 x 12 H2O 
KH2PO4 
1.37
27 
81
15
 M
 mM
 mM      
 mM
1x PBST 1x PBS (pH 7.4)
Tween 20 0.05 % (w/v)
50x TAE buffer (pH 7.5) Tris
Glacial acetic acid
EDTA
2     
5.7
50 
M
% (v/v)
mM
5x OrangeG loading 
buffer
OrangeG 
Glycerol
in 1x TAE (pH 7.5)
0.1
30   
% (w/v)
% (v/v)
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TfB-I (pH 5.8, adjusted 
with 200 mM acetic 
acid)*
RbCl
MnCl2
Potassium acetate
CaCl2
Glycerol
100
50
30
10
15
mM
mM
mM
mM
% (v/v)
TfB-II (pH 6.8)* RbCl
MOPS
CaCl2
Glycerol
10
10
75
15
mM
mM
mM
% (v/v)
4x Incubation buffer 
(pH 7.4) for IMAC
NaH2PO4
NaCl
Imidazole
200
1.2
40
mM
M
mM
Elution buffer (pH 7.4) 
for IMAC
NaH2PO4
NaCl
Imidazole
50
0.3
250
mM
M
mM
5x TGS (pH 8.3) Tris
Glycine
SDS
125 
960
0.5
mM
mM
% (w/v)
5x reducing protein 
loading buffer
Tris
Glycerol 
SDS 
Bromphenolblue 
ß-Mercaptoethanol 
62.5
30 
4   
0.05 
10 
mM
% (v/v)
% (w/v)
% (w/v) 
% (v/v)
Coomassie staining 
solution
Coomassie Brilliant Blue G250 
Methanol
→  mix  1  h,  filter  w.  folded 
paper filter, then add
Glacial acetic acid 
0.25
50
10     
% (w/v)
% (v/v)
% (v/v)
Coomassie destaining 
solution
Methanol 
Glacial acetic acid
10   
10
% (v/v)
% (v/v)
Transfer buffer for 
Western Blot
Tris
Glycine
Methanol
SDS
25
192
20
0.05
mM
mM
% (v/v)
% (w/v)
AP buffer (pH 9.6) Tris
NaCl
MgCl2
100
100
5
mM
mM
mM
Gb assay buffer (pH 7.4) NaCl
HEPES
DTT
EDTA
Glycerol
CHAPS
100
50
10
1
10
0.1
mM
mM
mM
mM
% (v/v)
% (v/v)
Annexin A5 binding 
buffer (pH 7.4)
HEPES
NaCl
KCl
CaCl2
100
1.5
50
20
mM
M
mM
mM
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Tab. 2.2: Standard media compositions.
Medium Composition Concentration
LB (pH 7.0) NaCl
Peptone
Yeast extract
(Agar)
1
1
0.5
1.5
% (w/v)
% (w/v)
% (w/v)
% (w/v)
TB (pH 7.4) Peptone
Glycerol
Yeast extract
1.3
0.8
2.7
% (w/v)
% (v/v)
% (w/v)
YEB (pH 7.0) Beef extract
Yeast extract
Peptone
Sucrose
(Agar)
MgSO4 (added after autocl.)
0.5
0.1
0.5
0.5
1.5
2
% (w/v)
% (w/v)
% (w/v)
% (w/v)
% (w/v)
mM
2x Infiltration medium 
(pH  5.6)
Sucrose
Glucose
MS salts
10
0.36
0.86
% (w/v)
% (w/v)
% (w/v)
RPMI complex medium RPMI 1640 plus GlutaMAX-I 
(Invitrogen)
FCS
Penicillin
Streptomycin
10
100
100
% (v/v)
U/ml
µg/ml
HL-1 medium HL-1 (Cambrex)
GlutaMAX-I (Invitrogen) 1 % (v/v)
2.1.3 Antibodies
Unless otherwise stated, for flow cytometric analyses 1 µl of fluorescence-labelled 
antibody was used in 50 µl PBS. All other antibodies were intended for Western Blots 
and were, if not stated otherwise, used in a 1:5000 dilution.
Tab. 2.3 lists all antibodies used.
Tab. 2.3: Antibodies used.
Target Antibody Characteristic Abbreviation
5x Histidine tag mouse-anti-penta-His (Qiagen) monoclonal αHis
5x Histidine tag
mouse-anti-penta-
His-Alexa488 
(Qiagen)
monoclonal αHis-Alexa488
Caspase-3, 
active form
mouse-anti-active-
caspase-3-FITC 
(BD)
monoclonal αCasp3-FITC
CD64 (human) mouse-anti-CD64-FITC (Serotec)
monoclonal (clone 10.1), 
conjugated to fluorescein 
isothiocyanate (FITC)
αCD64-FITC
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CD64 (human) mouse-anti-CD64-PE (Serotec)
monoclonal (clone 10.1), 
conjugated to 
phycoerythrin (PE)
αCD64-PE
Enterokinase 
cleavage site
rabbit-anti-ECS 
(Novus Biologicals) polyclonal αECS
Fc of mouse IgG
goat-anti-mouse-
AP
(Sigma)
polyclonal, conjugated to 
alkaline phosphatase 
(AP)
GαM-AP
Fc of rabbit IgG goat-anti-rabbit-AP(Dianova)
polyclonal, conjugated to 
alkaline phosphatase 
(AP)
GαR-AP
Granzyme B 
(Gb) (human)
mouse-anti-Gb-PE 
(ImmunoTools) 
monoclonal, conjugated 
to phycoerythrin (PE) αGb-PE
Granzyme B 
(Gb) (human)
mouse-anti-Gb 
(ImmunoTools) * monoclonal αGb
* taken from "Granzyme B matched pair for ELISA", detector antibody
2.1.4 Enzymes and reaction kits
All enzymes were purchased from NEB, with the following exceptions: Recombinant 
enterokinase  was delivered  by Novagen,  Taq DNA polymerase  was  from Bioline 
(BIOTAQ DNA Polymerase).
All enzymes and reaction kits (Tab. 2.4) were used according to the manufacturers' 
recommendations.
Tab. 2.4: Standard reagents and kits used.
Reagent / Kit Purpose Company
CellTiter 96 AQueous One Solution Cell viability assay Promega
FITC-conjugated  Monoclonal  Active 
Caspase-3 Antibody Apoptosis Kit I
Detection of active 
caspase-3
BD Biosciences
Human Active Caspase-3 CBA Detection of active 
caspase-3
BD Biosciences
NucleoSpin Extract II Kit DNA isolation from 
agarose gels
Macherey-Nagel
NucleoSpin Plasmid Kit Plasmid DNA isolation Macherey-Nagel
QIAEx II Gel Extraction Kit DNA extraction from 
agarose gels
Qiagen
QIAprep Spin Miniprep Kit Plasmid DNA isolation Qiagen
QIAquick Gel Extraction Kit DNA extraction from 
agarose gels
Qiagen
Quick Ligation Kit Ligation of DNA 
fragments
NEB
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2.1.5 Synthetic oligonucleotides 
Synthetic oligonucleotides as listed in Tab. 2.5 were provided by MWG Biotech. The 
purification was performed by the manufacturer's proprietary High Purity Salt Free 
(HPSF) method.
Tab. 2.5: Names and sequences of synthetic oligonucleotides. The melting temperature (Tm) was 
calculated using the primer3 software (http://frodo.wi.mit.edu/) (Rozen & Skaletsky, 2000) 
and refers to the initially hybridising region (uppercase) only. Restriction sites are shown 
in bold.
Name Sequence Tm [°C]
BGHrev TAGAAGGCACAGTCGAGG 54.78
CMVfor CGCAAATGGGCGGTAGGCGTG 73.43
fpUC CGCCAGGGTTTTCCCAG 62.59
Gbfor attacagctagccaccatgATCATCGGGGGACATGAGG 63.08
Gbrev GTATTAGAATTCTCAGTAGCGTTTCATGGTTTTC 53.26
Gb+BlpI+Eco
RIrev
attacagaattctcagtgctcagcGTAGCGTTTCATGGTTTTCTTTATC 59.51
H22+EcoRIrev attacagaattctcaTTTTGATCTCCAGCTTG 47.51
H22+NheIfor attacagctagccaccatgGCCCAGGTGCAGCTGGTGG 78.78
his-back TTAAACTCAATGATGATGATGATGATG 61.24
IVSrev ACAGCGAATTAATTC 40.10
pMS-Seq-Sac-
back
GCTCTCTGGCTAACTAGAGAACCC 61.20
primer3 TCAAGGAACAGGAGCCGACC 64.89
primer4 CTTGGCCTCATGTCCCCCGA 69.86
PS-5' AGAGAGAGATAGATTTGTAGAGA 48.76
PS-3' ATCCTTCGCAAGACCCTTCCTCT 65.72
rpUC GGAATTGTGAGCGGATAAC 55.57
T7prom AATACGACTCACTATAG 35.59
T7term GCTAGTTATTGCTCAGCGG 56.34
Vl-ohne-for GACATCCAGCTGACCCAGAGCCCAAGCAGCC 81.14
Xba-Entero-
Gb-back
CTCTAGACATATCGACGACGACGACAAGATCATCGGGGGACATG N/A
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2.1.6 Bacterial and plant strains and human cell lines
Tab. 2.6 shows the different organisms and strains used in this work.
Tab. 2.6: Organisms used.
Organism/strain/
cell line
Genotype/origin/remarks Reference
E. coli BL21(DE3) F– ompT hsdSB(rB– mB–) gal dcm (DE3) Novagen
E. coli DH5α supE44  lacU169  (Φ80dlacZ  ΔM15) 
hsdR17 recA endA1 gyrA96 thi-1 relA1
Invitrogen
E. coli Rosetta F
– ompT hsdSB(rB– mB–)  gal dcm  pRARE2 
(CamR)
Novagen
E. coli XL1-blue
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1  lac  [F´  proAB  lacIqZΔM15  Tn10 
(TetR)]
Stratagene
A. tumefaciens 
GV3101 pMP90RK Gen
R KanR RifR Koncz & Schell, 1986
N. tabacum  cv. 
Petit Havana SR1 tobacco Maliga et al., 1973
CHO-K1 chinese hamster ovary DSMZ, ACC 310
DU4475 human breast carcinoma DSMZ, ACC 427
FlpIn293 mod. HEK293 for stable expression Invitrogen
HEK293T human embryonic kidney ATCC, CRL-11268
HL60 human acute myeloid leukaemia DSMZ, ACC 3
IIA1.6 CD64+ murine  B  cell/macrophage  lineage, transfected to express human CD64 van Vugt et al., 1998
Jurkat human T cell leukaemia DSMZ, ACC 282
L540cy human Hodgkin lymphoma Kapp et al., 1992
MonoMac1 human acute monocytic leukaemia DSMZ, ACC 252
Raji human Burkitt lymphoma DSMZ, ACC 319
THP1 human acute monocytic leukaemia DSMZ, ACC 16
U937 human histiocytic lymphoma DSMZ, ACC5
2.1.7 Primary cells
Primary cells of healthy donors as well as primary cells from a CD64+ AML patient 
[~80%  blasts,  AML  subtype  M5  developed  secondarily  from  a  myelodysplatic 
syndrome,  cytogenetic  aberrations:  add(7)(q36)]  and a  CD64- AML patient  [~80% 
blasts,  AML  subtype  M1,  cytogenetic  aberrations:  t(1;3)(p36;q21)]  were  obtained 
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through Dr. Edgar Jost (University Hospital of Aachen) before treatment and after 
informed consent and with the approval of the Clinical Research Ethics Board of the 
RWTH Aachen University.
2.1.8 Plasmid vectors
The  following  different  vectors  were  used  for  cloning  purposes  and  for  the 
production of recombinant protein in different expression systems (Tab. 2.7).
Tab. 2.7: Vector systems used for cloning and protein expression.
Vector system Purpose Reference
pcDNA5/FRT Stable expression in mammalian cells Invitrogen
pMT Bacterial expression Tur et al., 2003
pMS Expression in mammalian cells Stocker et al., 2003
pTRAkc-AH Plant expression (apoplast) T. Rademacher
pTRAkc-ERH Plant expression (ER) T. Rademacher
pTRAkc-CTP Plant expression (chloroplasts) T. Rademacher
pUC57 Delivery of synthetic genes from GenScript -
2.1.9 Synthetic genes
In order to simplify cloning of plant expression constructs and adapter constructs for 
mammalian expression, the genes of interest flanked by the desired restriction sites 
were optimised in terms of codon usage, synthesised and delivered by GenScript in 
pUC57 vector backbones.
All synthetic sequences used in this work are listed in the appendix (8.2).
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2.2 Methods
2.2.1 Production and preparation of DNA
2.2.1.1 Minipreparation of plasmid DNA from E. coli
Plasmid DNA from 5 ml liquid cultures of recombinant  E. coli  was isolated using 
either  QIAprep Spin Miniprep Kit (Qiagen) or NucleoSpin Plasmid Kit (Macherey-
Nagel) according to the manufacturer's instructions. Quality of DNA was confirmed 
by analytical  agarose  gelelectrophoresis  (2.2.1.4).  Quantity  and concentration  was 
determined spectrophotometrically  (2.2.1.2).  Isolated DNA samples were stored at 
-20°C.
2.2.1.2 Photometric determination of the concentration of nucleic acid solutions
For spectrophotometrical analysis 5 µl DNA solution (2.2.1.1) were added to 50 µl 
elution  buffer  of  the  respective  kit.  The  OD260  was  determined  with  the 
BioPhotometer  plus  (Eppendorf),  which  calculated  the  DNA  concentration 
automatically according to the volumes of sample and diluent entered.
2.2.1.3 Restriction endonuclease digest of DNA
As  all  restriction  enzymes  were  supplied  by  NEB,  restriction  digests  were  done 
according to the manufacturer's recommendations using enzyme amounts between 1 
and 20 U, depending on the amount of DNA used.
Restriction endonuclease digests with two enzymes were carried out according to the 
NEB web page (http://www.neb.com/nebecomm/DoubleDigestCalculator.asp).
In  case  a  vector  backbone  fragment  was  generated  by  restriction  with  a  single 
enzyme, the fragment was dephophorylated following the restriction endonuclease 
digest by adding 1 µl CIP (NEB) and a 1 h incubation at 37°C.
For test restrictions of newly cloned constructs the restriction enzymes were chosen 
so, that it was possible to distinguish the new vector from the original vector by the 
band pattern.
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2.2.1.4 Agarose gel electrophoresis
DNA  fragments (2.2.1.3)  were  electrophoretically  separated  (U:  110  V,  run  time 
35 min) on 0.8 to  2.0% (w/v) agarose gels containing 0,3 µg/ml ethidium bromide 
prepared in TAE buffer (2.1.2). As molecular weight standard the 2-Log DNA Ladder 
(NEB) and in some cases additionally the Low MW DNA Ladder (NEB) was used. 
After  the  run  was  completed,  the  DNA  in  the  gel  was  visualised  on  a  UV 
transilluminator  (Geldoc  XR,  BIO-RAD).  In  case  a  certain  DNA  fragment  was 
intended for cloning, it was excised and the DNA was recovered using the QIAquick 
Gel Extraction Kit (Qiagen), the NucleoSpin Extract II Kit (Macherey-Nagel), or, in 
case the DNA fragment was smaller  than 70 bp,  the QIAEX II  Gel  Extraction Kit 
(2.1.4). 
2.2.1.5 Ligation of DNA fragments
The  ligation  of  DNA  fragments  (2.2.1.3,  2.2.1.4)  was  performed  with  the  Quick 
Ligation Kit (NEB) according to the manufacturer's instructions.
2.2.1.6 Production of heat shock competent E. coli
Heat shock competent E. coli cells were prepared basing on the protocol of Hanahan 
et al. (1983). Briefly,  20 ml of LB medium were given into a sterile 250 ml baffled 
Erlenmeyer  flask,  inoculated with  E.  coli  and cultured at  37°C and 225 rpm over 
night. The next day, 1 ml of this culture was transferred into 100 ml LB medium in a 
1000 ml baffled Erlenmeyer flask and culturing was continued. As soon as the OD at 
600 nm reached a value between 0.5 and 0.8, the culture was split into two 50 ml 
falcon  tubes,  cooled  on ice  for  15  min,  and finally  sedimented  by  centrifugation 
(10 min/4000 rpm/4°C). Each pellet was gently resuspended in 15 ml ice-cold TfB-I 
buffer while constantly kept on ice. The suspensions were combined, spun down by 
centrifugation as before and gently resuspended in 4 ml ice-cold TfB-II buffer. 100 μl 
aliquots  were  dispensed  into  sterile  pre-chilled  1.5  ml  Eppendorf  tubes,  frozen 
immediately in liquid nitrogen and stored at –80°C.
2.2.1.7 Heat shock transformation of competent E. coli
For the transformation of competent E. coli (2.2.1.6) the bacteria were slowly thawed 
on ice first. DNA (~1 µg plasmid (2.2.1.1) or one half of the ligation mixture (2.2.1.5)) 
was added. After gentle tapping, the tube was incubated on ice for 30 minutes. A 
heat shock at 42°C for 90 seconds was followed by a cooling phase for two minutes 
on ice.  800 µl LB medium were added and the tube was rotated at ~100 rpm for 
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45 minutes at 37°C. After a centrifugation step at 11000 g for 30 seconds the medium 
was discarded except for ~100 µl. Cells were resuspended and plated on LB agar 
plates containing the appropriate antibiotic (2.1.2).
2.2.1.8 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) was used for the in vitro amplification of a specific 
DNA  segment (Saiki et al.,  1988) as well as for the insertion of restriction sites or 
other short nucleotide sequences.
In general, every amplification was corroborated by a negative control without any 
template and a suitable positive control.
The standard PCR protocol using  Taq  DNA polymerase (2.1.4)  was primarily used 
for bacterial colony PCR to check colonies after a transformation (2.2.1.7). For this, 
bacteria from a single colony were transferred to the PCR tube with a sterile pipette 
tip,  for  other  applications  1-10 ng DNA were  added  to  the  PCR tube  instead.  A 
standard  reaction  was  performed  in  a  volume  of  20 µl  using  the  amplification 
protocol presented in Tab. 2.9 and contained the components listed in Tab. 2.8.
Tab. 2.8: Polymerase chain reaction composition using BIOTAQ DNA polymerase (Bioline). In case 
of colony PCR, bacteria from a single colony were used instead of DNA.
Component Volume [µl] Final concentr.
(DNA) (variable) (1-10 ng/20 µl)
10x PCR buffer 2 1x
50 mM MgCl2 1 2.5 mM
dNTPs 0.2 100 µM
5’ forward primer 1 1 µM
3’ backward primer 1 1 µM
Taq DNA polymerase 0.1 0.025 U/µl
MilliQ water ad 20 -
Tab. 2.9: PCR amplification protocol using BIOTAQ DNA polymerase (Bioline).
Temperature [°C] Time [min] Step
95 5 initial denaturation
95 0.5 denaturation
     30 cyclesvariable 0.5 primer annealing
72 1 elongation
72 10 final elongation
If possible, amplifications for cloning purposes were carried out using Phusion High-
Fidelity DNA Polymerase (Finnzymes/NEB), a proofreading polymerase with 3´→5´ 
exonuclease activity. To generate sufficient amounts of product, PCR reactions were 
set  up  in  volumes  from  20-100  µl.  The  following  tables  represent  the  pipetting 
scheme for a 50 µl reaction and the corresponding PCR programme, both according 
to the polymerase manufacturer's instructions.
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Tab. 2.10: Polymerase  chain  reaction  composition  using  Phusion  High-Fidelity  Polymerase 
(Finnzymes/NEB).
Component Volume [µl] Final concentr.
DNA variable 2.5-25 ng/50 µl
5x HF buffer 10 1x
dNTPs 0.5 100 µM
5’ forward primer 2.5 1 µM
3’ backward primer 2.5 1 µM
Phusion polymerase 1.25 0.05 U/µl
MilliQ water ad 50 -
Tab. 2.11: PCR amplification protocol Phusion High-Fidelity Polymerase (Finnzymes/NEB).
Temperature [°C] Time Step
98 30 s initial denaturation
98 10 s denaturation
     30 cyclesvariable 30 s primer annealing
72 15 s elongation
72 10 min final elongation
All primer annealing temperatures were chosen 1-3°C below the lower one of the 
melting temperatures of the initially hybridising regions of the primers (2.1.5). Those 
melting  temperatures  were  determined  using  the  Primer3  software 
(http://frodo.wi.mit.edu).
2.2.1.9 Sequencing of final constructs
All plasmid vectors (2.1.8) generated in this work were verified by DNA sequencing 
in the exchanged region.
DNA sequences were determined by the Fraunhofer IME DNA analysis core facility 
on  an  ABI  Prism  3730  DNA  Analyzer  (Applied  Biosystems)  using  BigDye™ 
terminator v3.1 chemistry. Premixed reagents were from Applied Biosystems.
Resulting chromatograms and sequences were analysed with the DNA Star software.
2.2.1.10 Preparation of E. coli glycerol stocks
As soon as a certain bacterial clone was identified as positive by colony PCR (2.2.1.8) 
and/or restriction endonuclease digest (2.2.1.3) of its plasmid DNA (2.2.1.1) and the 
plasmid DNA was confirmed by sequencing (2.2.1.9), glycerol stocks were prepared. 
For this, a 5 ml LB culture was inoculated and grown at 37°C and 225 rpm to mid-log 
phase (OD600 = 0.5-0.7). Cells were spun down at 3000 rpm for 5 min, resuspended in 
1.7 ml LB medium and 0.3 ml sterile glycerol and frozen at -80°C in two aliquots.
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2.2.2 Production of recombinant protein in E. coli
2.2.2.1 Cultivation and lysis of E. coli Rosetta or E. coli BL21(DE3)
E. coli Rosetta were transformed with the bacterial expression vector as described in 
2.2.1.7.  Following  colony  PCR  to  verify  obtained  clones,  glycerol  stocks  were 
prepared (2.2.1.8,  2.2.1.10). The production of recombinant protein was carried out 
under stress conditions as described by Barth et al. (2000). Briefly, 50 ml TB medium 
supplemented  with  kanamycin  (BL21(DE3))  or  kanamycin  and  chloramphenicol 
(Rosetta) were inoculated with bacteria from the glycerol stocks and cultured over 
night at 26°C and 225 rpm. As soon as an OD600 greater than 1.6 was reached, 0.5 M 
sorbitol (4.55 g), 4% (w/v) NaCl and 10 mM betaine (0.2 ml of 2.5 M stock) were 
added. Culturing was proceeded for 30 min, then protein expression was induced by 
adding 1 mM IPTG (50 µl of 1 M stock) and culturing was continued over night. On 
the  next  day  cells  were  lysed  using  CelLyticExpress  (Sigma)  according  to  the 
manufacturer's  instructions.  After  cell  lysis  the  culture  was  centrifuged 
(15 min/4000 rpm).  The  supernatant  was  subjected  to  protein  midipreparation 
(2.2.5.1).
2.2.3 Production of recombinant protein in N. tabacum
2.2.3.1 Transformation of competent A. tumefaciens
Electrocompetent  A. tumefaciens GV3101 (2.1.6) were obtained by Dr. Nicole Raven 
and  Manoj  Kumar  Mandal  (Fraunhofer  IME)  and  slowly  thawed  on  ice.  500  ng 
plasmid DNA (2.2.1.1) were added to 50 µl competent cells. After gentle tapping of 
the tube to mix DNA and cells, the sample was pipetted into the bottom of a chilled 
0.2  cm  electroporation  cuvette.  The  cuvette  was  inserted  into  the  Multiporator 
(Eppendorf) and electroporation was carried  out  at  2.5  kV for  5  ms.  950 µl  YEB 
medium were added immediately, and after short mixing cells were transferred to a 
sterile culture tube and incubated at 26°C shaking at 180 rpm for 2-4 h. Finally, 1 μl 
of cells was plated on YEB-Rif25-Kan25-Carb50  agar and incubated at 26°C. Following 
transformation, several clones were verified by colony PCR as described in 2.2.1.8.
2.2.3.2 Preparation of A. tumefaciens glycerol stocks
Bacteria from a positive  A. tumefaciens clone were transferred to 5-8 ml  YEB-Rif25-
Kan25-Carb50 medium (2.1.2). Cells were grown for 2-3 days at 26°C and 180 rpm. 
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A master glycerol stock was prepared by removing 800 µl of the culture, to which 
400 µl sterile glycerol (100% v/v) were added. After short vortexing, the master stock 
was immediately frozen at -80°C. The rest of the culture was spun down at 4000 rpm 
for 5 min and resuspended in 1.5 ml YEB without antibiotics. 2 ml sterile glycerol 
(40% v/v) were added. After vortexing, 50 µl aliquots were made and frozen at -80°C.
2.2.3.3 Syringe infiltration of N. tabacum
To subsequently infiltrate leaves of N. tabacum cv. Petit Havana SR1 (2.1.6), 5 ml YEB-
Kan25-Carb50 medium  (without  rifampicin)  (2.1.2)  were  inoculated  with  a  50  µl 
glycerol stock of transformed A. tumefaciens (2.2.3.2). After over night incubation at 
26°C and 180 rpm, acetosyringone was added to a final concentration of 20 µM, as 
well  as  glucose  to  10  mM  and  1  M  MES  (pH  5.6)  to  10  mM.  Incubation  was 
continued.  On the third day the OD at 600 nm was determined.  The culture was 
adjusted  to  an  OD  of  1.0  with  2x  infiltration  medium  and  water  if  necessary. 
Acetosyringone was added to a final concentration of 200 µM. The bottom side of 
several intercostal fields of mid-aged leaves of  N. tabacum, which had been grown to 
a height of ~40 cm, were slightly injured with a pipette tip. The bacterial suspension 
was injected into the leaves from the injured spots at the bottom side. Plants were 
incubated in a phytotron at ~23°C and a daily light phase of 16 h for at least three 
days. After different points of time leaf disks of 1.5 cm in diameter were punched 
out,  immediately  transferred  to  pre-chilled  Eppendorf  tubes  on  ice,  and 
homogenised on ice with an electric pistill with the twofold amount (w/w) of ice-cold 
PBS. Following centrifugation (5 min/13000 rpm/4°C),  the supernatant was in part 
analysed by SDS-PAGE (2.2.5.6)  and Western  Blot  (2.2.5.7)  or stored at  -20°C for 
subsequent analyses.
As  a  control  construct  a  pTRA  vector  carrying  the  expression  cassette  for  the 
fluorescent  protein  DsRed  (pTRAkc-rfp-cTP)  was  used.  DsRed  expression  was 
observed with a cold light source (KL 1500 LCD, Leica/Schott) with glass fiber optics, 
an additional excitation filter for green excitation (BP545/30) and a red colour foil 
(182 Light Red, Lee Filters) to optically eliminate chlorophyll autofluorescence.
2.2.4 Production of recombinant protein in mammalian cells
2.2.4.1 Cell culture of HEK293T, FlpIn293 and CHO cells
All three cell lines (2.1.6) were cultured in T75 cell culture flasks (Greiner) with RPMI 
complex medium and passaged 1:20-1:40 once a week. The cells were maintained in  
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vitro at 37°C in a humidified atmosphere of 5% CO2 for up to three months. After this 
period, a fresh cryo aliquot of cells was thawed and taken into culture.
For HEK293T cells, the serum concentration was occasionally reduced to 2.5% (v/v). 
However,  cells  proliferated significantly slower and thus poduced less  protein  in 
time. Therefore 10% (v/v) FCS was the standard culture regimen.
For serum-free expression in HEK293T cells,  cells  were directly passaged to HL-1 
medium (Cambrex) supplemented 1:100 with GlutaMAX-I (Invitrogen) and cultured 
as usual for up to two weeks.
Untransfected  FlpIn293  cells  were  maintained  in  RPMI  complex  medium 
supplemented with 100 µg/ml zeocin (2.1.2).
If  necessary,  cell  numbers  were  determined using a  CASY Cell  Counter  (Schärfe 
System) equipped with a 150 µm capillary. Cells were detached either with a cell 
scraper or by  trypsinisation. In the latter case, cells were rinsed with sterile PBS or 
serum-free RPMI 1640 plus Gluta-MAX-I (Invitrogen) and then incubated with 2 ml 
TrypLE Express (Invitrogen) at  37°C in a humidified atmosphere of 5% CO2.  The 
reaction was stopped by adding RPMI complex medium. In the end, 50 µl cells were 
suspended  in  10  ml  CASY  Ton  (Schärfe  System)  and  the  cell  number  was 
determined.
2.2.4.2 Transfection of HEK293T and CHO cells
HEK293T cells (2.1.6) and CHO cells (2.1.6) were transfected using Roti-Fect (Roth) 
according to the manufacturer's instructions.  Briefly, 1-2x105 cells were seeded into 
each  well  of  a  12-well  plate  and  incubated  over  night  at  37°C/5%  CO2/100% 
humidity. The following day 1-3 μg plasmid DNA were mixed with 300 μl serum-
free RPMI medium and 3 μl Roti-Fect and incubated for 20-40 min at RT. The cells in 
the  wells  were  optionally  washed  once  with  sterile  PBS.  PBS  or  medium  were 
replaced with the transfection mixture and cells were incubated for 1 h at 37°C/5% 
CO2/100% humidity, then 1 ml RPMI complex medium was added to each well and 
incubation was continued.  Three days after  transfection at  the earliest,  cells  were 
transferred to a cell culture flask with RPMI complex medium containing 100 µg/ml 
zeocin.
2.2.4.3 Transfection of FlpIn293 cells
For FlpIn293 cells  the complete  transfection procedure had to be established and 
optimised specifically. First, the lowest effective hygromycin B concentration had to 
be determined and turned out to be 50 µg/ml. The final procedure for transfection of 
FlpIn293 cells was as follows: 2x105 cells were plated out per well of a 6-well plate 
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containing  RPMI  complex  medium  supplemented  with  100  µg/ml  zeocin  for 
selection of cells containing the integrated FRT site.  To obtain a larger amount of 
transfected cells from the beginning, two wells per construct were used. The next 
evening after  incubation at  37°C/5% CO2/100% humidity, 0.4 µg expression vector 
(pcDNA5/FRT)  were  mixed  with  3.6  µg  Flp  recombinase  expression  plasmid 
(pOG44),  12 µl  Roti-Fect  (Roth)  and  1.2  ml  serum-free  HL-1  medium  (Cambrex) 
[supplemented  1:100  with  GlutaMAX-I  (Invitrogen)]  by  inverting  the  tube  a  few 
times. During a 20 min incubation at room temperature, the medium in the wells was 
removed and cells were washed three times with sterile PBS. To each well, 600 µl of 
the transfection mixture were added.  Following over night incubation at 37°C/5% 
CO2/100% humidity, the transfection mixture was removed and replaced with 2 ml 
RPMI complex medium containing 20% (v/v)  FCS without  antibiotics.  Incubation 
was continued for two days, then cells were transferred to a cell culture flask with 
RPMI complex medium containing 20% (v/v) FCS. Not before the next day 50 µg/ml 
hygromycin B were added and culturing was continued. When the culture was well 
established  after  one  or  two  weeks,  the  FCS  concentration  could  be  reduced  to 
10% (v/v).
2.2.4.4 Transfection of cancer cell lines
In  order  to  determine  the  sensitivity  of  cancer  cell  lines  (culture  conditions  see 
2.2.6.1)  towards  a  specific  toxin,  cells  were  transfected  with  a  pMS vector  (2.1.8) 
allowing cytosolic expression of the toxin. Transfection was carried out using the 
Nucleofector and the Cell Line Nucleofector Kit V (Amaxa Biosystems) according to 
the manufacturer's  instructions for the respective cell line. Briefly, per transfection 
sample  1x106 cells  were  spun  down  at  90  g for  10  min  and  resuspended  in 
Nucleofector Solution V at a final concentration of  1x106 cells/100 µl. 100 µl of cell 
suspension  were  mixed  with  1  µg  DNA  (2.2.1.1,  2.2.1.2),  transferred  to  the 
appropriate cuvette and nucleofected using the recommended programme for the 
respective cell line (U937: V-01, L540: T-001). Immediately after nucleofection, 500 µl 
pre-warmed RPMI complex medium (2.1.2) were added to the cuvette and cells were 
transferred  to  6-well  plates  containing 3  ml  prewarmed RPMI  complex  medium. 
Following a 24 h incubation at 37°C/5% CO2/100% humidity, cells were analysed by 
propidium iodide (PI) staining (c = 5 µg/ml) and flow cytometry (2.2.6.4).
2.2.4.5 Fermentation of HEK293T cells
With the aim to scale up the protein production from cell culture flasks to a stirred 
tank fermentation system,  culturing  of  HEK293T cells  on microcarrier  beads  was 
tested.  After  suboptimal  results  obtained  with  Cytodex  1  microcarriers  (GE 
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Healthcare),  Cytopore 2 microcarriers  (GE Healthcare)  turned out to be the better 
choice (3.2.2.3).
Following  optimisation,  the  protocol  finally  used  for  fermentation  and  its 
preparation comprised the steps listed in the following.
First, culturing of HEK293T cells was upscaled to four 3-level cell culture flasks to 
obtain ~1.8x108 cells.
The fermenter, a 3-litre stirred glass tank reactor with a height-to-tank diameter ratio 
of  2:1  (Applikon),  was  equipped  with  a  three-bladed  marine  impeller  stirrer 
(Ø 60 mm)  and  sensors  for  pH,  dO2 and  temperature.  Baffles  were  removed  to 
minimise  shear  stress.  pH  electrodes  were  calibrated  with  pH 4.0  and  pH  7.0 
reference  solutions.  Finally  the  bioreactor  was  sterilised  by  autoclaving  (20  min, 
121°C, 2 bar).
2 g Cytopore 2 beads were hydrated and swollen in PBS in a siliconised Erlenmeyer 
flask and autoclaved at 121°C/2 bar for 20 min. After two times washing in sterile 
PBS, the beads were incubated over night at 4°C in RPMI complex medium. The next 
day, medium was exchanged to obtain a total volume of 250 ml. Beads were split to 
125 ml each to two T175 cell culture flasks.
The medium was completely removed from the four 3-level cell culture flasks except 
50 ml in one of the flasks. In this flask, cells were detached by rough tapping. Cells 
were transferred to the next flask, cell were detached by tapping, and so on until all 
cells were suspended in 50 ml medium. 25 ml of cells were added to each T175 flask. 
Incubation  was  carried  out  at  37°C/5%  CO2/100% humidity  with  gentle  agitation 
every second hour to mix cells and beads.
Fig.  3.2: Fermentation of HEK293T cells growing on Cytopore 2 microcarriers in a  3-litre stirred 
glass tank reactor controlled by the Bio Controller ADI 1030 and Bio Console ADI 1035 
(all from Applikon).
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The next day cells and additional 700 ml RPMI complex medium were transferred to 
the  autoclaved  biorector  (Fig.  3.2).  Set  points  and  control  circuits  for  pH, 
temperature, dissolved oxygen concentration and stirrer speed were controlled and 
adjusted  by  the  Bio  Controller  ADI  1030  and  Bio  Console  ADI  1035  (both  from 
Applikon).  The  control  units  are  connected  to  a  computer  for  data  logging  and 
supervisory control using the BioXpert software (Applikon). Data were collected and 
reported to the computer in specific time intervals. Depending on pH, the head space 
was aerated by membrane filtered CO2. Temperature was maintained at 37°C. The 
stirrer  was  operated  at  30  rpm.  The concentration of  dissolved oxygen was kept 
above 30% (v/v) saturation by aeration with membrane filtered compressed air.
Fermentation was performed for 20 days, and samples were drawn every second or 
third day, of which 1 ml of supernatant was subjected to protein minipreparation 
(2.2.5.1).
Cells attached to the beads were finally stained using 5 µg/ml PI in 1x Perm/Wash 
Buffer (BD Biosciences).
2.2.5 Downstream processing
In  general,  the  first  step  to  enrich  the  protein  of  interest  from  any  protein 
supernatants  (whether  of  bacterial,  plant  or  mammalian origin)  was  immobilised 
metal affinity chromatography (IMAC).
In a small scale (up to 50 ml), those protein supernatants were subjected to a batch 
purification  with  Ni-NTA.  For  larger  scales,  the  whole  purification  process  was 
carried out with either the  ÄKTA FPLC or the ÄKTA purifier  system (both from 
Amersham  Pharmacia  Biotech) and  optimised  in  terms  of  kinds  of  purification 
methods, type of metal affinity resin, and order of purification/processing methods. 
The  final  order  of  purification/processing  steps  was  first  Co2+-based  IMAC,  then 
rebuffering  to  get  rid  of  high  concentrations  of  salt  and  imidazole,  enterokinase 
cleavage,  cation  exchange  chromatography  (CEX)  to  yield  high  purity,  and  final 
rebuffering to PBS.
Protein from serum-free cell culture supernatants showed a purity near 100% after 
IMAC, so a second purification step was not necessary in this case.
2.2.5.1 Protein mini-/midipreparation (Batch IMAC)
In  order  to  enrich protein  from any supernatant  in a small  scale,  Ni-NTA slurry 
(Qiagen)  was  first  washed  three  times  with  1x  incubation  buffer  (centrifugation 
1 min/3,300  g)  and  stored  in  1 x  incubation  buffer  at  4°C  until  use.  The  protein 
supernatant was centrifuged (2-5 min/3,300 g/RT) to pellet cells and cellular debris if 
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present.  The  desired  volume of  cleared  supernatant  was  transferred  into  a  clean 
1.5 ml microcentrifuge tube or 15 ml falcon tube, respectively, and combined with 1/3 
volume of 4 x incubation buffer and 30-80 µl Ni-NTA. After a 1 h incubation with 
slow  overhead  rotation  at  room  temperature,  the  tube  was  centrifuged 
(2-5 min/3,300 g/RT).  The  supernatant  was discarded,  and the pellet  was washed 
twice  with  750  µl  1x  incubation  buffer  (1  min/3,300 g/RT).  The  pellet  was 
resuspended in 30-100 µl  elution buffer  and incubated for 20 minutes  with slow 
overhead  rotation  at  room  temperature.  After  a  final  centrifugation  step 
(1 min/3,300 g/RT) the supernatant was transferred to a fresh microcentrifuge tube.
2.2.5.2 FPLC-based IMAC
Following  centrifugation,  cell-free  supernatants  were  blended  with  4x incubation 
buffer  (pH 7.4)  and filter  sterilised.  An XK16 column (Amersham/GE Healthcare) 
containing 5 ml Talon Superflow resin (Clontech/Takara) was allowed to equilibrate 
to  room temperature and connected to the FPLC system.  Pump wash steps were 
applied whenever the buffer had to be changed. The column was equilibrated with 
10 column volumes of 1x incubation buffer with a flow rate of 5 ml/min (which was 
applied throughout the whole purification). Following load of the supernatant, the 
column was washed with 10 column volumes of 1x incubation buffer.  Finally, the 
protein was eluted with elution buffer and the column was soaked with 20% (v/v) 
ethanol, disconnected, sealed and stored at 4°C.
A typical elution profile of Talon Superflow-based IMAC is depicted in Fig. 3.3.
2.2.5.3 FPLC-based rebuffering
For  rebuffering  a  protein  solution  to  PBS,  a  HiPrep  26/10  Desalting  column 
(Amersham Biosciences) was used. This gel filtration column is based on cross-linked 
dextran (Sephadex G-25 Fine), which forms micropores which can be entered by low 
molecular weight substances like salts but exclude high molecular weight substances 
like proteins. Thus proteins elute first and can be efficiently separated from the salt 
fraction which elutes later.
As the maximum volume to be loaded to the column was 15 ml, the protein solution 
had  to  be  concentrated  if  necessary.  For  this,  the  solution  was  transferred  to  a 
Vivaspin 6 ultrafiltration spin column (5 kDa MWCO; Sartorius) and concentrated by 
centrifugation at 3,800 g.
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Fig.  3.3: FPLC elution profile  of  HEK293T-derived  EGb-H22(scFv)  (2.2.4.2)  in  Talon Superflow-
based IMAC. Column volume 5 ml, flow rate 5 ml/min.
Fig. 3.4: Elution profile of HEK293T-derived EGb-H22(scFv) (2.2.4.2) rebuffered to PBS with HiPrep 
26/10 desalting column (GE Healthcare). The protein (blue) elutes first  in PBS, then 
conductivity (brown) increases as salts and imidazole elute. Flow rate 4 ml/min.
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The column was  connected only with its top end to the FPLC system. The bottom 
end was opened and not connected to the system to make a high flow rate possible 
for  equilibration.  After  having  set  the  alarm  pressure  value  to  0.15 MPa  (ÄKTA 
purifier: 0.35 MPa), the column was equilibrated with 60-70 ml PBS at a flow rate up 
to 12 ml/min (depending on the pressure). A syringe with an appropriate adapter 
was filled with the protein sample. Any air bubbles were removed completely. The 
lower end of the column was sealed, the syringe was connected with the upper end, 
the lower end was opened, and the sample was slowly applied manually. The lower 
end was sealed, the syringe was unscrewed, the upper and then the lower end were 
connected to the system. The flow rate was set to 4 ml/min. As can be seen in Fig. 3.4, 
the protein eluted directly and was collected immediately. When the protein peak (or 
plateau when rebuffering from 250 mM imidazole to PBS) had passed through and 
UV absorption started to  increase  again slowly,  salts  and/or  imidazole elute.  The 
flow rate was increased to 5-6 ml/min. When the salt/imidazole peak had passed 
through,  the  column  was  soaked  with  60-70 ml  20% (v/v)  ethanol,  disconnected, 
sealed and stored at 4°C.
2.2.5.4 Enterokinase cleavage
To generate a free N-terminus of Granzyme B, an enterokinase digest was performed 
after  rebuffering.  To  reduce  the  volume  of  the  protein  solution  (2.2.5.3),  it  was 
concentrated with a  Vivaspin 6 ultrafiltration spin column (5 kDa MWCO; Sartorius) 
by centrifugation at  3,800 g.  The solution was filter  sterilised,  combined with the 
appropriate  amount  of  recombinant  enterokinase  (Novagen/Merck)  depending  on 
the expected amount of protein and incubated over night at room temperature on an 
overhead tilt shaker.
2.2.5.5 FPLC-based cation exchange chromatography
As  the  isoelectric  point  (pI)  of  Gb-H22(scFv)  is  positive  (9.37  according  to  the 
software Clone Manager Professional Suite Version 8), it was possible to perform the 
final  purification  by  cation  exchange  chromatography  (CEX).  The  following 
procedure was adapted and optimised for Gb-H22(scFv) in PBS (137 mM NaCl).
A HiTrap SP HP 1 ml column (Amersham Biosciences) was connected to the FPLC 
system. First, pump B was washed with PBS containing 1 M NaCl, then pump A was 
washed  with  normal  PBS  (137  mM NaCl).  The  alarm  pressure  value  was  set  to 
0.3 MPa  (ÄKTA  purifier:  0.5  MPa).  At  a flow  rate  of  2 ml/min,  which  was  the 
maximum flow rate for this column, the column was equilibrated with PBS (137 mM 
NaCl). The bottom end of the column was sealed, and the protein sample was loaded 
with a syringe as described in 2.2.5.3.
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Fig. 3.5: Typical FPLC elution profiles of HEK293T-derived Gb-H22(scFv) (2.2.4.2) obtained during 
cation exchange chromatography (CEX) with a HiTrap SP HP 1 ml column (Amersham 
Biosciences). Flow rate 2 ml/min. A: Stepwise salt gradient to evaluate wash and elution 
conditions, B: final setup. Blue: UV (protein), brown: conductivity (salts).
A
B
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When the column was connected again, the flow rate was set to 0.8 ml/min. Then the 
salt concentration was either increased stepwise or, in the final setup, the column 
was washed with (150-)300 mM NaCl (18.9% B), and elution was carried out with 
(300-)500  mM  NaCl  (42.1%  B).  Following  elution,  the  salt  concentration  was 
increased to 1-2 M NaCl (100% B). Optionally, the column was regenerated with 1 M 
NaOH, neutralised with PBS (137 mM NaCl) and stored in 20% (v/v) EtOH at 4°C.
Corresponding FPLC elution profiles are depicted in Fig. 3.5.
2.2.5.6 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Discontinuous  SDS-PAGE  was  performed  for  the  separation  of  proteins.  10-
12% (w/v)  SDS  gels  were  used.  The  Prestained  Protein  Marker  (NEB)  served  as 
protein fragment size standard. Following electrophoresis, proteins in the gel were 
visualised by staining with Coomassie staining solution (2.1.2) and destaining the 
background either by over night incubation on a tilt shaker in Coomassie destaining 
solution (2.1.2) or by three cycles of cooking the gel in fresh water for 1 min and 
incubation for 15-30 min on a tilt shaker.
Tab. 2.12: Composition of SDS-PAGE gels. The total volume was 5 ml per separating gel and 1.5 ml 
per stacking gel.
Gel part Component Volume concentration
Separating gel 
(10% (w/v) 
acrylamide)
Acrylamide/Bisacrylamide (30:1% w/v)
1 M Tris (pH 8.8)
SDS (10% w/v)
TEMED
APS (20% w/v)
33.3
37.5
1   
0.1
0.3
% (v/v)
% (v/v)
% (v/v)
% (v/v) 
% (v/v)
Separating gel 
(12% (w/v) 
acrylamide)
Acrylamide/Bisacrylamide (30:1% w/v)
1 M Tris (pH 8.8)
SDS (10% w/v)
TEMED
APS (20% w/v)
40
37.5
1   
0.1
0.3
% (v/v)
% (v/v)
% (v/v)
% (v/v) 
% (v/v)
Stacking gel Acrylamide/Bisacrylamide (30:1% w/v)
1 M Tris (pH 6.8)
SDS  (10% w/v)
TEMED
APS (20% w/v)
13
12.5
1 
0.1
0.5 
% (v/v)
% (v/v)
% (v/v)
% (v/v)
% (v/v)
2.2.5.7 Western Blot
The Western Blot was performed using the Mini Trans-Blot® Electrophoretic Transfer 
Cell  (BIO-RAD)  according  to  the  manufacturer's  instructions  with  transfer  buffer 
(2.1.2). A nitrocellulose transfer membrane (Protran from Whatman) was used. After 
the transfer (100 V/1 h) of proteins separated by SDS-PAGE (2.2.5.6), the membrane 
was first washed for 10 min in PBST, then blocked with 1% (w/v) BSA in PBS either 
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for 1 h at room temperature or over night at 4°C. After three times washing with 
PBST, the membrane was incubated with the primary antibody in PBS for 30 min. 
The same procedure was done for incubation with the secondary antibody. After 
final washing (two times in PBST and one time in AP buffer) the membrane was 
developed  in  the  dark  with  NBT/BCIP  [3.33%  (w/v)  NBT,  1.67%  (w/v)  BCIP  in 
dimethylformamide] added to the 100x volume of AP buffer. Finally the membrane 
was rinsed in water and dried.
2.2.5.8 Protein quantification 
The concentration of protein solutions was determined in a Bradford assay in a 96-
well plate using 1x Roti-Nanoquant (Roth). All samples were pipetted in triplicates. 
As calibration standard a stock solution with 1 µg/µl purified bovine serum albumin 
(BSA) was used (0, 0.5, 1, 2, 3, 4, 5, 6, 7 µg/well). 200 µl Roti-Nanoquant were added 
per well. Absorption was measured at 595 or 630 nm in a microplate reader. Data 
were analysed with MS Office Excel software, and the total protein concentration of 
the samples was determined according to the BSA standard curve.
To determine the concentration of the protein of interest, purity was calculated after 
SDS-PAGE and Coomassie staining using  AIDA Image Analyzer Software (Raytest 
Isotopenmessgeräte) in the way that the ratio of the band of interest to the sum of all 
bands in the lane was determined.
2.2.6 Evaluation of protein functionality
2.2.6.1 Cell culture of cancer cell lines
All cancer cell lines (2.1.6) were cultured in RPMI complex medium (2.1.2) at 37°C in 
a humidified atmosphere of 5% CO2 for up to three months. After this period, a fresh 
cryo aliquot of cells was thawed and taken into culture.
For the majority of cancer cell lines, passaging to a cell concentration of 1x105 cells/ml 
was carried  out  twice  a  week  (exceptions:  HL60  and L540cy passaged to  0.5x105 
cells/ml).  Whenever  the  cell  concentration  exceeded  2x106 cells/ml,  cells  were 
discarded   and  replaced  by  freshly  thawed  cells.  Cell  concentrations  were 
determined using a CASY Cell Counter (Schärfe System) equipped with a 150 µm 
capillary.  50  µl  cells  were  suspended  in  10  ml  CASY  Ton  (Schärfe  System)  and 
concentration was measured.
If not otherwise stated, myeloid cell lines and primary myeloid cells were stimulated 
with IFN-γ prior to use. Especially for U937 cells, the stimulation conditions were 
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optimised specifically (3.6). In the setup applied for most assays, cells were passaged 
to a concentration of  1x105 cells/ml and human IFN-γ (Sigma) was added to a final 
concentration  of  500  U/ml  (or  1000  U/ml  with  IFN-γ  from  ImmunoTools). 
Subsequent assays were started 6-24 h after addition of IFN-γ.
2.2.6.2 Cell culture of primary cells
Mononuclear cells were isolated by density gradient centrifugation. For this, a buffy 
coat (or full blood, respectively) was diluted 1:2 with serum-free RPMI 1640 medium 
or PBS (both Gibco/Invitrogen). 50 ml falcon tubes were filled with 12.5 ml Ficoll-
Paque PLUS (GE Healthcare).  The Ficoll was overlayed very carefully and slowly 
with max. 30 ml of the diluted buffy coat. The tube was centrifuged in a Multifuge 3 
S-R centrifuge (Heraeus) at 400 g without break (“3”) and with slowest acceleration 
(“1”), which can be increased stepwise (5 g → “2”, 20 g → “3”, 30 g → “4”). Following 
centrifugation (Fig. 3.6), the plasma layer was removed first. Then the PBMC layer 
was transferred to a clean tube. Cells were spun down at 250-350 g for 5-10 min at RT 
and washed two times with 10 ml serum-free medium or PBS.  Finally cells  were 
transferred to RPMI 1640 medium containing 5-10% (v/v) FCS and cultured at 37°C 
in  a  humidified  atmosphere  of  5%  CO2.  In  case  of  cells  from  a  healthy  donor, 
monocytic cells were selected by plastic adherence in a petri dish.
If desired, stimulation was carried out with 500 U/ml IFN-γ (Sigma) 6-24 h prior to 
the respective assay.
plasma
mononuclear cells
Ficoll -Paque PLUS
erythrocytes /granulocytes /dead cells
Fig. 3.6: Primary cells after Ficoll density gradient centrifugation. Thanks to F. Kampmeier for holding 
the tube.
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2.2.6.3 Protease assay
The proteolytic activity of IMAC-purified (E)Gb-H22(scFv) (2.2.5.2) was compared 
with  that  of  free  Granzyme  B  (recombinant  from  E.  coli,  Calbiochem/Merck)  by 
cleavage  of  Ac-IETD-pNA  (Granzyme  B  Substrate  I,  colorimetric; 
Calbiochem/Merck),  a  synthetic  substrate  mimicking  the  cleavage  site  of 
procaspase-3. The protein solution and Gb assay buffer were combined to a volume 
of 100 µl/well in a 96-well plate. Samples were pipetted in triplicate. The reaction was 
started by adding Ac-IETD-pNA to a final concentration of 200 µM. Absorbance at 
405 nm was monitored in a microplate reader at 5 min intervals for 1 h.
Granzyme B and Gb assay buffer were stored at -80°C, the Gb substrate was stored at 
-20°C.
2.2.6.4 Flow cytometry
To evaluate the cell binding activity of any protein by flow cytometry, 2-4x105 cells 
were  washed  with  PBS  in  a  cell  washer  (Dade  Serocent,  Baxter)  and  optionally 
incubated for 30 min on ice with 1 µg protein in 50 µl PBS, 1 µl primary antibody in 
PBS or 500 µl cell culture supernatant. After another washing step, cells were treated 
with the detection antibody for 30 min on ice. After removing nonspecifically bound 
antibodies  by  washing,  cells  were  analysed  on  a  FACSCalibur  flow  cytometer 
(Becton Dickinson).
In case of detection of the surface receptor CD64 by an anti-CD64 antibody in order 
to compare stimulated and unstimulated cells,  the obtained shifts were related to 
each  other  by  calculating  the  ratio  of  the  geometric  mean  fluorescence  intensity 
(GMFI) of stimulated cells vs. the GMFI of unstimulated cells.
2.2.6.5 Cell viability assay
The  cytotoxic  effect  of  IMAC/CEX-purified  Gb-H22(scFv)  (2.2.5.2-2.2.5.5)  was 
monitored  by  bioreduction  of  MTS  to  a  colored  formazan  product  by  reduction 
equivalents generated by dehydrogenase enzymes of metabolically active cells. The 
quantity  of  formazan  product  as  measured  by  absorbance  at  490  nm  is  directly 
proportional to the number of living cells. 1:5 dilutions of Gb-H22(scFv) samples in 
RPMI  complex  medium  were  pipetted  into  a  96-well  plate  in  triplicates.  Wells 
containing  zeocin  (Invitrogen;  final  concentration  2 mg/ml)  or  PBS  were  used  as 
positive and negative controls, respectively. 5,000 cells were seeded out to each well. 
Following an incubation period of 72 h at 37°C, 100% humidity, and 5% CO2, 20 µl 
Cell Titer AQueous One Solution (Promega) was added per well. Measurement was 
carried out after 4 h at 490 nm against a reference wavelength of 630 nm using a 
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microplate  reader.  Gb-H22(scFv)  concentration-dependent  viability  of  cells  in 
relation to PBS and zeocin controls was calculated with GraphPad Prism software 
and  displayed  by  a  nonlinear  regression  sigmoidal  dose-response  curve  with 
variable slope.
2.2.6.6 Annexin A5 apoptosis assay
One of the hallmarks of apoptosis is the exposure of phosphatidylserine to the outer 
leaflet  of  the  cell  membrane.  Annexin  A5  is  a  protein  which  specifically  binds 
phosphatidylserine.  Fused  to  a  fluorescent  marker  like  eGFP,  Annexin  A5  can 
indicate  the presence of   phosphatidylserine on cell  surfaces  for example in flow 
cytometry applications.
To initiate apoptosis, 5x105 cells in 1 ml RPMI complex medium were seeded out per 
well of a 12-well plate and incubated with 150-240 nM Gb-H22(scFv) at 37°C, 100% 
humidity,  and 5% CO2.  Aliquots  of  cells  were  taken at  different  time points  and 
washed with PBS  in  the cell  washer  (Dade Serocent,  Baxter).  The  cell  pellet  was 
resuspended in 450 µl cell-free culture supernatants from HEK293T cells transfected 
with  a  pMS  vector  encoding  Annexin  A5-enhanced  green  fluorescent  protein 
(Stocker, 2008 #126), freshly supplemented with 5 µg/ml PI,  and 50 µl 10x Annexin 
A5 binding buffer, incubated at 4°C for 10-15 min, and analysed by flow cytometry.
2.2.6.7 JC-1 based detection of mitochondrial depolarisation
JC-1 is a cationic dye exhibiting potential-dependent accumulation in mitochondria. 
In  intact  mitochondria  JC-1  accumulates  in  red-fluorescent  J-aggregates,  whereas 
upon depolarisation JC-1 leaks out stronger to the cytosol, where it is present in a 
green-fluorescent monomeric form.
Apoptosis  was  induced  in  the  same manner  as  described  in  2.2.6.6.  At  different 
points  of  time,  500  µl  of  cells  were  mixed  with  5  µl  JC-1  (Promega)  by  short 
vortexing. Following a 10 min incubation at 37°C, 100% humidity, and 5% CO2, cells 
were analysed by flow cytometry using proper compensation.
2.2.6.8 Detection of active caspase-3
The  generation  of  active  caspase-3  by  cleavage  of  the  procaspase-3  zymogen  by 
Granzyme B was monitored using Human Active Caspase-3 CBA (BD Biosciences). 
Briefly, 5x105 cells in 1 ml RPMI complex medium were incubated with 150 nM Gb-
H22(scFv) for 24 h at 37°C, 100% humidity, and 5% CO2. After two washes with PBS 
in the cell washer (Dade Serocent, Baxter), the cells were incubated on ice in 250 µl 
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lysis buffer for 30 min while vortexing every 10 min. Cellular debris was pelleted by 
centrifugation. Clear cell lysate (50 µl) was added to 50 µl human caspase-3 capture 
beads and 50 µl human active caspase-3 PE detection reagent and incubated for 4 h at 
room  temperature  in  the  dark.  After  another  washing  step,  the  bead  pellet  was 
resuspended in 300 µl wash buffer and analysed by flow cytometry.
In apoptotic primary cells,  active caspase-3 was detected by confocal microscopy. 
3x105 cells were seeded into every well of a 12-well plate and incubated with 480 nM 
Gb-H22(scFv), 9.1 µM camptothecin or PBS. At different time points cells were co-
stained with αGb-PE (ImmunoTools) and αCasp3-FITC (BD Biosciences Pharmingen; 
taken from FITC-conjugated monoclonal active caspase-3 antibody apoptosis kit I) 
according  to  the  kit's  instructions  with  slight  modifications.  Briefly,  cells  were 
transferred to FACS tubes, washed twice with PBS in the cell washer (Dade Serocent, 
Baxter),  resuspended  in  Cytofix/Cytoperm  solution  at  a  concentration  of  1x106 
cells/0.5 ml, and incubated on ice for 20 min. After pelleting cells in the cell washer 
without any wash cycle,  Cytofix/Cytoperm solution was aspirated and discarded. 
Cells were twice washed manually with Perm/Wash buffer at a volume of 0.5 ml 
buffer/1x106 cells at room temperature. Then each sample was incubated with 10 µl 
αCasp3-FITC  and  2  µl  αGb-PE  in  50 µl  Perm/Wash  buffer  for  30  min  at  room 
temperature. Finally, each sample was washed manually in 1 ml Perm/Wash buffer, 
resuspended in Perm/Wash buffer and analysed by confocal microscopy (Leica DM 
RE + TCS SP confocal laser microscope (Leica)).
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3 Results
3.1 Sensitivity testing of target cell line
3.1.1 Cloning of pMS vectors for cytosolic expression of Granzyme B
To  obtain  a  plasmid  encoding  active  Granzyme  B  for  cytosolic  expression,  the 
sequence of mature Granzyme B was amplified (2.2.1.8) from pMS-LKGbII using the 
primers Gbfor and Gb+BlpI+EcoRIrev (2.1.5), introducing restriction sites for  NheI, 
BlpI, and  EcoRI. The 721 bp PCR product as well as the target vector pMS-LKGbII 
were restricted with NheI and EcoRI (2.1.4, 2.2.1.3) and ligated (2.2.1.5) to yield pMS-
Gb.  A  control  pMS  vector  encoding  H22(scFv)  (pMS-H22)  was  constructed  in  a 
similar manner using pMT-H22ETA' as the template but lacking a BlpI restriction site 
(primers  H22+NheIfor  and  H22+EcoRIrev).  The  resulting  constructs  were 
transformed by heat shock into E. coli DH5α (2.1.6, 2.2.1.7). Five clones were  checked 
for presence of the insert by plasmid preparation (2.2.1.1) and restriction digest with 
PstI  (pMS-Gb)  or  PvuII  (pMS-H22).  The  DNA  of  one  positive  clone  each  was 
sequenced (2.2.1.9) in the exchanged region using the primers T7prom, IVSrev and 
primer3 and turned out to be identical to the expected sequence in both cases.
Fig. 3.7 gives a schematic summary of the cloning of both constructs.
Fig.  3.7: Schematic  overview  of  the  cloning  procedure  of  pMS-Gb  and  pMS-H22.  The  DNA 
sequences encoding Granzyme B and H22(scFv) were amplified by PCR (2.2.1.8) with 
primers adding restriction sites for NheI and EcoRI. After restriction (2.2.1.3) with these 
enzymes, the PCR fragments were cloned into the backbone of pMS-LKGbII.  IRES: 
synthetic intron and internal  ribosome entry site,  eGFP: enhanced green fluorescent 
protein.
Results 51
3.1.2 Transfection of U937 cells
To determine whether Granzyme B could induce apoptosis  in U937 cells, the cells 
were nucleofected with pMS-Gb. pMS-H22, pMAXGfp (Amaxa) and plasmid elution 
buffer EB (Qiagen) without DNA served as controls. Following an incubation period 
of  24  h,  PI  staining and fluorescence-activated cell  sorting analysis  revealed  69% 
mortality in Granzyme B transfected cells, whereas negative control cells transfected 
without  DNA  showed  only  19%  mortality  (Fig.  3.8).  Control  plasmids  encoding 
H22(scFv) or GFP (pMAXGFP; Amaxa) each caused 28% mortality (data not shown).
Fig.  3.8: Sensitivity of U937 cells towards cytosolically expressed Granzyme B. Flow cytometric 
analysis (2.2.6.4) of PI-stained U937 cells 24 h after transfection. Left: cells transfected 
without DNA, right: cells transfected with pMS-Gb.
3.2 Construction and expression of EGb-H22(scFv)
3.2.1 Expression system E. coli  
3.2.1.1 Cloning of pET26b(+)LEGbH22IV
In  analogy  to  the  cloning  of  pMS-LEGbH22IV,  pET26b(+)LEGbH22IV  was 
constructed  by  the  exchange  of  Ki4(scFv)  in  pET26b(+)LEGbKIV  with  H22(scFv) 
derived  from  pMS-LGfpH22III.  A  schematic  overview  of  the  construction  of 
pET26b(+)LEGbH22IV is presented in Fig. 3.9.
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Fig.  3.9: Schematic  overview of  the cloning procedure of  pET26b(+)LEGbH22IV.  The Ki4(scFv) 
sequence of pET26b(+)LEGbKIV was exchanged with H22(scFv) via SfiI/NotI digestion 
(2.2.1.3).  pelB:  signal  sequence  for  periplasmic  localisation,  ECS:  enterokinase 
cleavage site, H: 6x histidine tag.
Briefly, the SfiI/NotI digested DNA fragments (pET26b(+)LEGb: 6075 bp, H22: 838 bp) 
were purified, ligated and transformed by heat shock into  E. coli  XL1-Blue (2.2.1.3-
2.2.1.7). The plasmid DNA of four clones was checked for the presence of the insert 
in a restriction digest with  EcoNI (2.2.1.3). Two of the clones showed the expected 
restriction pattern. A subsequent sequencing analysis (2.2.1.9) of one of the positive 
clones using the primer T7term (2.1.5) confirmed the integrity of the DNA sequence. 
Heat shock competent  E.coli Rosetta were transformed with the construct  (2.2.1.6, 
2.2.1.7).  The  DNA of  five  of  these  clones  was  restricted  with  EcoNI (2.2.1.3).  As 
expected,  the correct  band pattern occurred (besides  additional  bands due to  the 
pRARE²  plasmid,  cf.  2.1.6).  To finally  confirm the  identity  of  one of  the  positive 
clones, DNA was subjected to a sequencing analysis with T7term (2.1.5, 2.2.1.9) and 
turned out to be correct.
3.2.1.2 Expression of EGb-H22(scFv) in E. coli
EGb-H22(scFv) was expressed in  E. coli  Rosetta  under osmotic stress conditions as 
described in 2.2.2.1. Furthermore, H22(scFv) was expressed in E. coli BL21(DE3) as a 
control construct (vector: pMT-H22scFv). The cells of both cultures were lysed with 
CelLytic Express (2.2.2.1). The supernatants were purified using Ni-NTA (2.2.5.1).
As  Fig.  3.10 shows,  H22(scFv),  but  not  EGb-H22(scFv),  could  be  expressed  and 
purified successfully.  EGb-H22(scFv) was only expressed in HEK293T cells, which 
was done in parallel (3.2.2.2) and is documented by the 61.2 kDa bands in the same 
gel. The band from the bacterial expression, which should be 5 kDa smaller due to 
the missing glycosylation, could not be seen.
As expression of EGb-H22(scFv) was successful in HEK293T cells (3.2.2.2), bacterial 
expression was not pursued further.
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Fig. 3.10: Coomassie-stained SDS gel (2.2.5.6; A) and Western Blot (2.2.5.7; B) of different elution 
fractions of EGb-H22(scFv) and H22(scFv). 1-3: EGb-H22(scFv) expressed in HEK293T 
cells; 4-5: EGb-H22(scFv) expressed in  E. coli  Rosetta; 6: H22(scFv) expressed in  E. 
coli BL21(DE3). Antibodies used in Western Blot (2.2.5.7): αHis, GαM-AP (2.1.3).
3.2.2 Expression system mammalian cells
3.2.2.1 Cloning of pMS-LEGbH22IV
In  order  to  generate  pMS-LEGbH22IV,  in  the  eukaryotic  expression  vector  pMS-
LEGbKIV the DNA sequence encoding the CD30-targeting binding domain Ki4(scFv) 
was exchanged with the one of CD64-targeting H22(scFv). A schematic overview of 
the construction of pMS-LEGbH22IV is presented in Fig. 3.11.
Fig.  3.11: Schematic  overview  of  the  cloning  procedure  of  pMS-LEGbH22IV.  The  Ki4(scFv) 
sequence  of  pMS-LEGbKIV  was  exchanged  with  H22(scFv)  via  SfiI/NotI  digestion 
(2.2.1.3).  Ig-κ:  signal  peptide  sequence  of  immunoglobulin  kappa  light  chain  for 
secretion, ECS: enterokinase cleavage site, H: 6x histidine tag, IRES: synthetic intron 
and internal ribosome entry site, eGFP: enhanced green fluorescent protein.
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Briefly,  pMS-LEGbKIV  and  pMS-LGfpH22III  were  restricted  with  SfiI  and  NotI 
(2.2.1.3).  Following  agarose  gel  electrophoresis  (2.2.1.4),  the  vector  backbone 
fragment  of  pMS-LEGbKIV  (7423  bp)  and  the  H22(scFv)  fragment  from  pMS-
LGfpH22III (838 bp) were excised from the gel, purified and ligated (2.2.1.5).  The 
resulting construct was transformed by heat shock into E. coli XL1-Blue (2.2.1.7). Six 
of  the  obtained  clones  were  checked  for  presence  of  the  insert  by  plasmid 
preparation (2.2.1.1) and restriction digest with  SacI (2.2.1.3). Five of the six clones 
turned out to be positive. The DNA of two of the positive clones was sequenced in 
the exchanged region using the primer his-back (2.1.5,  2.2.1.9) and turned out to be 
identical to the expected sequence.
3.2.2.2 Expression of EGb-H22(scFv) in HEK293T cells
HEK293T cells were transfected with pMS-LEGbH22IV as described in 2.2.4.2. Three 
days  after  transfection,  the  successful  expression  of  EGb-H22(scFv)  could  be 
monitored on the one hand by flow cytometric analysis of cell culture supernatants 
(cf. comparison with CHO cells in  Fig. 3.16), and on the other hand by the green 
fluorescence of transfected cells (Fig. 3.12) due to the co-expression of eGFP, which is 
transcribed together with EGbH22 as one bicistronic mRNA.
20 µm
Fig. 3.12: HEK293T cells (2.1.6) transfected with pMS-LEGbH22IV (2.1.8) fluoresce brightly green 
due to bicistronic co-expression of eGFP.
A protein midipreparation (2.2.5.1) was performed with the cell culture supernatant. 
The  resulting  elution  fractions  were  compared  to  elution  fractions  from bacterial 
expression by SDS-PAGE and Western Blot. In contrast to the bacterial fractions, the 
HEK293T-derived  fractions  showed  a  band  in  the  expected  size  (Coomassie 
gel/Western Blot see  Fig. 3.10).  According to the DNA Star software,  the secreted 
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protein has a size of 56.2 kDa. However, Granzyme B is glycosylated at two different 
sites (Schmid & Weissmann, 1987; Griffiths & Isaaz, 1993), which add a molecular 
weight of about 5 kDa in total (Griffiths & Isaaz, 1993).  Thus the total  molecular 
weight of EGb-H22(scFv) is 61.2 kDa (Gb-H22(scFv): 60.0 kDa).
In  order  to  reduce  contaminating  proteins  still  present  after  IMAC  purification, 
different serum-free media were evaluated (Fig. 3.13). First, serum-free  RPMI  1640 
plus  Gluta-MAX-I  (Gibco/Invitrogen)  was  tested.  However,  as  cells  survived  but 
proliferated  only  very  slowly,  and thus  produced  markedly  less  protein  in  time, 
other  serum-free  media  moved  into  the  focus  of  interest,  of  which  one  was 
SFMHEK293 (HyClone). Although this medium was especially intended for use with 
HEK293 cells, the target protein yield was even lower than with RPMI medium. In 
contrast to that, two other media proved to be equally efficient compared with RPMI 
complex  medium:  HL1  medium  (BioWhittaker/Cambrex/Lonza)  and  FreeStyle293 
medium (Invitrogen). HL1 medium was selected for further serum-free expression. 
Cells could be passaged to that medium directly (i.e. without gradual reduction of 
the  serum  concentration)  and  cells  continued  to  proliferate  and  produce  EGb-
H22(scFv) unchanged for up to two weeks in that medium. This was documented by 
FACS analysis as well (data not shown).
For  both  RPMI  complex  medium  and  serum-free  HL-1  medium,  the  yield  of 
HEK293T cells expressing Gb-H22(scFv) was about 1 mg/l.
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Fig. 3.13: Coomassie-stained SDS gels (2.2.5.6) with Talon-purified EGb-H22(scFv) from HEK293T 
cells (2.1.6) cultured in different media. M: Prestained Protein Marker (NEB), 1: RPMI 
complex  medium  (Gibco)  supplemented  with  10%  (v/v)  FCS,  2:  serum-free  RPMI 
medium  (Gibco),  3:  SFM4HEK293  medium  (HyClone),  4:  HL1  medium 
(BioWhittaker/Cambrex), 5: FreeStyle293 medium (Invitrogen).
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3.2.2.3 Fermentation of HEK293T cells
In  order  to  scale  up  HEK293T  expression  of  EGb-H22(scFv)  to  a  stirred  tank 
fermentation system, Cytodex 1 microcarrier beads (GE Healthcare) were prepared 
in the first setup. Briefly, according to the manufacturer's instructions 5 g beads were 
equilibrated  in  PBS,  autoclaved,  and pre-incubated  with  RPMI  complex  medium 
containing 2.5% (v/v) FCS. Then 1x108 HEK293T cells were added. The medium was 
adjusted to ~250 ml, i.e. a final cell concentration of 4x105 cells/ml was reached. Beads 
and cells were transferred to the fermenter. The head room was flushed with air or 
CO2 depending on pH of the medium. Shortly after transfer of cells and beads, the 
medium was sparged once with  CO2 as it had become basic during the preparation 
procedure. For several hours, a 45 min rest phase was alternated with 1 min stirring 
at 30 rpm, then stirring was continued with 30 rpm.
As  Fig.  3.14 reveals,  in  principle  HEK293T  cells  do  grow  on  Cytodex  1  beads, 
however, the initial cell attachment phase in which beads should be colonised was 
obviously inefficient,  and/or  cell  attachment  was not robust  enough to withstand 
shear forces during transfer of beads to the fermenter. In addition, it is known that on 
the outside of the carriers, the cells are sheared off due to bead-to-bead collisions in 
the stirred tanks (GE Healthcare, 2006).
Fig. 3.14: Cytodex 1 beads (GE Healthcare) as microcarriers for HEK293T cells (2.1.6) expressing 
EGb-H22(scFv). Left panels: day 7, right panels: day 10 of the fermentation. Average 
size of the microcarriers: 190 µm.
For this reason microporous Cytopore 2 beads (GE Healthcare) were used in the next 
setup. Cells having colonised the pores of these microcarriers should be protected 
from the shear forces occurring during cell transfer and stirring.
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Therefore Cytopore 2 beads and HEK293T cells were prepared and fermentation was 
started as described in  2.2.4.5.  Samples of  beads and medium were  drawn every 
second or third day.
During the first week, a significant O2 consumption was recorded (data not shown). 
As the yellow colour on day 11 indicated the medium to be quite spent, 375 ml were 
replaced with 550 ml fresh medium. As again the next day the medium was yellow, 
the pH was regulated with 80 ml NaHCO3 (5.5% w/v). Fermentation was continued 
until day 20.  Fig. 3.15 shows the colonisation of Cytopore 2 beads with HEK293T 
cells on day 13.
Fig. 3.15: Cytopore 2 beads (GE Healthcare) as microcarriers for HEK293T cells (2.1.6) expressing 
EGb-H22(scFv).  Beads  were  transferred  to  1x  Perm/Wash  Buffer  (BD)  containing 
5 µg/ml  PI  to  stain  inherent  cells.  Left  panels:  bright  field  microscopy,  right  panels: 
fluorescence microscopy. Average size of the microcarriers: 230 µm.
An  SDS-PAGE  analysis  (2.2.5.6)  of  the  samples  drawn  and  subjected  to  protein 
minipreparation (2.2.5.1) revealed that the major amount of protein seemed to be 
generated in the first six days (data not shown), although the medium pH decreased 
as indicated by the yellow colour as recently as in the second week.
A significant increase of the volumetric productivity compared to conventional cell 
culture flask expression was not observed, however,  the total yield was increased 
proportionally due to the volume upscale (1 mg in 1 litre).
3.2.2.4 Expression of EGb-H22(scFv) in CHO cells
To evaluate another mammalian expression system, CHO-K1 cells were transfected 
with pMS-LEGbH22IV as described in 2.2.4.2. Another transfection of HEK293T cells 
was done in parallel with the same protocol and equal amounts of cells and DNA. 
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Three  days  after  transfection  cell  culture  supernatants  were  analysed  by  flow 
cytometry (2.2.6.4) for the presence of EGb-H22(scFv).
As  Fig. 3.16 shows, CHO-K1 cells do produce EGb-H22(scFv). However, as can be 
concluded from the markedly smaller shift, the yield is obviously much lower than 
with  HEK293T  cells.  A  protein  minipreparation  (2.2.5.1)  followed  by  protein 
quantification  (2.2.5.8)  confirmed  that,  showing  a  yield  of  about  0.15  µg/ml  cell 
culture supernatant. Therefore the main production of EGb-H22(scFv) was carried 
out with HEK293T cells further on.
Fig. 3.16: FACS analysis (2.2.6.4) of cell culture supernatants of CHO-K1 and different batches of 
HEK293T cells (2.1.6) transfected with pMS-LEGbH22IV (2.1.8). The pink and the light 
blue  curve  represent  supernatants  from cells  which  had  been  transfected  the  year 
before, the orange and the dark blue curve represent freshly transfected HEK293T and 
CHO cells.
3.2.2.5 Cloning of pcDNA5/FRT-LEGbH22IV
As expression  in  HEK293T cells  is  generally  considered  to  be  transient,  a  stable 
expression system with defined genomic integration sites for the gene of interest was 
tested as well. Using the Flp-In System (Invitrogen), at first the expression vector, in 
which the gene of  interest  is  flanked by a Flp recombination target  (FRT) site to 
facilitate integration into the FRT locus in the Flp-In host cell line, had to be cloned. A 
schematic overview of the construction of pcDNA5/FRT-LEGbH22IV is presented in 
Fig. 3.17.
Briefly,  the  target  vector  pcDNA5/FRT-LGfpH22III  and  pMS-LEGbH22IV  were 
restricted with NheI and PmeI (2.2.1.3). Following agarose gel electrophoresis (2.2.1.4), 
the vector backbone fragment of pcDNA5/FRT-LGfpH22III (4959 bp) and the desired 
fragment from pMS-LGfpH22III (3274 bp) were excised from the gel, purified and 
ligated (2.2.1.5).  The resulting construct was transformed by  heat shock into  E. coli  
DH5α (2.2.1.7). Five of the obtained clones were checked for presence of the insert by 
colony PCR (2.2.1.8) with the primers Gbfor and Gbrev (2.1.5). Four of the five clones 
turned out to be positive as they showed the correct PCR product of 715 bp. The 
DNA of one of the positive clones was further checked by restriction digest (2.2.1.3) 
Key Name Parameter Gate
U937 - -.001 FL2-H G1
U937 - αGbPE.002 FL2-H G1
U937 EGbH22-293Ta αGbPE.003 FL2-H G1
U937 EGbH22-293Tb αGbPE.004 FL2-H G1
U937 EGbH22-293T αGbPE.005 FL2-H G1
U937 EGbH22-CHOK1 αGbPE.006 FL2-H G1
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with HindIII and sequenced in the exchanged region using the primers CMVfor and 
BGHrev. The obtained sequences turned out to be identical to the expected sequence.
Fig.  3.17: Schematic overview of the cloning procedure of  pcDNA5/FRT-LEGbH22IV. The whole 
expression cassette in  pcDNA5/FRT-LGfpH22III  was exchanged by the one of pMS-
LEGbH22IV  via  digestion  with  NheI  and  PmeI  (2.2.1.3).  Ig-κ:  signal  sequence  of 
immunoglobulin kappa light chain for secretion, ECS: enterokinase cleavage site, H: 6x 
histidine tag, eGFP: enhanced green fluorescent protein.
3.2.2.6 Expression of EGb-H22(scFv) in FlpIn293 cells
In  order  to  obtain  cells  stably  expressing  EGb-H22(scFv),  FlpIn293  cells  were 
transfected with pcDNA5/FRT-LEGbH22IV and pOG44 as described in  2.2.4.3. The 
supernatants were tested for expression of EGb-H22(scFv) by flow cytometry (2.2.6.4) 
first.
As demonstrated in Fig. 3.18, the transfected FlpIn293 cells produced EGb-H22(scFv). 
However, as the smaller shifts indicated that FlpIn293 cells produced markedly less 
EGb-H22(scFv)  than  normal  293T  cells,  and  this  was  confirmed  by  protein 
minipreparation (2.2.5.1) and protein quantification (2.2.5.8) showing a yield of about 
0.1 µg/ml cell culture supernatant, culturing of FlpIn293 cells was discontinued.
Fig. 3.18: FACS analysis (2.2.6.4) with U937 
cells incubated with different cell 
culture  supernatants  containing 
EGb-H22(scFv).  Detection  of 
bound  protein  was  done  using 
αHis-Alexa488  (2.1.3).  Filled 
violet  curve:  cells  with  αHis-
Alexa488,  pink:  cells  with 
FlpIn293-derived  supernatants 
and  αHis-Alexa488, green: cells 
with  HEK293T-derived 
supernatants  and  αHis-
Alexa488.
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3.2.3 Expression system N. tabacum
Three different plant cell compartments were tested for expression of Gb-H22(scFv): 
apoplast,  endoplasmatic  reticulum  and  chloroplasts.  For  this,  the  Gb-H22(scFv) 
sequence,  which  had  been  codon-optimised  for  expression  in  N. tabacum  and 
synthesised by GenScript (8.2.1), was inserted into the respective pTRAkc vectors.
As cloning in the 5' region was accomplished with the EcoRI restriction site which 
precedes a 5' UTR followed by the respective leader peptide sequence, the 5' UTR, 
but  not  the  leader  peptide  sequences,  of  the  synthesised  DNA  regions  was 
maintained in the original sequence.
To  indicate  that  the  final  plasmids  contained  sequences  deviant  to  the  original 
sequences due to codon optimisation, the plasmids were given the name affix "opt".
3.2.3.1 Cloning of pTRAkc-GbH22opt-AH, -ERH and -CTP
A  schematic  overview  of  the  construction  of  the  final  plant  expression  vectors 
pTRAkc-GbH22opt-AH, -ERH and -CTP is presented in Fig. 3.19.
First,  pTRAkc-GbH22opt-AH and -ERH had to  be  generated.  For  this,  the  target 
vectors  pTRAkc-rfp-AH  and  -ERH  as  well  as  the  pUC57  vector  harbouring  the 
synthetic  GbH22 sequence preceded by the LPH signal  peptide sequence (8.2.1.1) 
were restricted with  EcoRI and  NotI (2.2.1.3). Following agarose gel electrophoresis 
(2.2.1.4),  the  vector  backbone  fragments  of  pTRAkc-rfp-AH  and -ERH (7537  and 
7555 bp) and the GbH22 fragment (1585 bp) were excised from the gel, purified and 
ligated (2.2.1.5). The resulting constructs were transformed by heat shock into E. coli  
XL1-blue (2.2.1.7, 2.1.6). At least three clones were checked for presence of the insert 
by colony PCR (2.2.1.8) with the primers PS-5' and PS-3' (2.1.5). The DNA of one of 
the positive clones, which showed a PCR fragment of 1740 bp (pTRAkc-GbH22opt-
AH)  or  1758  bp  (pTRAkc-GbH22opt-ERH),  respectively,  was  prepared  and 
sequenced in the exchanged region using the primers PS-5' and PS-3' (2.2.1.1, 2.2.1.9, 
2.1.5). The obtained sequences were identical to the expected sequence.
For cloning of pTRAkc-GbH22opt-CTP, pTRAkc-GbH22opt-AH as the target vector 
and the pUC57 vector harbouring the codon-optimised 5' sequence of Granzyme B 
preceded by the chloroplast transit peptide sequence (8.2.1.2) were restricted with 
EcoRI and  ApaI (2.2.1.3). Following agarose gel electrophoresis (2.2.1.4), the vector 
backbone fragment  of pTRAkc-GbH22opt-AH (8844 bp) and the GbH22 fragment 
(395  bp)  were excised  from  the  gel,  purified  and  ligated  (2.2.1.5).  The  resulting 
construct was transformed by heat shock into E. coli XL1-blue (2.2.1.7, 2.1.6). Of three 
clones plasmid DNA was isolated (2.2.1.1) and restricted with NheI and PstI (2.2.1.3) 
to check for the presence of the insert. The plasmid DNA of a positive clone was 
sequenced in the exchanged region using the primers PS-5' ans PS-3' (2.2.1.1, 2.2.1.9, 
2.1.5). The obtained sequences were identical to the expected sequences.
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Fig. 3.19: Schematic overview of the cloning procedure of pTRAkc-GbH22opt-ERH (1), -AH (2) and 
-CTP  (3).  5'UTR:  5'  untranslated  region  of  chalcone  synthase  from  Petroselinum 
hortense (Reimold  et al.,  1983),  LPH: murine N-terminal  signal  peptide sequence of 
mAb24 (Voss  et al., 1995), H: 6x histidine tag, K: SEKDEL ER retention signal, CTP: 
chloroplast  transit  peptide  of  small  subunit  of  RuBisCO  from  Solanum  tuberosum 
(Wolter et al., 1988).
3.2.3.2 Expression of Gb-H22(scFv) in N. tabacum
Following separate transformation of electrocompetent A. tumefaciens GV3101 (2.1.6) 
with the three pTRAkc-GbH22 constructs, three clones of each plate were subjected 
to colony PCR (2.2.1.8) using the primers PS-5' and PS-3'. All clones proved to be 
positive.
After  glycerol  stocks had been prepared (2.2.3.2),  liquid cultures  were  inoculated 
from the glycerol stocks and treated as described in 2.2.3.3. The same was done with 
agrobacteria transformed with the control construct pTRAkc-rfp-CTP encoding the 
fluorescent DsRed protein. Finally, leaf regions of three different tobacco plants were 
infiltrated with the agrobacteria (2.2.3.3).
In  all  three  plants,  leaf  regions  infiltrated  with  GbH22-AH  or  GbH22-ERH 
agrobacteria  developed  a  withered phenotype (Fig.  3.20).  In  contrast  to  that,  leaf 
regions infiltrated with GbH22-CTP or rfp-CTP agrobacteria remained viable.  The 
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fluorescence of DsRed could be seen using a fluorescence lamp and a red colour foil 
(2.2.3.3) as well as with the naked eye (Fig. 3.20).
Fig.  3.20: N. tabacum leaves of three different plants locally infiltrated with  A. tumefaciens (2.1.6) 
transformed with pTRAkc-GbH22opt-AH, -ERH, -CTP or pTRAkc-rfp-CTP. Photos taken 
three to seven days after infiltration. Right panels: Detection of DsRed fluorescence on 
day 7 using a fluorescence lamp and a red colour foil.
On day 3, 5 and 7 after infiltration leaf disks of the respective infiltrated areas and 
uninfiltrated areas as control were taken and homogenised with PBS on ice to yield 
crude extracts (2.2.3.3), which were analysed by flow cytometry (2.2.6.4), SDS-PAGE 
(2.2.5.6) and Western Blots (2.2.5.7).
In the FACS binding analysis, binding to MonoMac1 cells was indicated by a small 
shift observed with the day 3 raw extracts expected to contain Gb-H22opt-AH and 
-ERH,  whereas  the  Gb-H22opt-CTP extracts  and  the  extracts  from days  5  and  7 
showed no binding activity (Fig. 3.21).
In the SDS-PAGE/Western Blot analysis, in which αHis/GαM-AP and αGb/GαM-AP 
(2.1.3) were used as detection antibodies, no specific bands could be seen. The same 
was true for the eluate of a protein minipreparation (2.2.5.1) carried out with a raw 
extract from a Gb-H22opt-CTP leaf disk taken on day 11 (data not shown).
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Fig.  3.21: Binding analysis  (2.2.6.4)  of  raw extracts  of  N. tabacum leaves  locally  infiltrated with 
A. tumefaciens (2.1.6) transformed with pTRAkc-GbH22opt-AH, -ERH, or -CTP. Filled 
curve: MonoMac1 cells +  αHis-Alexa488, green: MonoMac1 + wild type raw extract + 
αHis-Alexa488, pink:  MonoMac1 + GbH22opt-AH raw extract  +  αHis-Alexa488, blue: 
MonoMac1  +  GbH22opt-ERH raw  extract  +  αHis-Alexa488,  orange:   MonoMac1  + 
GbH22opt-CTP raw extract + αHis-Alexa488.
3.2.4 Summary of expression of Gb-H22(scFv) in different expression systems
Five  different  expression  systems  (bacterial:  E.  coli Rosetta, plant:  N.  tabacum, 
mammalian: HEK293T, CHO-K1, FlpIn293) were tested for their ability to produce 
Gb-H22(scFv). The respective expression yields are summarised in Tab. 2.13.
Tab. 2.13: Expression yield of Gb-H22(scFv) produced in different expression systems (3.2.1-3.2.3). 
Yields from plant expression (3.2.3) marked with * mean that Gb-H22(scFv) has been 
weakly  detectable  in  a  FACS analysis  (2.2.6.4)  of  the  raw extracts  three  days  after 
infiltration (2.2.3.3), however, as producing plant cells rapidly underwent cell death, it was 
not possible to yield significant amounts of the protein.
Expression system Target compartment Yield
E. coli Rosetta periplasm 0 mg/l culture medium
HEK293T secretory pathway 1 mg/l culture medium
CHO-K1 secretory pathway 0.15 mg/l culture medium
FlpIn293 secretory pathway 0.1 mg/l culture medium
N. tabacum cv. Petit Havana SR1 apoplast 0 mg/kg leaf material*
N. tabacum cv. Petit Havana SR1 ER 0 mg/kg leaf material*
N. tabacum cv. Petit Havana SR1 chloroplasts 0 mg/kg leaf material
In terms of yield, the most efficient system for the expression of Gb-H22(scFv) turned 
out  to  be  HEK293T  cells.  About  1  mg/l  cell  culture  supernatant  was  obtained 
irrespective of the culture format (cell culture flasks, roller bottles, fermentation, cf. 
3.2.2.2, 3.2.2.3, 4.3.2), and both with serum-containing media (RPMI) and serum-free 
media  (HL1  and  FreeStyle293)  (3.2.2.2).  Compared  to  that,  the  expression  yields 
obtained with the alternative mammalian expression systems CHO-K1 and FlpIn293 
were up to one magnitude lower.
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As expression in HEK293T cells was successful from the very beginning, bacterial 
expression, which worked well with H22(scFv) but not with Gb-H22(scFv) (3.2.1.2), 
was not pursued further.
In contrast to the failed expression of Gb-H22(scFv) in the chloroplasts of N. tabacum, 
Gb-H22(scFv) was produced in the apoplast and ER of N. tabacum (3.2.3.2). However, 
the respective  leaf  areas  withered within few days.  Hence it  was  not possible  to 
extract utilisable amounts of Gb-H22(scFv).
In conclusion, Gb-H22(scFv) was continuously produced in HEK293T cells cultured 
in  cell  culture  flasks  to  obtain  protein  for  subsequent  functional  analyses.  In 
concordance with that, the purification strategy was optimised for HEK293T-derived 
cell culture supernatants as starting material.
3.3 Optimisation of the purification strategy
Several downstream processing steps to obtain active Gb-H22(scFv) from HEK293T 
cell culture supernatants had to be established and optimised separately and as well 
brought to an appropriate order. On the one hand IMAC was the method of choice to 
initially enrich the protein of interest.  On the other hand, in case of expression in 
serum-containing media, a second purification step was desired to yield the protein 
in high purity. Furthermore, enterokinase cleavage had to be performed to obtain 
fully active Gb-H22(scFv) featuring a free NH2 terminus. Between these three steps 
rebuffering to PBS was necessary to get rid of high imidazole or NaCl concentrations. 
In addition, for several applications the volume of the sample had to be reduced, i.e. 
a  concentration  step  had  to  be  introduced.  Finally,  the  appropriate  method  for 
storage had to be found.
3.3.1 First purification step (IMAC)
Immobilised metal affinity chromatography (IMAC) can be carried out using resins 
based on nickel ions (Ni-NTA) or cobalt ions (e.g. Talon). During this thesis, three 
different  IMAC  resins  were  tested:  Ni-NTA  agarose  (Qiagen),  Talon  Superflow 
(Clontech), and Chelating Sepharose Fast Flow (GE Healthcare) loaded with 50 mM 
CoCl2.  The purifications were carried out as described in chapter  2.2.5.2. With the 
analysis of the elution fractions by SDS-PAGE it became clear that the  Talon resin 
and the  Cobalt-loaded chelating sepharose  were  superior  to  Ni-NTA in  terms  of 
purity of the target protein, whereas the yield was comparable (data not shown).
As an alternative to IMAC in the first purification step, benzamidine sepharose was 
tested as well. The ligand,  p-aminobenzamidine, is an inhibitor of serine proteases 
and therefore should be able to bind Granzyme B. It is covalently linked to highly 
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cross-linked 4% agarose. This resin (Benzamidine Sepharose 4 Fast Flow (high sub), 
Amersham  Biosciences)  was  filled  into  an  XK16  column.  Briefly,  EGb-H22(scFv) 
supernatants were combined with 4x binding buffer (0.2 M Tris, 2 M NaCl, pH 7.4) 
and loaded to the resin. After washing with 1x binding buffer until a stable baseline 
was obtained, competitive elution was performed with 20 mM  p-aminobenzamidine 
in 1x binding buffer. However, analysis of elution fractions by SDS-PAGE revealed 
that protein binding to benzamidine sepharose is highly unspecific (data not shown).
Hence, in the final setup, IMAC was carried out as the first purification step using 
Talon Superflow as described in chapter 2.2.5.2.
3.3.2 Rebuffering to PBS/Reduction of sample volume
Different rebuffering methods were evaluated, which can be grouped as follows:
▪ Dialysis methods using 
- standard dialysis tubings (Roth)
- dialysis cassettes (Slide-A-Lyzer, Pierce)
- dialysis tubes (D-Tube Dialyzer Maxi MWCO 12-14 kDa, Novagen)
▪ Ultrafiltration methods using
- a solvent-resistant stirred cell (Millipore) with PES ultrafiltration 
  membrane filters (type 146, Ø 47 mm, 10 kDa MWCO, Sartorius)
- Centriprep centrifugal filter units 30 kDa MWCO (Millipore)
- Vivaspin 6 ultrafiltration spin column 5 kDa MWCO (Sartorius)
▪ FPLC-based method using
- HiPrep 26/10 desalting column (Amersham/GE Healthcare)
Among the dialysis  methods the dialysis  tubes  clearly  were  the most  convenient 
method in terms of handling. Furthermore the tubes could be stored in 20% (v/v) 
EtOH at 4°C and reused as often as desired. However, whenever the protein was 
very pure, e.g. after the second purification step or due to serum-free expression, it 
tended to precipitate. This problem occurred from time to time during any dialysis 
method as well as during ultrafiltration using the compressed-air chamber. For these 
reasons other ultrafiltration methods were tested.
As for all ultrafiltration methods several cycles of adding PBS and concentrating the 
sample are necessary,  these methods are relatively  time-consuming.  Furthermore, 
remainders of FCS gradually clog the membrane the more cycles are carried out. 
Thus these methods can be classified as inconvenient as well.
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Therefore (E)Gb-H22(scFv) was finally rebuffered by means of FPLC with the HiPrep 
26/10 desalting column as described in 2.2.5.3.
Whenever a reduction of the sample volume was necessary, Vivaspin columns were 
used as described in  2.2.5.3. This method was the most rapid and convenient one 
among the ultrafiltration methods. Furthermore, it was possible to store the columns 
with 20% (v/v) EtOH at 4°C to use them several times.
3.3.3 Enterokinase cleavage
As precipitation of Gb-H22(scFv) also occurred during enterokinase (EK) cleavage in 
case the protein was already pure, the cleavage was finally performed between the 
first and the second purification step. As an additional benefit it was possible to get 
rid of the enterokinase in the second purification step. Fig. 3.22 shows the results of 
enterokinase  cleavage  in  SDS-PAGE  and  Western  Blot.  The  slight  reduction  of 
protein size due to enterokinase cleavage is seen in the Coomassie-stained SDS gel. 
Whereas uncleaved protein yields a band in the Western Blot upon detection with 
the  αECS  antibody,  the  band  disappears  when  protein  was  digested  with 
enterokinase.
Fig.  3.22: SDS-PAGE  (2.2.5.6)  and  Western 
Blot  (2.2.5.7)  analysis  of 
enterokinase cleaved vs.  uncleaved 
Granzyme B-H22(scFv). All samples 
were purified by Talon-based IMAC 
(2.2.5.2)  before  incubation  with  or 
without  enterokinase  (2.2.5.4). 
Antibodies  used  in  Western  Blot: 
αECS/GαR-AP (2.1.3).  E1/G1:  EGb-
H22(scFv)  and  Gb-H22(scFv) 
purified  from  serum-containing  cell 
culture  supernatants;  E2/G2:  EGb-
H22(scFv)  and  Gb-H22(scFv) 
purified from serum-free cell  culture 
supernatants  (all  from  HEK293T 
cells).
3.3.4 Second purification step (CEX)
With the aim to yield the target protein in high purity, two strategies for the second 
purification step were tested first: Size exclusion chromatography using a Superdex 
75  10/200  GL column  (Amersham/GE  Healthcare),  and  the  depletion  of  albumin 
(which is the main component of the residual FCS still present after IMAC) using a 
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HiTrap Blue HP column (GE Healthcare) (both used according to the manufacturer's 
instructions).  However,  the  major  part  of  the  target  protein  was  lost  with  both 
methods.
Hence another  strategy for the secondary purification of  Gb-H22(scFv) had to be 
found. As the isoelectric  point (pI) of this protein is 9.37 (determined with Clone 
Manager  Professional  Suite  version 8  software),  cation exchange chromatography 
(CEX) using a HiTrap SP HP 1 ml column (GE Healthcare) was the method of choice. 
In the first setup, salt concentration was increased stepwise to find out the optimum 
conditions for washing and elution. Apart from the FPLC elution profile (Fig. 3.5 in 
chapter 2.2.5.5), SDS-PAGE analysis of the different fractions (Fig. 3.23) indicated that 
300 mM NaCl for washing and 500 mM NaCl for elution were appropriate, and thus 
were used in all following applications as desribed in 2.2.5.5.
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Fig.  3.23:  Establishment of cation exchange chromatography (2.2.5.5) to find appropriate elution 
conditions  for  Gb-H22(scFv)  (expressed  in  HEK293T  cells,  IMAC-purified  and 
enterokinase-digested).  SDS-PAGE  analysis  (2.2.5.6)  of  different  fractions.  M: 
Prestained Protein Marker (NEB), 1: load, 2: flowthrough, 3: wash (137 mM NaCl), 4: 
fractions 6-8 (0.2 M NaCl), 5: fractions 12-13 (0.3 M NaCl), 6: fraction 16 (0.4 M NaCl), 
7: fraction 17 (0.4 M NaCl), 8: fractions 18-22 (0.4 M NaCl), 9: fractions 25-26 (0.5 M 
NaCl), 10: fraction 29 (1 M NaCl), 11: fraction 30 (1 M NaCl), 12: fraction 35 (2 M NaCl).
3.3.5 Storage
Several  manufacturers  of recombinant Granzyme B supply the protein in PBS for 
storage at -80°C. Therefore, this method of storage was also tested for Gb-H22(scFv) 
and proved to  be  suitable  for  the  fusion protein  as  well.  Hence  the protein  was 
rebuffered to PBS following CEX.
As one supplier used a supplement of 10% (v/v) glycerol for storage, this was tested 
as well. However, glycerol turned out to interfere with cell viability in the toxicity 
assay, although it was diluted 1:10 in the highest protein concentration applied. Thus 
glycerol was not used further.
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Lyophilisation was tested as well, but it was not possible to completely resuspend 
the protein afterwards.
3.3.6 Final purification of Gb-H22(scFv)
Fig.  3.24 demonstrates  the  complete  (E)Gb-H22(scFv)  purification  and  activation 
process from IMAC to final desalting and concentration. Lane 12 represents the final 
sample which was aliquoted and stored at -80°C.
Fig.  3.24:  SDS-PAGE (2.2.5.6; A) and Western Blot (2.2.5.7; B) analysis of all obtained fractions 
throughout the whole downstream procedure to obtain HEK293T-derived Gb-H22(scFv). 
Antibodies (2.1.3) used for Western Blot: αHis/GαM-AP. 1: flowthrough (IMAC), 2: wash 
(IMAC),  3:  eluate  (IMAC),  4:  desalted  eluate,  5:  desalted  eluate  after  Vivaspin 
ultrafiltration  and  sterile  filtration,  6:  flowthrough  ultrafiltration,  7:  Gb-H22  (after  EK 
cleavage),  8:  flowthrough (CEX,  137 mM NaCl),  9:  wash (CEX, 300 mM NaCl),  10: 
eluate (CEX, 500 mM NaCl),  11:  desalted eluate, 12: desalted eluate after Vivaspin 
ultrafiltration and sterile filtration, 13: flowthrough ultrafiltration.
3.4 In  vitro and  ex vivo evaluation of  the functionality of  (E)Gb-
H22(scFv)
3.4.1 Proteolytic activity of Gb-H22(scFv)
The synthetic granzyme B substrate Ac-IETD-pNA, which mimics the cleavage and 
activation site of human procaspase-3, was used to determine the proteolytic activity 
(2.2.6.3) of enterokinase-cleaved Gb-H22(scFv) compared with the uncleaved EGb-
H22(scFv).  Equimolar  amounts  of  Gb-H22(scFv)  and  commercially  available 
Granzyme  B  showed  the  same  proteolytic  activity,  whereas  the  uncleaved  EGb-
H22(scFv) showed no reaction even when applied in 1,000-fold molar excess (Fig.
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3.25). Therefore,  Gb-H22(scFv) was the main protein of interest  for all subsequent 
assays, and EGb-H22(scFv) was only used occasionally for comparison purposes.
Fig.  3.25:  Cleavage  of  the  synthetic  Granzyme  B  substrate  Ac-IETD-pNA  (2.2.6.3)  by  EGb-
H22(scFv),  Gb-H22(scFv),  or  free  Granzyme  B  during  a  60  min  incubation  (free  Gb: 
7.84 nM equals 20 ng in a reaction volume of 100 µl). The release of pNA was monitored 
every 5 min by absorbance at 405 nm. Data show the results after 0, 30, and 60 min. 
Measurements were obtained in triplicate. Bars represent SD.
3.4.2 Flow cytometric analysis of binding
For  all  cell-based  assays,  stimulation  of  CD64+ cells  was  optimised  as  described 
separately in chapter 3.6.
In order to analyse the binding properties of Gb-H22(scFv), the purified protein was 
incubated with CD64+ U937 and CD64- Raji cells and subsequently with αGb-PE, then 
cells were analysed by flow cytometry (2.2.6.4). As shown in Fig. 3.26, the anticipated 
functionality of the single-chain antibody was confirmed. In contrast, no binding was 
observed to CD64- Raji cells, showing the specificity of the interaction.
The same results were obtained for purified EGb-H22(scFv) as well as for cell culture 
supernatants (data not shown).
Apart  from the main target  and the negative control  cell  line,  further  CD64+ and 
CD64- cell lines, which were all used unstimulated in this assay, were tested for the 
binding of Gb-H22(scFv) in the same manner (Fig. 3.27). As expected, CD64+ HL60, 
MonoMac1,  Thp1,  and  murine  IIA1.6  cells,  the  latter  ones  stably  transfected  to 
express human CD64, show binding of Gb-H22(scFv).  The CD64- cell  line L540cy 
shows no binding of Gb-H22(scFv), Jurkat cells show marginal binding, and DU-4475 
cells show a certain binding of Gb-H22(scFv). As all cell lines were checked for the 
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expression of CD64, and the results were as expected (data not shown), binding of 
Gb-H22(scFv) to DU-4475 and Jurkat cells is clearly unspecific.
U937 Raji
Fig. 3.26: Flow cytometric analysis (2.2.6.4) of CD64+ U937 and CD64- Raji cells. A: CD64 detection 
with αCD64-FITC (2.1.3). B: Binding of Gb-H22(scFv), detected with αGb-PE (2.1.3). 
Filled violet curve: untreated cells, turquiose: background control (cells + αGb-PE), red: 
protein sample (cells + Gb-H22(scFv) + αGb-PE).
Fig. 3.27: Flow cytometric analysis (2.2.6.4) of CD64+ HL60, MonoMac1, THP1, and IIA1.6 (stably 
transfected to  express human CD64),  and CD64- L540cy,  Jurkat  and DU4475 cells 
(2.1.6). Binding of Gb-H22(scFv) was detected with αGb-PE (2.1.3).
Results 71
3.4.3 Toxicity assays
The concentration-dependent cytotoxic effect of Gb-H22(scFv) was evaluated in an 
MTS-based  colorimetric  cell  proliferation  assay  (2.2.6.5)  using  CD64+ U937 
(stimulated with  500 U/ml  IFN-γ)  and CD64- Raji  cells.  After  a  3-day  incubation 
period with Gb-H22(scFv), the viability of U937 cells was dramatically reduced in a 
concentration-dependent  manner,  whereas  Raji  cells  remained  unaffected  (Fig.
3.28 A). IC50 values were between 1.7 and 17 nM (n  = 9 samples in 6 experiments). 
EGb-H22(scFv)  showed  ~10x  lower  toxicites  than  Gb-H22(scFv);  unconjugated 
Granzyme B showed no toxicity (data not shown).
Fig. 3.28: Cytotoxic activity of GbH22(scFv). Cells were incubated with increasing concentrations of 
Gb-H22(scFv)  for  72  h  in  a  humidified  37°C,  5% CO2  atmosphere.  Cell  viability  in 
relation  to  a  100%  PBS  control  and  a  0%  zeocin  control  was  determined  with  a 
colorimetric  MTS-based  cell  viability  assay  (2.2.6.5).  Samples  were  measured  in 
triplicate wells. Bars represent SD. A: U937 cells (squares) and Raji cells (triangles); B: 
HL60  (red),  MonoMac1  (blue),  THP1  (green),  IIA1.6  (stably  transfected  to  express 
human CD64) (yellow), L540cy (purple), Jurkat (brown) and DU-4475 cells (light grey).
Having optimised the  stimulation conditions  for  other  CD64+ cell  lines  (3.6),  Gb-
H22(scFv) was tested on these cell lines as well. Prior to this, all cells were passaged 
to 1x105 cells/ml.  HL60 cells  were stimulated with 1000 U/ml IFN-γ,  all other cell 
lines,  including  for  control  purposes  the  CD64- cell  lines,  were  stimulated  with 
2000 U/ml IFN-γ. Six hours after addition of IFN-γ, cells were subjected to a toxicity 
assay with Gb-H22(scFv). Slight concentration-dependent toxic effects  can be seen 
with HL60 and MonoMac1 cells; however, an IC50 is not reached (Fig. 3.28 B).
For these reasons further assays were carried out with U937 cells only.
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3.4.4 Annexin A5 assays
3.4.4.1 U937 cells
Apoptosis was detected in U937 cells incubated for 72 h with 150 nM Gb-H22(scFv) 
by Annexin A5/PI staining (2.2.6.6). Whereas Raji cells remained viable during the 
whole incubation period, the number of viable U937 cells decreased to 3% in Gb-
H22(scFv)-treated samples compared with 79% in the PBS control. Among the cells 
treated with Gb-H22(scFv), 18% were early apoptotic (Annexin A5+/PI-), whereas 79% 
were late apoptotic or dead (Annexin A5+/PI+; Fig. 3.29).
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Fig.  3.29:  Induction of  apoptosis in CD64+ U937 cells.  U937 and Raji  cells were incubated with 
150 nM Gb-H22(scFv) for 72 h in a humidified 37°C, 5% CO2 atmosphere. Apoptosis 
was detected by Annexin A5-eGFP/PI staining and flow cytometry (2.2.6.6). Bottom left, 
viable cells; bottom right, early apoptosis; top right, late apoptosis/dead cells. Numbers 
in the quadrants represent the percentage of cells of each category.
3.4.4.2 Primary myeloid cells of healthy donor
In contrast to primary AML cells, the subpopulation of primary monocytic cells of a 
healthy  donor  which  is  activated  enough  to  be  susceptive  to  (E)Gb-H22(scFv), 
quickly moves out and thus disappears from the respective forward scatter/sideward 
scatter gate during the course of apoptosis. On the other hand, weakly activated cells 
of the same gate do not respond to (E)Gb-H22(scFv) and thus do not show any or 
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only weak signs of apoptosis. Hence an analysis by Annexin A5 staining is almost 
impossible,  as  gating  the  monocytes  in  the  mixed  leukocyte  population  is 
indispensable for this assay. However, using an αCD64-FITC staining, which does 
not necessarily require gating, shows disappearance of CD64+ cells upon incubation 
with Gb-H22(scFv), in this case independent of stimulation with IFN-γ (Fig. 3.30). An 
incubation with EGb-H22(scFv) yielded the same results (data not shown).
Fig.  3.30:  Targeting of myeloid cells of a healthy donor. After selection by plastic adherence, cells 
were incubated with Gb-H22(scFv) for 24 h in a humidified 37°C, 5% CO2 atmosphere 
and analysed by staining with αCD64-FITC (2.1.3) and flow cytometry (2.2.6.4).  Left 
panels: Unstimulated cells, right panels: cells stimulated with 500 U/ml IFN-γ 24 h prior 
to use. A: Prior to incubation with Gb-H22(scFv). B: 48 h after start of incubation.
α
Results 74
3.4.4.3 Primary AML cells
Primary  CD64+ and  CD64- AML  cells  were  left  unstimulated  or  stimulated  with 
500 U/ml IFN-γ and the next day incubated for 48 h with 238 nM Gb-H22(scFv). 
Apoptosis was detected via Annexin A5/PI staining. As depicted in  Fig. 3.31, Gb-
H22(scFv)  induced  apoptosis  in  stimulated  CD64+ AML  cells  as  indicated  by 
reduction of the viable population (Annexin A5-/PI-; bottom left quadrant) combined 
with an increase in the populations of early apoptotic (Annexin A5+/PI-; bottom right 
quadrant) and late apoptotic/dead cells (Annexin A5+/PI+; top right quadrant). In this 
assay,  also unstimulated CD64+ AML cells  were eliminated by Gb-H22(scFv) to a 
slightly  lower  extent  (data  not  shown).  However,  as  this  effect  was  not  seen  in 
another assay performed eight days before with another unstimulated aliquot of the 
same cells (whereas stimulated cells had responded well to Gb-H22(scFv)), and as 
well was not seen with unstimulated cells from two other CD64+ AML patients (data 
not  shown),  this  result  can  be  seen  as  an  artefact  possibly  being  the  result  of 
activation due to culturing.
Cells from a patient with CD64- AML were, whether stimulated or unstimulated, left 
unaffected by Gb-H22(scFv).
Fig. 3.31: Detection of apoptosis in primary CD64+ and CD64- AML cells. 24 h after stimulation with 
500 U/ml IFN-γ, cells were incubated with 238 nM Gb-H22(scFv) for 48 h in a humidified 
37°C, 5%  CO2 atmosphere. Apoptosis was detected by Annexin A5-eGFP/PI staining 
and flow cytometry (2.2.6.4). Bottom left, viable cells; bottom right, early apoptosis; top 
right, late apoptosis/dead cells. Red numbers in the quadrants represent the percentage 
of cells of each category.
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3.4.5 Caspase-3 detection
3.4.5.1 U937 cells
The  potential  of  Gb-H22(scFv)  to  initiate  the  proteolytic  cascade  culminating  in 
apoptosis in U937 cells was also investigated via the detection of active caspase-3 in 
the cytosol (2.2.6.8). Cell lysates were incubated with caspase-3 capture beads. Bound 
caspase-3 was detected with a PE-labelled antibody specific for active caspase-3 but 
not procaspase-3. Significant activation of caspase-3 was observed in lysates of the 
cells  treated  with  Gb-H22(scFv)  compared  with  the  untreated  control  (Fig.  3.32), 
indicating  that  the  induction  of  apoptosis  by  Gb-H22(scFv)  was  mediated  by 
caspase-3.
Fig.  3.32:  Caspase-3 activation.  After 24 h incubation of U937 cells with Gb-H22(scFv), cytosolic 
cleavage  of  procaspase-3  was  monitored  by  incubation  of  cell  lysates  with  active 
caspase-3 capture beads, detection with a PE-labelled anti-active caspase-3 antibody 
and flow cytometry  (2.2.6.8).  Violet filled  curve,  beads lacking cell  lysate;  red open 
curve, beads incubated with lysate from PBS-treated cells; blue curve, beads incubated 
with lysate from Gb-H22(scFv)-treated cells.
3.4.5.2 Primary AML cells
In  primary  cells  of  a  CD64+ AML  patient,  internalisation  of  Gb-H22(scFv)  and 
activation  of  cytosolic  caspase-3  was  monitored  simultaneously  by  staining  with 
fluorescence-labelled  antibodies  and  confocal  microscopy.  For  this,  cells  were 
incubated with Gb-H22(scFv), or PBS or camptothecin as controls, respectively. After 
24 h, cells were fixed, permeabilised and stained with anti-Gb-PE and anti-active-
Caspase-3-FITC antibodies (2.1.3). Overlays of transmission light, green FITC and red 
PE signals are shown in Fig. 3.33. Whereas viable cells (left panel) do not show any 
fluorescent signal,  camptothecin-treated cells  (middle panel) show the green FITC 
signal  indicating  caspase-3  activation.  The  internalisation  of  Gb-H22(scFv)  (right 
panel) is monitored by the red fluorescent signal. Activation of caspase-3 can be seen 
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in  a  part  of  the cells,  which appear  yellow due to  the  overlay  of  green  and red 
signals. The red spots seen occasionally in all three samples are due to cytotoxic T 
cells and natural killer cells, which natively express Granzyme B and secrete it from 
vesicles.
Fig.  3.33:  Confocal microscopy of caspase-3 activation, overlays of transmission light, green FITC 
and  red  PE  signals.  After  24  h  incubation  of  primary  CD64+ AML  cells  with  Gb-
H22(scFv), internalisation of the immunotoxin and cytosolic cleavage of procaspase-3 
was monitored by simultaneous staining with αGb-PE and αCasp3-FITC (2.1.3). Left: 
PBS-treated, middle: camptothecin-treated, right: Gb-H22(scFv)-treated cells. Scale bar: 
20 µm.
3.4.6 Detection of mitochondrial depolarisation
Another hallmark of apoptosis is the loss of the mitochondrial membrane potential 
leading to mitochondrial depolarisation. This effect in reaction to application of Gb-
H22(scFv) was detected in U937 cells by staining with JC-1 (2.2.6.7).
As  Fig.  3.34 shows,  the  red  fluorescence  (seen  in  FL2-H) characteristic  for  the  J-
aggregates present in intact mitochondria markedly decreases upon incubation with 
Gb-H22(scFv), whereas the green fluorescence (seen in FL1-H) of the cytosolic JC-1 
monomers has increased.
Fig.  3.34:  FACS analysis of JC-1-based staining (2.2.6.7) of mitochondrial depolarisation in U937 
cells after 24 h incubation with Gb-H22(scFv). Left: PBS-treated, middle: camptothecin-
treated, right: Gb-H22(scFv)-treated cells.
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3.5 Structural optimisation of Gb-H22(scFv)
3.5.1 Cloning of adapter variants of Gb-H22(scFv)
Hetzel  et  al.  (2008)  showed  for  the  immunotoxin  H22(scFv)-Angiogenin  that  the 
specific cytotoxicity could be enhanced by the implementation of adapter sequences 
containing a membrane transfer peptide (MTP) and a cytosolically cleavable peptide 
(CCP) (cf. 1.3.2). However, from these results it could not be concluded whether the 
increased toxicity is due to the MTP which enhances endosomal release of the protein 
or  due to  the  CCP which generates  a  free  N-terminal  sequence,  which has  been 
described as crucial for the function of angiogenin (Harper et al., 1988).
Therefore  minimal  adapter  variants  of  Gb-H22(scFv),  in  particular  variants 
containing MTP or CCP alone, were designed to clarify this issue. Suitable restriction 
sites were introduced flanking the DNA sequences of interest. However, as in case of 
Granzyme B it  was necessary to  fuse CCP to the toxin directly,  cloning in the 3' 
region of the fragment was accomplished with a BsmBI restriction site located about 
100 bp downstream of the N-terminus of Granzyme B.
Fig. 3.35 gives a schematic representation of the cloning of all variants.
The adapter  sequences  to  be introduced into  pMS-LEGbH22IV or pMS-LH22GbII 
(latter one obtained by Christian Hetzel)  were codon-optimised and synthesised by 
GenScript  and  delivered  in  a  pUC57  vector  (8.2.2).  The  final  pMS  plasmids 
containing these adapter sequences were given the name affix "-OPT" to indicate that 
due to codon optimisation a part of the sequence deviates from the original sequence.
In analogy to the work of Hetzel et al. (2008), variants of pMS-LH22GbII were cloned 
first. For this, MTP, CCP and MTP-CCP were isolated from the pUC57 backbone by 
restriction  endonuclease  digest  (MTP:  XbaI,  CCP:  XbaI/BsmBI,  MTP-CCP: 
NotI/BsmBI). As the MTP sequence comprised only 45 bp and was thus under the 
detection  limit  in  a  normal  restriction  digest  setup,  the  sequence  was  amplified 
(2.2.1.8)  prior  to  that  from the  pUC57 vector  using  the  primers  fpUC and rpUC 
(2.1.5). After restriction of the adapter fragments and the target vector, which was, in 
case of the cleavage with  XbaI  only,  additionally dephosphorylated by incubation 
with CIP (2.2.1.3),  agarose gel  electrophoresis  (2.2.1.4) was performed.  The vector 
backbone  fragments  of  pMS-LH22GbII  (XbaI:  8218  bp,  XbaI/BsmBI:  8115  bp, 
NotI/BsmBI: 8101 bp) and the corresponding adapter fragments (MTP: 45 bp, CCP: 
133 bp, MTP-CCP: 192 bp) were excised from the gel, purified and ligated (2.2.1.5). 
The resulting constructs were transformed by heat shock into  E. coli  DH5α (2.2.1.7, 
2.1.6). As all three plates had more than 180 clones, whereas the control plates, for 
which the vector backbone only had been transformed, showed no or just very few 
clones, the DNA of one clone from every plate was isolated directly and sequenced 
(2.2.1.9) in the exchanged region using the primers Vl-ohne-for and Gbrev (2.1.5).
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Fig.  3.35: Schematic overview of the cloning procedure of adapter variants of pMS-LH22GbII and 
pMS-LEGbH22IV.  1:  pMS-LH22MTPGbII-OPT,  2:  pMS-LH22CCPGbII-OPT,  3:  pMS-
LH22MTPCCPGbII-OPT,  4:  pMS-LCCPGbH22IV-OPT,  5:  pMS-LMTPCCPGbH22IV-
OPT.
In case of pMS-LH22CCPGbII-OPT and pMS-LH22MTPCCPGbII-OPT the sequence 
turned out to be identical to the expected sequence.  For pMS-LH22MTPGbII-OPT 
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five further clones were checked by colony PCR (2.2.1.8) with the primers Vl-ohne-
for and primer4 (2.1.5). Two of these showed the correct product of 426 bp. The DNA 
of these clones was prepared. A test restriction (2.2.1.3) with SacI yielded for both the 
fragments of correct size (414/528/7321 bp). The DNA of both clones was sequenced 
(2.2.1.9)  with  Vl-ohne-for  and  Gbrev  (2.1.5).  The  first  clone  showed  the  correct 
sequence. The second clone turned out to harbour a double insertion of MTP. The 
additional DNA fragment of 45 bp, which should have been observed in the  SacI 
digest, was not detectable in the gel due to its small size. This double MTP clone was 
maintained as well, as it might have been interesting whether a second membrane 
transfer peptide would be able to further enhance the endosomolytic potential. The 
respective plasmid was termed pMS-LH22MTPMTPGbII-OPT.
As it was furthermore unclear whether the MTP was properly functional in a setup 
between binder and toxin without being exposed by endosomal cleavage, it was also 
tempting to  place  the MTP-CCP adapter  to  the N-terminus  of  Gb-H22(scFv)  and 
address the question whether this constitutively exposed MTP results in unspecific 
toxicity or not. In addition, with this setup or with CCP alone it would be possible to 
omit enterokinase cleavage and thus discard the enterokinase cleavage site, as the N-
terminus of Granzyme B would be released by the CCP inside the target cell.
In order to implement all this, pMS-LCCPGbH22IV-OPT was cloned first (Fig. 3.35). 
Briefly, pMS-LEGbH22IV was digested with XbaI and BsmBI (2.2.1.3). The backbone 
fragment (8053 bp) was ligated with CCP (133 bp) (2.2.1.5).  The resulting construct 
was  transformed by  heat  shock into  E.  coli  XL1-blue  (2.2.1.7,  2.1.6).  As  a  normal 
colony PCR approach to check clones was not possible as the replaced fragment and 
the  insert  fragment  differ  only  9  bp  in  length,  five  of  the  obtained  clones  were 
prechecked by an indirect colony PCR approach with the primers Xba-Entero-Gb-
back and Gbrev (2.1.5). As the insert sequence is codon-optimised, the Xba-Entero-
Gb-back primer is not able to bind to it. A PCR product would only be generated 
with  the  original  pMS-LEGbH22IV,  which  was  used  as  positive  control  as  well. 
Indeed,  three  of  the  five  tested  clones  showed  the  positive  control  fragment  of 
709 bp.  Hence the two other clones were grown in a 5 ml liquid culture and the 
plasmid DNA was prepared.  The sequencing analysis  confirmed the sequence  of 
these clones to be identical to the expected one (primers: T7prom, Gbrev) (2.2.1.9).
In the next step, the MTP sequence was integrated upstream of the CCP sequence. 
For this, pMS-LCCPGbH22IV was digested with  XbaI and dephosphorylated with 
CIP  (2.2.1.3).  The  backbone  fragment  (8186  bp)  was  ligated  with  MTP  (45  bp) 
(2.2.1.5).  The resulting construct was transformed by  heat shock into  E. coli  DH5α 
(2.2.1.7,  2.1.6).  Following plasmid preparation (2.2.1.1) of two of the clones,  a test 
restriction  with  SacI  was  carried  out  (2.2.1.3).  As  the  agarose  gel  electrophoresis 
(2.2.1.4)  revealed,  the  correct  fragments  had  been  generated  (165/1155/6911  bp). 
Sequencing in the exchanged region with the primers pMS-Seq-Sac-back and Gbrev 
(2.2.1.9, 2.1.5) confirmed successful cloning of pMS-LMTPCCPGbH22IV-OPT.
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3.5.2 Expression in mammalian cells/Flow cytometric analysis of binding
HEK293T cells were transfected (2.2.4.2) with pMS-LH22GbII and pMS-LEGbH22IV 
and all six corresponding adapter variants. Three days after that, MonoMac1 cells 
were  incubated  with  centrifugation-cleared  HEK293T  supernatants,  stained  with 
αGb-PE  (2.1.3)  and  analysed  by  flow  cytometry  (2.2.6.4).  The  obtained  shifts 
documented the production of all target proteins as well as specific binding to CD64+ 
MonoMac1 cells (Fig. 3.36).
MonoMac1
L540cy
Fig. 3.36: Flow cytometric analysis of binding (2.2.6.4) of different Granzyme B-H22(scFv) variants 
to MonoMac1 and L540cy cells. Bound protein was detected wth αGb-PE (2.1.3).
However, the producing HEK293T cells did not survive passaging to RPMI complex 
medium containing 100 µg/ml zeocin. The transfection was repeated several times. 
As  long  as  cells  were  adherent,  they  survived  the  zeocin  selection  pressure  and 
proliferated, but as soon as they became detached to be transferred from a T25 to a 
T75 cell culture flask most of the cells died. Only few cells survived, and of these only 
the  cells  transfected  with  pMS-LEGbH22IV,  pMS-LH22GbII  or  pMS-
LMTPCCPGbH22IV-OPT  produced  enough  protein  to  be  clearly  visible  in  a 
Coomassie-stained SDS gel after minipreparation (data not shown). All eight batches 
of transfected cells could not be maintained in culture longer than three months.
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3.6 Optimisation of the stimulation of U937 cells
As the reproducibility of stimulation of U937 cells with IFN-γ turned out to be a 
major obstacle,  the following questions were addressed,  partly as well  for further 
CD64+ cell lines:
▪ Which is the best  time point for stimulation? Is there a best point of time? 
(concerning cell number, physiological state, etc.)
▪ Which concentration of IFN-γ is sufficient to get maximum CD64 expression? 
▪ When does maximum CD64 expression occur after addition of IFN-γ?
▪ How long does upregulation of CD64 last?
▪ What is the best time point for starting a toxicity assay after addition of IFN-γ?
3.6.1 Time point for stimulation
Three different concentrations of IFN-γ were tested at three different time points. For 
this, cells were passaged to 1x105 cells/ml (U937) or 5x104 cells/ml (HL60). 0, 24 and 
48 h after passaging IFN-γ (Sigma) was added (4, 20, 100 U/ml). Aliquots of cells 
were analysed by flow cytometry after incubation with a fluorescence-labelled anti-
CD64 antibody 24,  48 and 72 h after addition of IFN-γ, and obtained shifts were 
related to each other as described in 2.2.6.4. Fig. 3.37 presents the results.
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Fig.  3.37:  CD64 expression of stimulated cells in relation to unstimulated cells, expressed as the 
ratio  between  the  geometric  mean  fluorescence  intensity  (GMFI)  of  stimulated  vs. 
unstimulated cells  stained with  αCD64-FITC (2.1.3)  and analysed by flow cytometry 
(2.2.6.4). Blue: Cells stimulated with 4 U/ml IFN-γ, pink: cells stimulated with 20 U/ml 
IFN-γ, yellow: cells stimulated with 100 U/ml IFN-γ. Left panels: IFN-γ added directly 
after passaging to 1x105 cells/ml, middle panels: IFN-γ added one day after passaging, 
right panels: IFN-γ added two days after passaging.
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For U937 as well as HL60 cells, the greatest degree of CD64 expression was reached 
with the highest of the applied IFN-γ concentrations (100 U/ml) after 48 h. However, 
a significant activation of  cells  (expressed by CD64 upregulation) is  only reached 
when  cells  are  stimulated  directly  after  passaging.  Even  a  fivefold  higher  IFN-γ 
concentration  applied  24 h  later,  when  cell  number  has  approximately  doubled, 
yields a weaker CD64 upregulating effect, i.e. not the cell number itself but rather the 
physiological state of the cells is decisive.
As the highest possible degree of stimulation did not seem to be reached with an 
IFN-γ concentration of 100 U/ml, further concentrations were tested (3.6.2).
3.6.2 IFN-γ concentration/Time point for start of toxicity assay
Five different concentrations of IFN-γ were tested. Immediately after passaging U937 
cells to 1x105 cells/ml, 10 ml aliquots of cells were stimulated with 0, 20, 100, 500, 
1000, or 2000 U/ml IFN-γ (Sigma). 24, 48, and 72 h after addition of IFN-γ aliquots of 
cells were taken and subjected to flow cytometry (2.2.6.4) and a toxicity assay (2.2.6.5; 
without  dilution  series:  three  wells  PBS,  three  wells  2 mg/ml  zeocin,  three  wells 
325 nM Gb-H22(scFv)).
For U937 cells, an IFN-γ concentration of 500 U/ml seems to be sufficient to reach 
maximum and most long-lasting expression of CD64 (Fig. 3.38) as well as maximum 
sensitivity towards Gb-H22(scFv) (Fig. 3.39). However, although CD64 expression is 
already high after 24 h and even slightly increases until 72 h, a strong toxic effect of 
Gb-H22(scFv)  is  only  seen  when  applied  24  h  after  addition  of  IFN-γ,  i.e.  the 
sensitivity of cells decreases the later the cells are recruited for the toxicity assay. In 
other words, the degree of CD64 expression is not the limiting factor for display of 
the full toxic potential of Gb-H22(scFv).
days after addition of IFN-γ
ra
tio
G
M
FI
 (s
tim
.)
/G
M
FI
 (u
ns
tim
.)
1 ,0
2 ,0
3 ,0
4 ,0
5 ,0
0 1 2 3 4
ra
tio
G
M
FI
 (s
tim
.)
/G
M
FI
 (u
ns
tim
.)
Fig. 3.38: CD64 expression of stimulated cells in relation to unstimulated U937 cells, expressed as 
the ratio between the GMFI of stimulated vs. unstimulated cells stained with αCD64-
FITC  (2.1.3)  and  analysed  by  flow  cytometry  (2.2.6.4).  Pink:  Cells  stimulated  with 
20 U/ml IFN-γ,  yellow:  cells stimulated with 100 U/ml IFN-γ, brown: 500 U/ml IFN-γ, 
turquoise: 1000 U/ml IFN-γ, violet: 2000 U/ml IFN-γ.
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Fig. 3.39: Toxic activity of Gb-H22(scFv) towards U937 cells depending on IFN-γ concentration and 
time point of start  of  toxicity assay (2.2.6.5).  Left  panel:  Incubation of cells with Gb-
H22(scFv) started one day after addition of  IFN-γ, middle panel: start two days after 
IFN-γ addition, right panel: start three days after IFN-γ adddition.
For HL60 cells, a similar tendency was observed, however,  the toxic effect  of Gb-
H22(scFv) was only very weak (viability decreased to ~80%; data not shown).
3.6.3 Comparison of U937 with other CD64-positive cell lines
U937, HL60, MonoMac1, THP1 (human cell  lines) and CD64+ IIA1.6 cells  (murine 
cells stably transfected to express human CD64) were passaged to  1x105 cells/ml in 
6-well  plates.  Transfected  IIA1.6  cells  were  selected  with  2.5 µg/ml  MTX.  IFN-γ 
(Sigma) was added to concentrations of 0, 20, 100, 500, 1000, and 2000 U/ml. Aliquots 
of cells were taken and subjected to FACS analysis and toxicity assay as described in 
3.6.2 with Gb-H22(scFv) (c = 108 nM) and H22(scFv)-ETA' (c = 28 nM) 6, 12, 24 and 
48 h after addition of IFN-γ.
In  general,  the  behaviour  concerning  the  time course  of  CD64 expression  differs 
markedly among the five cell  lines.  In the considered time frame U937 and HL60 
cells show the highest degree of CD64 expression at the end of the examined time 
scope (48 h), whereas MonoMac1 cells reach the peak at 24 h (Fig. 3.40). THP1 cells 
seem to upregulate CD64 very quickly, as the first expression maximum is reached 
already after  6 h.  Then intensive  downregulation  takes  place  during  the  next  six 
hours, before CD64 is slightly upregulated again. IIA1.6 cells behave similar to THP1 
cells during the first 12 h. For the following hours the degree of CD64 expression 
seems  to  depend  on  at  least  one  threshold  concentration  of   IFN-γ,  which  lies 
between 500 and 1000 U/ml.
Except  IIA1.6  cells,  500  U/ml  IFN-γ  are  sufficient  to  trigger  maximum  CD64 
expression.
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Fig.  3.40:  CD64 expression of stimulated cells in relation to unstimulated cells, expressed as the 
ratio between the GMFI of stimulated vs. unstimulated cells stained with αCD64-FITC 
(2.1.3) and analysed by flow cytometry (2.2.6.4). Dark blue: 20 U/ml, pink: 100 U/ml, 
yellow: 500 U/ml, turquoise: 1000 U/ml, violet 2000 U/ml IFN-γ.
As  Fig.  3.41 shows,  among  the  different  cell  lines  U937  cells  are  most  sensitive 
towards Gb-H22(scFv). In this assay, stimulation with IFN-γ concentrations between 
100 and 1000 U/ml are sufficient to properly sensitize cells towards Gb-H22(scFv). 
However,  the  greatest  toxic  effects  of  Gb-H22(scFv)  are  observed  when cells  are 
subjected to the toxicity assay 6 h after addition of IFN-γ. This tendency is seen with 
HL60 and MonoMac1 cells as well. For MonoMac1 cells an IFN-γ concentration of 
2000 U/ml has to be applied to yield maximum toxic effects. For HL60 cells the IFN-γ 
concentration is obviously not decisive. THP1 cells and IIA1.6 cells do not seem to 
respond properly to Gb-H22(scFv) with the conditions tested in this assay.
On all cell lines except IIA1.6 similar but weaker effects are observed with H22(scFv)-
ETA'.  In  contrast  to  Gb-H22(scFv),  IIA1.6  cells  do  respond  to  H22(scFv)-ETA', 
however, in connection with the time course of CD64 expression dependent on IFN-γ 
concentration (Fig. 3.41), cytotoxicity data are difficult to interpret.
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Fig. 3.41: Toxic activity of Gb-H22(scFv) (108 nM) or H22(scFv)-ETA' (28 nM) towards different cell 
lines in dependence on  IFN-γ concentration and time point  of start  of  toxicity assay 
(2.2.6.5).  Start  of  toxicity  assay  6  h  (blue),  12  h  (purple),  24  h  (yellow),  or  48  h 
(turquoise) after addition of IFN-γ.
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4 Discussion
4.1 Target cell sensitivity towards Granzyme B
Based upon the approach described by Zhao et al. (2004c), the sensitivity of U937 cells 
towards Granzyme B was evaluated by expressing Granzyme B in the cytosol of 
these  cells.  69%  of  Granzyme  B-transfected  cells  were  killed,  whereas  negative 
control cells transfected without DNA showed only 19% mortality (Fig. 3.8). Control 
plasmids  encoding  H22(scFv)  or  GFP  (pMAXGFP;  Amaxa)  each  caused  28% 
mortality (data not shown).
With this  setup,  it  was  demonstrated that  the designated target  cell  line U937 is 
sensitive for Granzyme B. However,  sensitivity towards a certain toxin might not 
only be an intrinsic property of the cell but might also be regulated upon external 
stimuli (as it is discussed below for the Granzyme B inhibitor PI-9). Hence the state of 
activation of the cell  might also be crucial for the susceptibility towards a certain 
toxin. In this respect the mortality of Gb-transfected cells is interesting as cells had 
not been stimulated with IFN-γ in this assay. However, the nucleofection procedure 
itself is very stressful for the cells, and thus might activate cells and, with this, make 
them sensitive for Granzyme B. The more common way of interpretation would be 
that U937 cells are generally Gb-sensitive, but, in case of the externally administered 
Gb-H22(scFv), IFN-γ promotes the internalisation and cytosolic translocation of the 
protein.  This  would  be  in  accordance  with  the  observation  that  IFN-γ  enhances 
receptor functions of CD64, among which is also internalisation (Fanger et al., 1989). 
Details concerning stimulation are further discussed in chapter 4.8.
In  general,  resistance  to  Gb-mediated  apoptosis  might  be  generated  on  different 
levels. Apart from downstream blocking steps, which could be mediated e.g. by the 
caspase-3  inhibitor  XIAP  (Deveraux et  al.,  1997)  or  the  well-studied  inhibitor  of 
mitochondrial  apoptosis  bcl-2  (Sutton et  al.,  1997;  Pinkoski et  al.,  2001),  direct 
inhibition of Granzyme B occurs through the cytosolically expressed serine protease 
inhibitor PI-9, also known as serpin B9 (Sun et al., 1996; Bird et al., 1998). This protein 
was also shown to inhibit the serine protease elastase as well as caspase-1 (= IL-1β-
converting enzyme) and caspase-4 in vitro (Bladergroen et al., 2001). Taken together, 
the Gb-related biological  functions  of  PI-9  comprise  the protection  of  monocytes, 
lymphocytes, antigen-presenting cells, and bystander cells from apoptosis through 
their own or misdirected Granzyme B (Sun et al., 1996; Bird et al., 1998; Kanamori et  
al., 2000; Young et al., 2000; Bladergroen et al., 2001; Buzza et al., 2001; Medema et al., 
2001b; Hirst et al., 2003; Classen et al., 2006), hence presumably also homeostasis of 
NK cells, cytotoxic T lymphocytes, and antigen-presenting cells (Classen et al., 2006), 
furthermore  the inhibition of  IL-1β- and IL-18-driven inflammation (Young et  al., 
2000; Kannan-Thulasiraman & Shapiro, 2002).
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PI-9 expression was tested during this thesis by cell fixation and permeabilisation 
and anti-PI-9  staining.  However,  as  all  cell  lines  tested  showed the  same strong 
degree of staining although an isotype control showed no signal (data not shown), an 
unspecific reaction was assumed, and later on confirmed by a Western Blot approach 
using cell lysates. On the mRNA level, U937 cells were PI-9-negative (Grit Hehmann, 
personal communication). However, as the cells used for the mRNA extraction had 
been unstimulated, the results have to be verified using increasing concentrations of 
IFN-γ and/or other stimulating agents.
The sensitivity of U937 cells towards cytosolic Granzyme B demonstrated here is in 
accordance with the observation that U937 cells undergo cytotoxic granule-mediated 
cell death (Grullich et al., 2008). In further accordance with that, PI-9 expression has 
been reported to be absent in U937 cells, furthermore also in HL60 and THP1 cells 
(Sun et al., 1996). However, there is also one publication in which U937 cells showed 
low PI-9 expression (Grullich et al., 2005) and a publication which reports moderate 
PI-9 expression in HL60 cells (Classen et al., 2004). This might be due to differences in 
culture parameters, and it also points to the fact that, depending on the cell type, PI-9 
expression must  not  always be an intrinsic  property  of  cells  but  may be  also  be 
regulated depending on external stimuli. In general, the regulation of PI-9 expression 
is  known to  be  transduced  via  NfκB-,  AP-1-,  and  oestrogen-responsive  elements 
(Classen et al., 2006), and cytokines and hence the stimulation status of the cell are 
crucial parameters in the regulation of its expression (Classen et al., 2004).  Tab. 2.14 
summarises the literature on this issue.
Tab. 2.14: Regulation of  PI-9  expression depending on external  stimuli.  +  upregulation,  - down-
regulation,  ± no  effect/basal  expression  unchanged;   m:  detection  on  mRNA  level, 
p: detection on protein level.
Stimulus Effect Cell type Reference
IFN-α + m, + p primary hepatocyteshepatoma cell line Huh-7 Barrie et al., 2004
IFN-γ + m hepatoma cell line Huh-7 Barrie et al., 2004
IFN-γ ± p± p
monocytes
lymphocytes Classen et al., 2006
IL-1β ± ? endothelial cellsmesothelial cells Buzza et al., 2001
IL-1β
+ m, + p 
 
+ m
+ m
+ m
+ m
oestrogen-receptor-α-transfected liver 
carcinoma cell line HepG2ER7
PI-9-promoter-transfected liver carcinoma 
cell line HepG2
PI-9-promoter-transfected breast 
adenocarcinoma cell line MCF7
PI-9-promoter-transfected chinese hamster 
ovary cell line CHO-S
PI-9-promoter-transfected cervical cancer 
cell line HeLa
Kannan-Thulasiraman 
& Shapiro, 2002
IL-2 + p± p
monocytes
lymphocytes Classen et al., 2006
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IL-2 ± p T cells Hirst et al., 2003
IL-2/
IL-12 + m, ± p
CD8+ T lymphocyte clone
NK cell line YT-N10 Horie et al., 2005
IL-2/
irrad. MM-
170 cells
± p NK cells Hirst et al., 2003
IL-2/PHA ± p non-adherent PBMCs Classen et al., 2006
IL-4/
GM-CSF + p monocytes Hirst et al., 2003
IL-6 ± m EBV-transformed B cell clone Horie et al., 2005
LiCl + p± p
monocytes
lymphocytes Classen, 2007
LPS + m, + p Burkitt's lymphoma cell line Daudi Kannan-Thulasiraman & Shapiro, 2002
LPS + p± p
monocytes
lymphocytes Classen et al., 2006
oestrogen + m, + p
oestrogen-receptor-α-transfected liver 
carcinoma cell line HepG2ER7
human liver biopsy sample
Kanamori et al., 2000
oestrogen + m PI-9-promoter-transfected liver carcinoma cell line HepG2
Kannan-Thulasiraman 
& Shapiro, 2002
PDTC
+ p
± p
- p
- p
- p
monocytes
lymphocytes (in presence of monocytes)
T cells
B cells
NK cells
Classen et al., 2006
PHA ± p T cells Classen et al., 2006
TNF-α + m hepatoma cell line Huh-7 Barrie et al., 2004
TNF-α + p monocyte-derived dendritic cells Hirst et al., 2003
TNF-α + m PI-9-promoter-transfected liver carcinoma cell line HepG2
Kannan-Thulasiraman 
& Shapiro, 2002
TPA
+ m, ± p
+ m, ± p
+ m
CD8+ T lymphocyte clone
NK cell line YT-N10
EBV-transformed B cell clone
Horie et al., 2005
TPA ± p non-adherent PBMCs Classen et al., 2006
TPA + m, + p oestrogen-receptor-α-transfected liver carcinoma cell line HepG2ER7
Kannan-Thulasiraman 
& Shapiro, 2002
TPA
+ p
+ p
+ m
umbilical vein endothelial cells
mesothelial cells
endothelial cell line C11STH
Buzza et al., 2001
TPA
/Con A + p T cells Hirst et al., 2003
The cytokine applied by default during this thesis, IFN-γ, was tested by Classen et al. 
as well, and no effect was observed (Classen et al., 2006). However, as only one single 
concentration was tested,  a  final  conclusion about  the effects  of  IFN-γ cannot  be 
drawn yet. In contrast to that, in a human hepatoma cell line 500 U/ml IFN-γ led to 
an  upregulation  at  least  on  the  mRNA  level.  Moreover,  in  murine  hepatocytes 
expression of the PI-9 analogue SPI-6 and thus resistance to Granzyme-dependent 
cytotoxicity is enhanced by IFN-γ exposure (Barrie et al., 2004). 
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However,  several  studies  emphasize that  differences  between  in vitro  and  in  vivo  
settings are given and hence might lead to misinterpretations and cloud the issue 
(Horie et al., 2005; Bots et al., 2006b; Classen et al., 2006).
In another study, AML subtypes M1-M4 were tested for serpin expression on the 
mRNA level. In contrast to other serine protease inhibitors, PI-9 expression was not 
detected except  a  very marginally visible  band in  AML M1 (Missen et  al.,  2006). 
However, as PI-9 mRNA was also not detectable in all other cell types tested, neither 
in monocytes, granulocytes, platelets, haematopoietic progenitor cells nor in any cell 
lines nor in lymphoblastic leukemia blasts of subtypes L1-L3, a poor function of the 
PI-9 primers used can be suspected, as a positive control was not shown. At least in 
paediatric  acute  lymphoblastic  leukemia,  PI-9  had  been  reported  before  to  be 
expressed  in  all  main  subtypes  (Classen et  al.,  2004).  The  same  is  true  for  high 
percentages of different lymphoma patients (Bladergroen et al.,  2002). Hence,  PI-9 
expression was suggested to represent an immune escape mechanism for tumours 
(Medema et al., 2001a; Bladergroen et al., 2002). Despite that, PI-9 expression might 
not be sufficient to fully explain resistance to Gb-mediated apoptosis, as Godal et al.  
observed  in vitro that lymphomas can be sensitive to perforin-dependent cytotoxic 
pathways despite expression of PI-9 and overexpression of bcl-2 (Godal et al., 2006).
As Granzyme M was suggested to cleave PI-9 (Bots & Medema, 2006a), it might have 
been a helpful approach for PI-9-positive target cells to coadminister a Granzyme B-
based  and  a  Granzyme  M-based  immunotoxin.  However,  as  the  expression  and 
purification of a Granzyme M-based immunotoxin has been difficult so far (Müller, 
2007), this approach has not been realised yet.
During work on this  thesis,  another  direct  Granzyme B inhibitor,  serpina3n,  was 
identified in Sertoli cells (Sipione et al., 2006), and seems to be known to be involved 
in stress responses (Swiderski et al., 2007), which should be considered for handling 
and cytokine treatment of any target cells. Furthermore, besides naturally occurring 
Gb  inhibitor  proteins  from  bovine,  rat,  murine,  plant,  bacterial,  and  viral  origin 
(reviewed in Poe et al., 1991; Kam et al., 2000), two human plasma protease inhibitors, 
among which α1 has been attributed physiological significance, have been reported 
once (Poe et al., 1991).
For  future  applications  of  cytosolic  expression,  an  approach  allowing  inducible 
expression  might  help  to  exclude  artefacts  due  to  the  transfection  process  itself. 
Indeed,  for  Granzyme B this  has  already  been  published in  Chinese  journals  (of 
which only  the abstract  was  available  in  English)  (Wang et  al.,  2004;  Zhao et  al., 
2004b). Using a similar approach, a Granzyme B gene mutated in the active center 
region  (Zhao et  al.,  2004a)  or  cotransfected  siRNA  targeting  Gb  might  serve  as 
controls.
In  conclusion,  and  with  respect  to  the  final  aim  of  immunotoxin  application  in 
humans, the susceptibility of cancer cells towards a Granzyme B-based immunotoxin 
is likely to vary between patients and cell types. For example, it has been shown that 
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three out of seven patients with acute myeloid leukemia and one out of six patients 
with acute lymphoblastic leukemia were resistant to Granzyme B/perforin-mediated 
apoptosis (Grullich et  al.,  2008).  Therefore,  with an aim to develop individualised 
therapies, the cytosolic expression approach could provide an efficient pre-screening 
method to evaluate the sensitivity of malignant cells from particular patients toward 
Granzyme B ex vivo. However, the sensitivity of a given target cell towards a given 
toxin might also vary depending on external  stimuli.  This would make necessary 
elaborate  and  extensive  testing  of  various  culture  conditions  and  stimuli,  which 
clearly exceeded the scope of this thesis. Thus a pre-testing as carried out here might 
only give a hint about the choice of the toxin to be used.
4.2 Bacterial expression of Gb-H22(scFv)
Bacterial  expression  of  Gb-H22(scFv)  in  the  periplasm  was  tested  in  parallel  to 
expression  in  mammalian  cells.  Although  a  protocol  for  periplasmic  expression 
under osmotic stress conditions had been successfully established and applied in our 
group (Barth et al., 2000; Tur et al., 2003; Nachreiner et al., 2008), and H22(scFv) was 
expressed within the frame of this thesis following that protocol (3.2.1.2), periplasmic 
expression and purification of Gb-H22(scFv) could not be realised. In contrast to that, 
even a slightly higher yield of Gb-H22(scFv) compared to H22(scFv) was expected, as 
E.  coli Rosetta  was  used  for  expression  of  the  fusion  protein,  whereas  E.  coli  
BL21(DE3) was used for expression of the single chain fragment. The E. coli  Rosetta 
strain features an additional plasmid encoding tRNAs rarely used by E. coli.
As  bacterial  expression  of  human  Granzyme B  and  respective  fusion  proteins  is 
generally possible, and the functionality of the protein seems to be given despite the 
lack of glycosylation (Liu et al., 2003a; Liu et al., 2003b; Kurschus et al., 2004), several 
steps might be undertaken to realise the expression of Gb-H22(scFv). These include 
codon optimisation (in case a normal strain without additional expression of rare 
tRNAs was used),  the change of  the  signal  peptide  mediating secretion  (Baneyx, 
1999), the introduction of special fusion tags in order to stabilise the protein and/or 
increase  solubility  (Baneyx,  1999),  overexpression  of  helper  proteins  (reviewed in 
Swartz, 2001), and finally the change of growth conditions like temperature or media 
contents.  Besides  periplasmatic  expression,  cytosolic  or  even  cell-free  expression 
(Swartz, 2001) might provide another interesting alternatives.
However,  as  mammalian  expression  was  successful  from  the  beginning,  it  was 
decided to abandon further bacterial expression.
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4.3 Mammalian expression of Gb-H22(scFv)
4.3.1 Expression in cell culture flasks
Besides expression in E. coli (Liu et al., 2003a; Liu et al., 2003b; Kurschus et al., 2004) 
and Pichia pastoris  (Dalken et al., 2006), Granzyme B-based immunotoxins have also 
been expressed in mammalian cells (Zhang et al., 2003; Zhao et al., 2004c; Wang et al., 
2007). However, in these studies the immunotoxin was not purified; instead of that, 
producing  cells  were  cocultivated  with  target  cells  and  apoptosis  induction  was 
observed, or the apoptosis-inducing potential was shown by transfection of the target 
cells with the same vector. In that case, the immunotoxin was reported to be secreted 
and then re-internalised by target antigen-mediated endocytosis (Zhang et al., 2003; 
Zhao et al., 2004c; Wang et al., 2007).
After having established and repeatedly used a mammalian expression and vector 
system in our own group (Stocker et al., 2003; Paetz et al., 2005; Kampmeier et al., 
2009), it was  self-evident to express Gb-H22(scFv) in mammalian cells as well. As 
expected,  the  fusion  protein  was  successfully  expressed  by  HEK293T  cells  and 
secreted into the culture supernatant with yields of ~1 mg/l (3.2.2.2). The same yield 
was  obtained  with  serum-free  HL-1  medium.  However,  as  the  downstream 
procedure was optimised so that  after  serum-containing expression a purity  near 
100% was reached, serum-free expression was not further pursued, as the costs for 
this  medium  were  significantly  higher  than  for  RPMI  medium  and  FCS. 
Furthermore,  in case of serum-free medium was used, (E)Gb-H22(scFv) tended to 
precipitate after IMAC because contaminating FCS, which obviously stabilised the 
protein, was missing.
During the months of culturing, the yield decreased more and more, with a final 
expression level of 300-400 µg/l. Silencing might be a reason for this phenomenon. 
Following transfection, also supercoiled plasmid DNA was reported to be linearised 
and  integrated  randomly  into  the  host  cell's  genome  by  nonhomologous 
recombination  (Wurm,  2004).  The  site  of  integration  has  a  major  effect  on  the 
transcription rate of the transgene.  In case of integration into active euchromatin, 
expression is generally possible, whereas integration into inactive heterochromatin 
results  in  little  or  no  transgene  expression.  However,  integration  into  active 
euchromatin is  not sufficient to  ensure  long-term expression of  a  constantly high 
level.  Post-integration gene  silencing  has  been  observed  in  many cases,  and was 
assumed to be due to the influence of neighbouring condensed chromatin (Wurm, 
2004).
Another effect that might account for the reduction of the expression level even more 
is the outgrowth of high-producing cells by low-producing cells. Although highly 
producing, i.e. highly green fluorescent clones were enriched by several rounds of 
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manual  subcloning,  these  clones  tended  to  proliferate  slightly  or  even  markedly 
slower than clones with a weaker green fluorescence (Browne & Al-Rubeai, 2007 and 
own observation), as metabolic resources are targeted towards protein production, so 
the expression of housekeeping genes is relatively lower. It has been reported that a 
growth advantage of as little as 9% is sufficient for overgrowth by low- and/or non-
producers  to  occur  after  25  passages  (Kromenaker  &  Srienc,  1994).  In  order  to 
overcome this problem it was tried several times to isolate highly green fluorescent 
cells by cell sorting (FACS), but these cells either failed to survive further culturing 
(in case the sorting was carried out a few days after transfection) or production rates 
were not markedly improved compared to unsorted cells (data not shown), possibly 
again due to overgrowth of low producers.
Besides  the  production  rate  of  HEK293T  cells  in  the  course  of  time,  interesting 
differences were also observed between different transfection batches generated at 
different time points. The highest toxic potential as  evident from the obtained IC50 
values  was  always  obtained  from  protein  produced  by  the  very  first  batch  of 
transfection,  whereas  protein  from  later  transfections  tested  in  the  same  toxicity 
assays showed lower toxicities (data not shown). In addition, the periodically seen 
unspecific binding to L540 cells (as discussed in chapter  4.6.1) only occurred with 
protein derived from later transfection batches and never with protein from the first 
transfection batch. This can only be explained by a variation in the post-translational 
modification,  which,  as  mentioned  earlier,  might  vary  within  a  single  cell  line 
depending  on  culture  conditions  and  physiological  state  (Rai  &  Padh,  2001; 
Gerngross, 2004; Twyman et al., 2005; GE Healthcare, 2006).
With  FlpIn293  cells  (3.2.2.6)  and  CHO cells  (3.2.2.4),  two  alternative  mammalian 
expression systems were tested. However, both cell lines turned out to be even lower 
in productivity (3.2.2.4, 3.2.2.6). However, the protein produced by FlpIn293 cells did 
at  least  not  show  unspecific  binding  to  L540  cells  (cf.  4.6.1),  which  should  be 
considered in future applications.
Furthermore,  as  homologues  of  the  mannose-6-phosphate  receptor  (M6PR)  are 
ubiquitously expressed  throughout the animal kingdom (Dahms et  al.,  2008),  it  is 
theoretically possible that an interaction of a Granzyme B-based protein with its own 
producing cell might occur (for further discussion of Granzyme B-M6PR interactions 
see chapter 4.6.1).
Taken  together,  HEK293T  cells  are  a  convenient  system  for  the  production  of 
pharmaceutical  proteins.  In  order  to  improve  the  yield  of  Gb-H22(scFv),  further 
optimisations  of  the culture  format  and conditions,  especially  using microcarrier-
based fermentation, are promising. 
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4.3.2 Microcarrier-based fermentation
The microcarrier-based fermentation was successfully established, although there is 
still  room for further  optimisation.  In terms of  volumetric  yield of Gb-H22(scFv), 
neither suspension culture in roller bottles (cf.  Fig. 3.42) nor adherent culture using 
microcarrier-based fermentation (3.2.2.3) was superior to the conventional static flask 
culture.
Fig.  3.42:  HEK293T cells  (2.1.6)  producing Gb-H22(scFv)  cultured in a vented roller  bottle  (BD 
Falcon 2000 ml) rotated at 10 rpm in a humidified atmosphere with 5% CO2 at 37°C. 
300  ml  RPMI  complex  medium  containing  2.5%  (v/v)  FCS  were  inoculated  with 
transfected HEK293T to yield a density of 1x105 cells/ml.  Cells viably  grew in large 
clusters. Picture taken on day 3.
Several  suggestions  for  the  optimisation  of  microcarrier-based  fermentation 
processes have been made by the supplier of the microcarriers (GE Healthcare, 2006). 
Based on this guideline and concerning the production of Gb-H22(scFv) in HEK293T 
cells, the points mentioned in the following paragraph might be of interest in future 
applications.
The productivity of fermentation-based cell culture can be increased either by scaling 
up to larger volumes  or by intensifying the process in smaller  volumes but  with 
higher cell densities. When intensifying cell densities, more frequent media changes 
and other  media  compositions  might  be  needed,  and  the  fermentation  might  be 
carried  out  in  a  perfusion  setup.  In  conjunction  with  that,  different  reactor 
configurations,  like  e.g.  airlift  or  fluidised  bed,  could  be  an  option.  Having  the 
equipment given, in particular the initial attachment phase is of great importance. 
Hence,  a  closer  examination  of  the  time  required  for  robust  attachment  to  the 
microcarriers  is indispensable.  During the fermentation, regulation of pH and gas 
supply  are  the  most  critical  parameters.  For  future  setups,  it  might  be  more 
convenient to choose a constant  CO2  tension of 5% (and 95% air), stabilise the pH 
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with a HEPES buffer supplement in the culture medium, and increase the pH with 
5.5%  NaHCO3,  if  necessary.  pH  decrease  over  time  is  mainly  due  to  lactate 
accumulation.  This  can  be  reduced  by  running  the  system  in  perfusion  mode, 
increasing  the  concentration  of  alternative  carbon  sources  such  as  glutamin, 
increasing  the  oxygen  tension,  and/or  medium  supplementation  with  biotin. 
Furthermore,  as  serum  is  primarily  required  for  cell  attachment,  the  serum 
concentration could be reduced stepwise after several days, or the serum can then be 
replaced  with  protein  hydrolysates  such  as  lactalbumin  hydrolysate  or  tryptose 
phosphate broth.
Taken together,  many more  parameters  can be optimised,  and already optimised 
parameters  could  be  subjected  to  some  more  fine-tuning.  Today's  industrial  cell 
culture  fermentation  has  proven  the  potential  of  the  technique,  e.g.  Rentschler 
Biotechnology accomplished a long-term fermentation process using fluidised bed 
perfusion technology for 7.5 months with constant productivity and product quality 
(GE Healthcare, 2006).
4.4 Plant expression of Gb-H22(scFv)
As detected in a flow cytometric analysis with the crude extracts of Nicotiana tabacum 
leaf discs, Gb-H22(scFv) was expressed in the apoplast and ER (3.2.3.2). However, it 
was not possible to produce Gb-H22(scFv) in usable quantity, as leaf areas infiltrated 
with  the  respective  agrobacteria  died  by  withering  within  few  days.  In  the 
chloroplasts, neither the flow cytometric analysis nor any withering gave indication 
for  expression  of  functional  Gb-H22(scFv) (3.2.3.2).  This  could  be  due  to  the 
environment of the cytosol and/or the chloroplasts, which might not be appropriate 
for  correct  folding  of  Gb-H22(scFv).  Another  interpretation  would  be  lack  of 
expression. In general, with a functional DNA sequence given, lack of expression (as 
obviously given for the chloroplast GbH22 construct) can be either due to insufficient 
or  failed  transformation,  to  epigenetic  silencing  or  to  rapid  degradation  of  the 
produced  protein.  As  DsRed has  been  expressed  in  chloroplasts  successfully,  the 
transformation process itself can be excluded as a possible reason.
Gene  silencing  can  occur  either  through  repression  of  transcription  e.g.  by 
hypermethylation, termed transcriptional gene silencing (TGS), or through mRNA 
degradation, termed post-transcriptional gene silencing (PTGS), the latter one being 
an analogue with slight differences to RNA interference in animals (Vaucheret et al., 
2001;  Vaucheret  &  Fagard,  2001).  A  direct  link  between  both  mechanisms  was 
observed with the finding that transcriptionally inactive heterochromatin gives rise 
to small interfering RNAs (Lippman & Martienssen, 2004), which in turn can mediate 
chromatin-based  silencing  resulting  in  transcriptional  shutdown  of  homologous 
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transcription units and the formation of centromeric heterochromatin (Schramke & 
Allshire, 2004; Matzke et al., 2009).
As  Agrobacterium-mediated  T-DNA  integration  into  the  plant  genome  happens 
randomly (van Attikum et  al.,  2001;  Gelvin & Kim, 2007),  the transgene position, 
redundancy  as  well  as  the  structure  itself  might  account  for  TGS  (Vaucheret  & 
Fagard,  2001).  However,  as the major part  of  the transgene structure of  pTRAkc-
GbH22-AH, -ERH, and -CTP is identical, and the genomic distribution of the three 
constructs  should be statistically identical,  it  is  rather  unlikely that  TGS occurred 
with the GbH22-CTP construct but not with the two other GbH22 constructs as well 
as with the DsRed-CTP construct. Furthermore, transgene expression after transient 
transformation  does  not  necessarily  require  T-DNA  integration  into  the  plant 
genome (Gelvin & Kim, 2007), hence, gene silencing effects are less likely to account 
for lack of expression in transient expression compared to stable expression.
The same is true for PTGS – neither the GbH22 nor the chloroplast signal peptide 
sequence  should  for  themselves  be  able  to  trigger  RNA  silencing  or  RNA 
interference-based  heterochromatic  silencing,  as  both  GbH22  constructs  and  a 
chloroplast-targeted DsRed construct have been expressed.
Thus,  regulation  on  the  protein  level  remains  as  the  last  possibility  for  failed 
expression  in  chloroplasts.  Interestingly,  signal  peptide  directed  import  into 
chloroplasts  is  carried  out  post-translationally,  whereas  ER  import  happens  co-
translationally  (Alberts et  al.,  2002).  That  means that  exposure  to  cytosol-resident 
proteases is higher for chloroplast-targeted proteins than for apoplast- or ER-targeted 
proteins. Calculating the estimated half-life and the instability index of the expressed 
proteins  using  the  ProtParam  tool  on  the  ExPASy  server 
(http://www.expasy.ch/tools/protparam.html),  for  Gb-H22(scFv)  an estimated half-
life of 20 h in mammalian reticulocytes,  30 min in yeast, and >10 h in  E. coli was 
found, and the protein was classified as unstable. In contrast to that, DsRed half-lifes 
are computed as 30 h in mammalian reticulocytes, >20 h in yeast, and >10 h in E. coli, 
and the protein was classified as stable. Unfortunately the software does not include 
a  calculation  for  plant  cells,  still,  it  might  be  conjectured  that  Gb-H22(scFv)  is 
unstable in plant cells as well.  However, this does not explain why Gb-H22(scFv) 
was  not  even  detected  in  chloroplast  expression,  whereas  in  apoplast  and  ER 
expression the amounts of the immunotoxin were sufficient for detection in a FACS 
analysis on the one hand and triggering of cell death on the other hand.
Obviously functional human Granzyme B finds substrates to cleave in planta. Indeed, 
caspase-like activities have been detected in plant extracts, and studies using caspase 
substrates  and inhibitors  have demonstrated that  these activities  are  required for 
programmed cell death (PCD) (reviewed in Rotari et al., 2005). However, it became 
clear that plant orthologues for animal caspases do not exist, and the plant proteins 
with the closest relationship to caspases, termed metacaspases, do not exert caspase-
like activities although there is support for a role in PCD (Bonneau et al., 2008; He 
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et al., 2008). In addition, the synthetic caspase substrates are not stringently caspase 
specific but rather can also be cleaved by other non-caspase proteases (Rotari et al., 
2001; Bonneau et al., 2008). In other words, plant proteases involved in PCD do not 
necessarily have to do something with caspases. So far, only few of these proteases 
have been identified (reviewed in Rotari et al.,  2005; Bonneau et al.,  2008), among 
them also two serine proteases cleaving several synthetic caspase substrates as well 
as a synthetic Granzyme B substrate (Coffeen & Wolpert, 2004). Proteases involved in 
plant PCD have been localised in different species in vacuoles, storage organelles, the 
ricinosome (a  putative  lytic  compartment  derived  from the  ER),  cytosol,  and the 
nucleus (Rotari et al., 2005). If ER-resident Gb-H22(scFv) is hypothesised to cleave 
und thus activate some of those proteases, it necessarily first has to leave the ER and 
reach  the  compartment  harbouring  the  respective  protease.  These  ER-efferent 
pathways are known for example during quality control of nascent proteins. In the 
normal  protein  synthesis  and  maturation  process,  malfolded  and  incompletely 
assembled  proteins  emerge  as  by-products.  For  proteins  being  recognised  as 
malfolded, it is known that they can undergo transport to the vacuole via a Golgi-
mediated  pathway,  or  undergo  retrograde  transport  from  the  ER  lumen  to  the 
cytosol  and cytosolic  degradation,  a  process known as ER-associated degradation 
(ERAD) (Brandizzi et al., 2003).
Moreover, an accumulation of protein in the ER might in general signal the cell to 
clear  the  protein  from  the  ER.  In  mammalians  as  well  as  in  plant  cells,  the 
phenomenon of 'ER stress', which is also given when an imbalance between the rate 
of protein synthesis in the cytosol and the rate of protein folding in the ER occurs, is 
well-known (Zuppini et al., 2004; Marciniak & Ron, 2006; Ron, 2006; Liu et al., 2007), 
and can lead by itself to programmed cell death (Zuppini et al., 2004).
As retrograde transport  obviously does not require  full  unfolding (Fiebiger et  al., 
2002;  Brandizzi et  al.,  2003),  it  is  theoretically  possible  that  some functional  Gb-
H22(scFv) reaches the cytosol and cleaves an apoptosis-inducing target. That this is 
generally possible has been shown for example for ETA and Ricin A, which upon 
having reached the ER of a mammalian target cell also undergo retrograde transport 
by exploiting the ERAD pathway and, due to their low lysine content, achieve to at 
least  partly  escape  the  cytosolic  ubiquitination/degradation  machinery  (Hazes  & 
Read, 1997; Deeks et al., 2002; Teter & Holmes, 2002). A hydrophobic reach, which is 
crucial for membrane translocation of ETA and Ricin (Hazes & Read, 1997), is also 
present in the N-terminal region of Gb (cf. 4.5). However, as Gb-H22(scFv) harbours 
32 lysine residues, of which 21 are located throughout the Gb sequence, it remains 
unclear how Gb manages to escape the ubiquitin-proteasome pathway, which is not 
only present in mammalian target cells but also in plants (Moon et al., 2004).
With a GFP fusion protein undergoing retrograde transport in a plant cell, it has been 
observed that  cytosolic  degradation  proceeds  only  slowly (Brandizzi et  al.,  2003). 
Furthermore, this protein was seen to accumulate in the nucleoplasm. This is as well 
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interesting for Gb-H22(scFv), as Granzyme B is also known to appear at the nucleus 
in  target  cells  (Pinkoski et  al.,  2000)  and to  cleave  nuclear  substrates  like  PARP, 
NuMA,  DNA-PK,  ICAD-L  or  lamin  B  (Bots  &  Medema,  2006a).  Indeed,  plant 
orthologues of PARP (Amor et al., 1998), NuMA (Yu & Moreno Diaz de la Espina, 
1999),  ICAD (Li et  al.,  2004),  and lamins (McNulty & Saunders,  1992) are known, 
whereas  the  catalytic  subunit  of  DNA-PK  seems  to  be  restricted  to  vertebrates 
(Tamura et al., 2002).
Taken together,  it is likely that human Granzyme B is able to find substrates and 
trigger  programmed  cell  death  in  plant  cells.  However,  research  of  the  plants' 
pathways of programmed cell death is still in its infancy, and  many more studies 
have to be conducted to build a robust scenario that integrates the various recruited 
proteases and other proteins conjectured to play a role in plant PCD.
4.5 Purification and activation of Gb-H22(scFv)
The downstream process in the preparation of Gb-H22(scFv) from supernatants of 
HEK293T cells has been optimised so that the target protein was obtained with a 
convenient process in high purity (3.3.1-3.3.6). The only unsatisfactory part in this 
process was the enterokinase (EK) cleavage (3.3.3).
In  spite  of  several  attempts  to  optimise/increase  the  enterokinase/protein  ratio, 
cleavage of the entire amount of protein (as documented by the loss of the ECS band 
in  the  Western  Blot,  cf.  Fig.  3.22)  was  very  rarely  achieved,  thus  it  could  be 
speculated that the obtained IC50 values might be even lower. It has been observed 
that  the  nature  of  sequences  adjacent  to  the  canonical  cleavage  site  might  have 
influence on the cleavage efficiency (Liew et al., 2007; Lee et al., 2009). In addition, a 
certain degree of undesired secondary cleavage in the middle of the protein always 
occurred (Fig. 3.22), resulting in a purity lower than 100% after CEX. Although this 
could have been caused by SDS, this possibility could be excluded as SDS was not 
used during or before EK cleavage. In the literature, numerous secondary cleavage 
sites have been described (e.g. Huang et al., 1998; Bowman et al., 2006; Liew et al., 
2007; Shahravan et al., 2008; Lee et al., 2009), however, it can be speculated that there 
may be even more.
Another problem encountered during enterokinase cleavage was salt precipitation. 
As  the  basis  of  all  buffers  used  throughout  the  whole  downstream  processing 
procedure was phosphate,  combining the protein sample with Ca2+-containing 10x 
enterokinase  cleavage  buffer  resulted  in  Ca3(PO4)2 precipitation.  According  to  a 
personal communication with the manufacturer (Novagen),  Ca2+ is not necessarily 
required for proper function of enterokinase. Therefore, before enterokinase cleavage 
the protein was finally rebuffered to PBS containing 20 mM Tris, as a test cleavage in 
PBS only had not been satisfactory due to unspecific cleavage fragments.
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To overcome the problems associated with EK cleavage, different strategies could be 
pursued.  First,  analysis  of  the  undesired  cleavage  fragments  by  MALDI  mass 
spectrometry might allow the determination of the cleavage site. If the functionality 
of the protein is not going to be compromised, single amino acids in this site and 
potential adjacent influencing sequences could be mutated. Another strategy is the 
introduction of functional oligopeptides flanking the canonical cleavage site, thereby 
supporting preferential cleavage of this site (Lee et al., 2009).
Yet the easiest way to obtain a free N-terminus of Gb-H22(scFv) would be to fuse the 
gene sequence directly to that of the leader peptide sequence, as it was already done 
using  yeast  expression  (Dalken et  al.,  2006;  Giesubel et  al.,  2006).  In  case  of  the 
HEK293T  cells  and  the  pMS  plasmid  used  in  this  thesis,  the  protein  is  co-
translationally imported into the ER. Thus, with a direct fusion as described before, 
theoretically no functional Gb-H22(scFv) should be present in the cytosol, where it 
would have access to death cascade substrates. However, as discussed for plant cells 
in chapter 4.4, it is not unlikely that retrograde transport of some protein molecules 
takes place, and these could be sufficient to trigger cell death of the producing cell. 
Moreover, it is known from proteins like ETA that they are able to translocate from 
ER to cytosol by post-cleavage exposure of a hydrophobic region which penetrates 
the ER membrane (Hazes & Read, 1997). If Granzyme B is analysed for hydrophobic 
regions  by  using  the  TMpred  software 
(http://www.ch.embnet.org/software/TMPRED_form  .html  ),  a  hydrophobic  region 
located near the N-terminus (amino acids 38 to 55) is found. Potentially this region is 
involved  in  the  membrane  crossing  of  Granzyme B  into  the  cytosol.  This  might 
explain  the  requirement  for  a  free  N-terminus  of  Granzyme  B  to  obtain  full 
cytotoxicity,  as  otherwise  sterical  hindrance  might  prevent  the  exposure  of  the 
hydrophobic region. Indeed, the only published immunotoxin with Granzyme B at 
the  C-terminal  position  was  not  functional  unless  furin  cleavage  sites  mediating 
endosomal  cleavage  and  thus  release  of  the  N-teminus  of  Granzyme  B  were 
introduced (Wang et al., 2007).
Taken together, it is not completely unprobable that a direct fusion of Gb-H22(scFv) 
to the leader peptide would result in apoptosis of the producing cell. Nevertheless 
this hypothesis awaits to be proven yet.
Another option is to change the orientation of the immunotoxin to the H22(scFv)-Gb 
format,  with  an  adapter  sequence  including  a  furine  or  cathepsin  cleavage  site 
located between the functional subunits.  This  strategy would also circumvent  the 
necessity for EK cleavage and is discussed in chapter 4.7.
In addition, serum-free expression of proteins lacking an EK cleavage site would be 
an interesting option again, as the high purity obtained after serum-free expression 
and  IMAC  purification  has  been  a  problem  as  the  protein  tended  to  precipitate 
during EK cleavage (3.3.3).
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4.6 Functional characterisation of Gb-H22(scFv)
4.6.1 Specificity in biological activity of Gb-H22(scFv)
Having shown the functionality of Gb-H22(scFv) compared to free Gb in terms of 
proteolytic properties (3.4.1), the capability to selectively bind and eliminate CD64+ 
cells by the induction of apoptosis had to be shown. 
With the two main model  cell  lines,  CD64+ U937 and CD64- Raji  cells,  a  specific 
interaction of Gb-H22(scFv) and CD64 was documented, as the protein only bound 
to and killed U937 cells, whereas Raji cells were not bound nor killed (3.4.2,  3.4.3, 
3.4.4.1). Later on, additional CD64+ and CD64- cell lines were analysed in binding and 
toxicity analyses as well. The strong binding of Gb-H22(scFv) to the CD64+ cell lines 
HL60, MonoMac1, THP1 and IIA1.6(CD64+) (3.4.2) further confirmed the capability 
of the immunotoxin to bind its target receptor. However, a markedly lower degree of 
binding occurred as well to Jurkat, DU4475 (3.4.2), and occasionally also to L540 cells 
(data not shown). As all cell lines were checked for the expression of CD64, and the 
lastly  mentioned  cell  lines  were  clearly  CD64- (data  not  shown),  binding  of  Gb-
H22(scFv) to these cells is clearly unspecific.
Indeed, over the last years, the interaction of Granzyme B with cell surfaces has been 
a matter of intense discussion. Apart from CD44 (Toyama-Sorimachi et al., 1995) and 
Hsp70 (Gross et al., 2003), especially the mannose-6-phosphate receptor (M6PR) has 
been shown to be involved in binding of native Granzyme B (Motyka et al., 2000; 
Veugelers et  al.,  2006),  which  is  glycosylated  with  mannose-6-phosphate  (M6P) 
residues  (Griffiths & Isaaz,  1993),  whereas  other  groups disproved an interaction 
with M6P (Trapani et al., 2003b; Dressel et al., 2004; Kurschus et al., 2005). However, 
another  indication  that  the  nature  of  post-translational  modification  accounts  for 
binding  to  cell  surfaces  comes  from  the  fact  that  EGb-H22(scFv)-containing 
supernatants  from  HEK293T  cells  cultured  in  serum-free  medium  as  well  as 
supernatants from FlpIn293 cells (cultured in serum-containing medium) showed no 
binding to L540 cells, whereas in the same assays supernatants from HEK293T cells 
of the second and third transfection batch (cf.  4.3.1) cultured in serum-containing 
medium did (data not shown).  Possibly M6P glycosylation was different  in these 
cases. This would again support the thesis that glycosylation is dependent on cell 
type and culture conditions (Rai & Padh, 2001; Gerngross, 2004; Twyman et al., 2005; 
GE Healthcare, 2006).
In addition, the positive pI of Granzyme B, which made possible the purification of 
Gb-H22(scFv) via cation exchange chromatography, also accounts for the capability 
of binding to negatively charged cell surface molecules such as heparan sulfate (Bird 
et al., 2005; Raja et al., 2005; Shi et al., 2005; Veugelers et al., 2006). This interaction has 
been  demonstrated with HL60 cells  (Kurschus et  al.,  2005;  Kurschus et  al.,  2008), 
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which are highly heparan sulfate-positive, but U937 cells, which lack one heparan 
sulfate epitope, did not show binding of Gb (Kurschus et al., 2005). This could be 
confirmed in this thesis as well, as in a FACS analysis free Gb bound to L540, but not 
to U937 cells (data not shown). The free Gb used in that assay was a commercially 
available protein from Calbiochem produced in E. coli, hence M6P glycosylation can 
in this case be excluded as possible cause for the binding.
As third possible pathway apart  from receptor-mediated endocytosis and charge-
mediated  adsorptive  pinocytosis,  fluid  phase  pinocytosis  has  been  suggested  as 
possible mechanism for Gb uptake as well (Trapani et al., 2003b; Bird et al., 2005).
Taken together,  different  effects,  which might act  individually  or in a synergistic 
manner depending on the nature of the target cell, seem to account for unselective 
binding of Gb to cell surfaces and endosomal uptake.
Still  this  unspecific  binding  and  potential  endosomal  uptake  does  not  provide 
grounds for serious concerns, as cytotoxicity assays revealed that all CD64- cell lines 
were unaffected by Gb-H22(scFv) (3.4.3), except for some occasions in which L540 
cells  had  been  affected  to  a  certain  degree  (data  not  shown).  However,  this 
occasionally seen phenomenon can not be attributed to the unspecific binding itself, 
as  additional  mechanisms  are  necessary  which  mediate  endosomal  release  and 
facilitate triggering of apoptosis. It has been clearly shown that  the efficacy of Gb 
translocation  into  the  cytosol  of  target  cells  was  not  affected  by  heparan  sulfate 
structures,  thus no impact of  heparan sulfate binding on apoptosis induction has 
been  observed  (Kurschus et  al.,  2005).  Furthermore,  the  mutation  of  cationic 
sequences involved in heparan sulfate binding has been shown to have no impact on 
the apoptotic potential itself (Bird et al., 2005; Kurschus et al., 2008).
Nevertheless,  in  the  long  term  the  reduction  of  all  unspecific  interactions  of 
Granzyme B with any kind of cells is desirable. As the glycosylation of Gb does not 
contribute to its apoptosis-inducing potential, as can also be concluded from the full 
functionality of prokaryotically expressed Gb (commercially available) and Gb-based 
immunotoxins  (Liu et  al.,  2003a;  Liu et  al.,  2003b;  Kurschus et  al.,  2004), 
deglycosylation  of  Gb-H22(scFv)  or  its  production  in  M6P-glycosylation-deficient 
systems  such  as  bacteria,  Pichia  pastoris or  a  glycosylation-modified  mammalian 
system  would  be  possible  approaches  to  obviate  unspecific  interactions. 
Furthermore, the elimination of heparan sulfate binding motifs of Granzyme B (Bird 
et  al.,  2005;  Kurschus et  al.,  2008),  might  represent  a  helpful  approach  in  future 
applications of Granzyme B-based immunotoxins.
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4.6.2 Cytotoxic/apoptosis-inducing potential of Gb-H22(scFv)
4.6.2.1 Cytotoxicity
Towards U937 cells stimulated with 500 U/ml IFN-γ, significant toxic effects of Gb-
H22(scFv)  with  IC50 values  between  1.7  and  17  nM  (equaling  0.1-1  µg/ml)  were 
observed (3.4.3). This is in accordance with or even better than the published IC50 
values of other Granzyme B-based immunotoxins (Tab. 2.15). Lower IC50 values were 
only obtained with two immunotoxins targeting ErbB2 and EGFR in the presence of 
50  µM  of  the  endosome-disrupting  agent  chloroquine.  Without  chloroquine,  no 
toxicity was observed at all (Tab. 2.15). Hence membrane transfer of Granzyme B 
seems to be ligand- and/or target cell-dependent.
Tab. 2.15: IC50 values of other Granzyme B-based immunotoxins.
Target antigen Binding unit IC50 
[nM]
Target
cell line
Reference
VEGF receptors VEGF (121 aa isoform) ~10 PAE/FLK-1 Liu et al., 2003b
gp240 scFvMEL
20
A375-M
Liu et al., 2003a
32
Liu et al., 200650 MEL-526
158 TXM-18L
Lewis Y carbo-
hydrate antigen dsFv-B3
140 MCF-7
Kurschus et al., 200435 MCF-7casp3
98 SK-BR3
EGFR TGFα 0.25* MDA-MB468
Dalken et al., 2006
ErbB2 (HER2) scFv(FRP5) 0.29* Renca-
lacZ/ErbB2
*  These  IC50 values  were  only  obtained  in  the  presence  of  the endosomolytic  agent  chloroquine 
(50 µM). Without chloroquine, no cytotoxicity was observed at all.
With Gb-H22(scFv) targeting U937 cells,  fortunately,  no endosomolytic  agent was 
needed to observe cytotoxicity. Even the uncleaved EGb-H22(scFv), which was not 
able to cleave the synthetic substrate mimicking procaspase-3 (3.4.1), was cytotoxic, 
albeit  with  ~10x  lower  toxicities  compared  to  Gb-H22(scFv).  This  points  to  the 
cytosolic modes of action of Granzyme B apart from procaspase-3 cleavage (cf. 1.5). 
Thus Granzyme B has additional benefits as a toxic component as the development 
of avoidance strategies by tumour cells is much more difficult than with toxins acting 
by a single apoptosis-inducing mechanism.
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Slight  concentration-dependent  toxic  effects  were  also  seen  with  HL60  and 
MonoMac1  cells,  but  an  IC50 was  not  reached  (3.4.3).  However,  as  discussed  in 
chapter 4.1, an equal sensitivity of all cells towards Granzyme B cannot be expected.
Apart from the immunotoxins listed in  Tab. 2.15, further Gb-based immunotoxins 
have been developed.  However,  as the cytotoxic potential  of these immunotoxins 
was only evaluated either in an approach in which producing cells and target cells 
were  cocultivated,  or  by  transfection  of  the  target  cells  with  the  immunotoxin-
encoding plasmid, IC50 values were not calculated (Zhang et al.,  2003; Zhao et al., 
2004c; Wang et al., 2007; Zhang et al., 2008). Thus, a comparison with these other Gb-
based immunotoxins is difficult.
In general, large variations in cytotoxicity of Gb-H22(scFv) towards U937 cells were 
seen during  this  thesis.  One reason for  that  is  the stimulation of  the target  cells, 
which was analysed and established during the course of time (cf. 3.6, 4.8). For future 
applications, it might be crucial to investigate the presence or absence of Granzyme B 
inhibitors  such  as  PI-9  or  serpina3n  (cf.  4.1)  depending  on  different  culture 
conditions,  especially  different  IFN-γ  concentrations.  Another  point  which  might 
reflect also physiological and hence sensitivity changes in U937 cells is the fact that, 
similar to HL60 and HEK293T cells,  slight morphological variations of U937 cells 
were microscopically detectable between different batches of cells obtained from the 
stock cell culture facility of the group over the years. Furthermore, the glycosylation 
of  the  protein  is  important  for  the  function  of  protein-based  pharmaceuticals  in 
general (cf. 4.6.1). Apart from the variation of glycosylation due to culture conditions, 
it  is  known  that  mammalian  cells  typically  express  a  heterogenous  mixture  of 
glycoforms at the same time (Gerngross, 2004), which might account for changes in 
cytotoxicity as soon as the proportions of the glycoforms to each other change. This 
could  be  overcome  by  production  in  glycosylation-deficient  or  glycosylation-
modified expression systems, or by enzymatic degradation of the glycosyl residues 
after purification from a conventional mammalian expression system.
With the aim to increase cytotoxicity and thus reduce the  IC50,  different strategies 
could be pursued. Apart from the internalisation into endosomes, which could be 
enhanced by  receptor  crosslinking  through the  use  of  bi-  or  multivalent  binding 
domains  which also  impede recycling of  receptor-ligand complexes  (Raghavan & 
Bjorkman, 1996), a known bottleneck in the application of all immunotoxins is the 
translocation  from  the  endosomes  to  the  cytosol.  The  co-administration  of 
endosomolytic  agents  can help  in  that  process.  Dalken  et  al.  (2006)  worked with 
Granzyme B immunotoxins targeting EGFR and ErbB2,  respectively,  and showed 
that Granzyme B-induced cell death was achieved within 14 h if the endosomolytic 
agent chloroquine was coadministered,  whereas  in the absence of chloroquine no 
cytotoxicity  of  the immunotoxins  was observed  at  all.  Furthermore,  Heisler  et  al. 
(2005) could  successfully  enhance  the  cytotoxicity  of  of  a  saporin-3-based 
immunotoxin by pre-incubation with a triterpenoid saponin. During this thesis, both 
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chloroquine and the triterpenoid saponin were tested. However, at least with U937 
and HL60 cells cell death occurred in the presence of these reagents alone, even at 
concentrations  significantly  lower  than  the  ones  applied  in  literature  (data  not 
shown).
Therefore  another  strategy,  the  incorporation  of  adapter  sequences  mediating 
endosomal release, moved into the focus of interest and is discussed in chapter  4.7. 
Furthermore, with this strategy the necessity of enterokinase cleavage (4.5) might be 
circumvented, which saves downstream processing work and might result in more 
active protein and hence better and better reproducible IC50 values.
Apart  from  protein-based  apoptosis-inducing  therapeutics  as  developed  in  this 
thesis,  nucleic  acid-based approaches  might represent  interesting alternatives,  not 
only in terms of reduced immunogenicity. In addition to the cytosolic expression of 
Granzyme B in target cells carried out in vitro in this thesis (3.1), a similar approach 
has also proven to be useful  in the fight of  ovarian carcinoma xenografts  in  vivo 
(Caldas et al.,  2006). In the genetic immunotoxin approaches as applied by Zhang 
et al., either a plasmid encoding a Gb-based immunotoxin was injected into muscle 
cells neighbouring tumour tissue, or plasmid-expressing Jurkat cells were injected 
intravenously, and both led to tumour regression and prolonged animal survival in a 
nude mouse xenograft tumour model (Zhang et al., 2003; Wang et al., 2007; Zhang et  
al., 2008). Using a protein-based binding domain coupled to DNA encoding a toxin 
(for which the term 'genetic immunotoxin' was coined originally), specific targeting 
of cells  would be possible as well  without the need for producing secretory cells 
(Chen et al., 1995). Another possibility for replacement of the toxin would be the use 
of an siRNA mediating knockdown of a house-keeping gene directly involved in cell 
survival  (Song et  al.,  2005;  Wullner et  al.,  2008).  The latter  approach is  especially 
attractive as issues of sensitivity towards a certain toxin are not given. Finally, the 
protein-based binding moiety could be replaced by an RNA aptamer (Wullner et al., 
2008).
4.6.2.2 Detection of apoptosis
The staining of phosphatidylserine exposure to the outside of the cell membrane by 
Annexin A5 coupled to eGFP confirmed the results of the cytotoxicity assays: Gb-
H22(scFv)  specifically  triggered  apoptosis  in  CD64+ AML  cells  and  U937  cells, 
whereas CD64- AML cells and Raji cells were unaffected (3.4.4.1, 3.4.4.3).
With primary cells of healthy donors, it was not possible to carry out Annexin A5 
assays  as  explained  in  chapter  3.4.4.2.  As  an  alternative,  cells  were  stained  with 
αCD64-FITC. In cells treated with PBS, the putative monocyte population was clearly 
seen as CD64+ in the FL-1/FL-3 plot, whereas no CD64+ cells were detectable after 
exposure to Gb-H22(scFv). However, as the monocyte population could still be seen 
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in the FSC/SSC plot,  the result  could be an artefact  due to masking of  the CD64 
antigen by the H22(scFv) portion of the immunotoxin, but as it is known that αCD64-
FITC (clone 10.1) and H22(scFv) recognize different epitopes of CD64 (Wallace et al., 
1997;  Harrison  &  Allen,  1998),  this  possibility  could  be  ruled  out,  at  least  if 
Granzyme B does not account for sterical hindrance in the binding of αCD64-FITC. 
Another possible explanation would be that after 24 h all CD64 receptors with Gb-
H22(scFv)  bound  are  already  internalised,  CD64  expression  is  completely 
downregulated,  and Granzyme B has not killed the cells  yet.  However,  the issue 
remains speculative.
In order to obtain new CD64+ cell lines for further apoptosis and cytotoxicity assays, 
it was tried to establish different batches of primary AML cells in long-term culture, 
among them also  cryo-conserved AML cells  used by Tur  et  al. in  2003.  For that, 
serum  concentrations  from  0-20%  (v/v)  FCS,  different  media  such  as  RPMI1640, 
AIM-V,  IMDM,  DMEM  supplemented  with  F12  nutrient  mixture  (all  from 
Invitrogen),  in part supplemented with U937-conditioned RPMI complex medium 
were tested.  Although, after an initial 90% loss in cell  number,  it  was possible to 
maintain the 2003 cells for several months either in AIM-V medium, RPMI medium 
with 5% (v/v) FCS or a 1:1 mixture of AIM-V medium and U937-conditioned RPMI 
medium with 10% (v/v) FCS (i.e. remainders of 5% (v/v) FCS in total), cell numbers 
did not change for a longer phase, but finally declined. Hence, it might be speculated 
that culture conditions for these cells were still suboptimal and/or that cells were in a 
quiescent state.
The detection of active caspase-3 in Gb-H22(scFv)-treated U937 and primary AML 
cells  by  antibody-based  approaches  (3.4.5.1,  3.4.5.2)  and  the  detection  of 
mitochondrial  depolarisation in  Gb-H22(scFv)-treated U937 cells  by  staining with 
JC-1 (3.4.6) confirmed the apoptosis-inducing potential of Gb-H22(scFv). 
However, the JC-1 dye is always present in both the green- and the red-fluorescing 
conformation, and only the ratio between both dye populations within cells changes. 
Hence a single-stain compensation, as it  is  usually done before carrying out two-
colour FACS analyses, is not possible. Although compensation for FITC and PE was 
recommended  to  give  a  good  approximation,  compensation  remains  highly 
subjective  depending  on  the  researcher.  Furthermore,  the  order  and  number  of 
washing steps in the cell washer were observed to cause slight variations in the result 
(data not shown). Therefore, results obtained by JC-1 staining should be treated with 
caution in general.
4.7 Adapter variants of Gb-H22(scFv)
In its natural function, translocation of Granzyme B into the cytosol of the target cell 
is  mediated  by  perforin  (Metkar et  al.,  2002;  Kurschus et  al.,  2008).  Thus,  a 
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translocation  domain  as  known  for  e.g.  Pseudomonas  Exotoxin  A  (ETA)  is  not 
necessary or at least is not described in the literature. Although efficacious Gb-based 
immunotoxins have been described (Liu et al., 2003a; Liu et al., 2003b; Kurschus et al., 
2004; Zhao et al., 2004c; Dalken et al., 2006) and hence translocation takes place also 
without perforin, the additional incorporation of a translocation domain holds great 
promise. For Gb-based immunotoxins, this approach has been realised by a Chinese 
group  that  evaluated  different  portions  of  the  ETA  translocation  domain  and 
observed significant  improvements  of  cytotoxicity (Zhang et  al.,  2003;  Zhao et  al., 
2004a; Wang et al., 2007; Zhang et al., 2008).
The group of  Hendrik Fuchs in Berlin  evaluated a molecular  adapter  which was 
located between the binding and the toxic moiety and consisted of three components: 
the  endosome cleavable peptide (ECP), the  membrane transfer peptide (MTP), and 
the cytosolically cleavable peptide (CCP). Upon internalisation into endosomes, the 
ECP is  cleaved by furine.  Through this,  the MTP becomes exposed and mediates 
translocation. In the cytosol, the CCP, which is located between the MTP and the 
toxin, is cleaved to release the toxin. Using this adapter, the cytotoxicity of a saporin-
EGF  immunotoxin  was  significantly  enhanced  (Heisler et  al.,  2003).  In  our  own 
group, this adapter,  and a variant containing MTP and CCP only, were shown to 
improve the IC50 of the immunotoxin H22(scFv)-Ang (Hetzel et al., 2008). However, 
from these results it could not be concluded whether the increased toxicity is due to 
the MTP which enhances endosomal release of the protein, or due to the CCP which 
generates a free N-terminus of the toxin, which has been described as crucial for the 
function of angiogenin (Harper et al., 1988). In order to clarify this, minimal adapter 
variants of Gb-H22(scFv) featuring MTP or CCP alone,  or a combination of both, 
were cloned and expressed in HEK293T cells during this thesis (3.5). The produced 
proteins specifically bound to CD64+ MonoMac1 cells, whereas L540cy cells showed 
no binding. However, two problems prevented further characterisation in terms of 
cytotoxicity. First, the transfection protocol as stated in chapter 2.2.4.2 did not work 
well  any more,  as  most of  the HEK293T cells  detached and later  on died.  As an 
alternative,  cells  were  transfected  either  by  the  same  protocol  but  using  serum-
containing medium or by nucleofection (2.2.4.4) using 1 µg DNA per 1.2x106 cells 
and  nucleofector  programme  Q-001.  Although  both  protocols  yielded  viable, 
proliferating  cells,  the  green  fluorescence  of  cells  disappeared  almost  completely 
within one week, and even more crucial, cells were not able to resist zeocin selection 
pressure  as  soon as they were  detached for  passaging.  As this  phenomenon had 
never occurred before, it could have been speculated that the adapter components 
themselves have a negative impact on the producing HEK293T cells, e.g. by MTP-
mediated translocation to the cytosol. However, EGb-H22(scFv)- and H22(scFv)-Gb-
transfected cells showed the same problem. Another possible explanation would be 
that HEK293T cells modified their expression of adhesion molecules  during time, 
and  Granzyme  B  now  induced  cleavage  of  these  proteins  and  hence  triggered 
anoikis. However, with HUVECs and MCF-7 cells it has been demonstrated that Gb-
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mediated loss of adherence was clearly dependent on a free N-terminus of Gb, as the 
Gb zymogen with the N-terminal propeptide attached failed to detach cells (Buzza 
et al., 2005). This is in accordance with the results of the protease assay obtained in 
this thesis, with Gb-H22(scFv) but not EGb-H22(scFv) being able to cleave a synthetic 
substrate (3.4.1), albeit this substrate mimics procaspase-3 cleavage only.
As  other  workers  also  had  difficulties  to  carry  out  successful  transfections  with 
HEK293T cells  during that  time,  CHO cells  were employed for expression of  the 
proteins  (all  work with adapter  constructs  in CHO cells  done by Grit  Hehmann, 
PharMedArtis). These cells proliferated quickly after transfection and produced the 
target  proteins  at  a  low  but  constant  level.  However,  after  batch  purification 
cytotoxicity assays were not successful due to the crucial second problem: Over time, 
U937  cells  had  lost  their  sensitivity  towards  Gb-H22(scFv)  (cf.  4.8).  Although 
stimulation was carried out as usual, and a single batch of cells was never held in 
culture longer than 12 weeks, only weak or even no toxic effects were observed, and 
an IC50 was  not  reached.  An upregulation  of  CD64 expression also  could  not  be 
observed  any  more.  These  problems  could  not  be  solved  by  working  with  new 
master batches of cells or other batches of IFN-γ.  With H22(scFv)-ETA' (Tur et al., 
2003), the same effects were observed, and as the toxicity assays were carried out by 
different  workers,  a  person-related  failure  could  be  excluded.  FACS  analyses 
revealed  that  CD64 expression  was  extremely  low despite  stimulation  (Reinhard 
Rosinke,  personal  communication).  As  none  of  the  culture  parameters,  whether 
media or media supplements or physical parameters, had been changed in the group, 
a  mycoplasma  contamination  could  have  been  an  explanation  for  the  observed 
effects.  However,  mycoplasma  tests  were  carried  out  regularly,  and  the  master 
culture,  from which  batches  were  handed  out  to  the  workers,  was  mycoplasma-
negative (Reinhard Rosinke, personal communication).
Taken together, all this stresses the fact that it is crucial to have a highly sensitive and 
reliable model system. Hence the comparative evaluation of the cytotoxic potential of 
the minimal adapter proteins has to be postponed until a sensitive model system has 
been established again, and this clearly falls beyond the time frame of this thesis.
4.8 Stimulation of myeloid cells
The  stimulation  of  myeloid  cells  turned  out  to  be  a  major  obstacle.  As  the 
reproducibility of the cytotoxicity of Gb-H22(scFv) towards U937 cells initially was 
not satisfying, and stimulation is crucial to the susceptibility of cells towards anti-
CD64-based  immunotoxins,  different  conditions  for  stimulation  were  evaluated 
(3.6.1-3.6.3). The major findings for U937 cells from these studies were that an IFN-γ 
concentration of 500 U/ml applied directly after passaging of cells  to a density of 
1x105 cells/ml was sufficient to obtain maximum and most enduring expression of 
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CD64, which reached its peak at about 48 h after addition of  IFN-γ. In contrast to 
that,  maximum  cytotoxic  efficacy  of  Gb-H22(scFv)  was  seen  when  cells  were 
recruited for the toxicity assay 6-24 h after addition of IFN-γ. This clearly indicates 
that  not  the  number  of  CD64  receptor  molecules  on  the  surface  but  rather  an 
endogenous state of activation is the crucial factor for potent cytotoxicity. This was 
also reported by Thepen et al., who worked with anti-CD64-Ricin A immunotoxins to 
resolve cutaneous inflammation (Thepen et al., 2000). Further support for this finding 
comes from the fact that, compared to U937 cells, HL60 and MonoMac1 cells show a 
higher degree of CD64 expression but a lower sensitivity towards Gb-H22(scFv).
Nevertheless it was tried to determine the number of CD64 receptors on cell surfaces 
using the QuantiBrite  system (BD Biosciences),  however,  FACS analyses revealed 
that saturation of binding of labelled anti-CD64 antibody to CD64 was not reached 
even when the antibody was used undiluted (data not shown).
As  cytotoxicity  of  different  H22-based  immunotoxins  is  mediated  by  different 
mechanisms, the sensitivity-rendering effect of stimulation is more likely to lie in the 
internalisation  and  trafficking  process  of  the  CD64-bound  immunotoxin  (which 
might be regulated differently in different cell lines) than in the accessibility of target 
proteins  or  downregulation  of  inhibitor  proteins.  This  is  in  accordance  with  the 
results  of  the  cytosolic  expression  assays  presented  in  chapter  3.1.2,  in  which 
cytotoxicity of Granzyme B was observed although cells had not been IFN-γ-treated.
Although the obtained results give a first-line indication of the issue of stimulation-
dependent sensitivity of cells, variations in the response of U937 cells over time and 
also markedly depending on the lot of IFN-γ used occurred (data not shown). The 
lot-dependent  variation suggests  that  impurities  might  play a  role.  Although the 
IFN-γ used is sold as cell culture-tested and endotoxin-depleted, LPS was reported to 
be a common contaminant in recombinant IFN-γ (Mosser, 2003). Assuming an LPS 
contamination,  intriguing  explanations  for  the  variations  in  the  lot-dependent 
response to IFN-γ could be speculated upon. Whereas it is known for macrophages 
that  a  combination of  LPS  and IFN-γ triggers  the classical  activation pathway,  a 
combination of LPS and ligation of Fc γ receptors (of which CD64 is the high affinity 
receptor)  leads  to  type  II  activation,  and  this  is  independent  of  the  presence  or 
absence  of  IFN-γ  (Gerber  &  Mosser,  2001;  Mosser,  2003).  Classically  activated 
macrophages are characterised by, amongst other things, upregulation of IL-12, an 
enhanced  degradation  of  intracellular  microorganisms  and  enhanced  antigen 
presentation. Type II-activated macrophages are characterised by downregulation of 
IL-12 and upregulation of IL-10 (Mosser, 2003), which is a pleiotropic cytokine with 
mainly  anti-inflammatory  functions,  e.g.  reduction  of  antigen  presentation  in 
monocytes (Grutz, 2005). With these scenarios in mind, two different ways to explain 
the lot-dependent variations in stimulation and hence cytotoxicity of Gb-H22(scFv) 
can be  imagined.  On one hand,  LPS  could enhance  the endosomal  and cytosolic 
degradation machinery,  leading to  rapid loss  of  functional  Gb-H22(scFv).  On the 
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other  hand,  as  H22(scFv)  is  able  to  trigger  CD64 functions (otherwise  H22-based 
immunotoxins would not be internalised), it could be speculated that, in the presence 
of  contaminating  LPS,  Gb-H22(scFv)  changes  the  activation  state  of  U937  cells 
towards a type II response. It cannot be excluded that this signaling pathway is also 
inducible in U937 cells and, although IL-10 is known to enhance expression of CD64 
in monocytes (te Velde et al., 1992), either impedes translocation of Gb-H22(scFv) to 
the cytosol or triggers upregulation of Granzyme B inhibitors like PI-9 (cf.  4.1). As 
such a signaling process is likely to be threshold-dependent, and the threshold itself 
might depend on the physiological state of the cell, varying outcomes of cytotoxicity 
assays are imaginable. This would be at least one possibility of explanation which 
could also explain why,  even with a specific lot of IFN-γ, the stimulation was not 
always reproducible.
In many cases stimulated cells underwent morphological changes or even cell death. 
A  concentration-dependent  inhibitory  effect  of  IFN-γ  was  also  demonstrated  by 
Zhong  et  al. (2001),  who  showed  that,  upon  incubation  with  increasing 
concentrations of IFN-γ, the viability of U937 cells decreased markedly stronger than 
that of HL60 or NB4 cells (a human AML M3 cell line). Differences between different 
cell lines in the response to IFN-γ were are also observed during this thesis both 
concerning CD64 expression (cf.  Fig. 3.40) and cell  viability and morphology (Fig.
3.43), both dependent on the particular lot of IFN-γ used: Whereas - in this assay - 
U937  cells  underwent  apoptosis  upon  exposure  to  500 U/ml  IFN-γ,  HL60  cells 
showed  only  slightly  more  apoptotic  cells  but  a  slightly  bigger  cell  size  in 
comparison to unstimulated cells, and L540 cells seemed to be organised in more 
clumps.  Only Raji  cells  showed no macroscopic  differences  to  their  unstimulated 
counterparts. In this phase of the thesis, the dilemma of stimulation vs. cell viability 
could not  be  balanced in  terms of  proper  cytotoxicity  assays  with  Gb-H22(scFv), 
whereas H22(scFv)-ETA' and H22(scFv)-Ang, which are stronger toxins and require 
only a lower state of target cell activation to be effective, could be applied in toxicity 
assays, albeit with markedly lower IC50 values than usual. Finally, towards the end of 
the thesis  and as  already mentioned in  chapter  4.7,  it  was  no longer  possible  to 
stimulate U937 cells with IFN-γ at all. Although the cell viability was not notably 
decreased, no upregulation of CD64 and also no more sensitivity towards Gb-based 
immunotoxins  and  only  weak  sensitivity  towards  H22(scFv)-ETA'  (Reinhard 
Rosinke, personal communication) was observed, this despite novel lots of IFN-γ, 
novel batches of cells, and different batches of protein had been used in the hands of 
different workers. The basal CD64 expression was only marginal as well.
Changes in sensitivity over time were also observed with H22(scFv)-ETA' on HL60 
cells.  Whereas  in  the  first  publication  from  2003,  H22(scFv)-ETA'  was  cytotoxic 
towards HL60 and U937 cells (Tur et al., 2003), at least since 2005 H22(scFv)-ETA' 
was no more able to induce apoptosis in HL60 cells  (Tanja Ribbert  and Reinhard 
Rosinke, personal communication).
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To overcome the problems associated with IFN-γ,  stimulation of  U937 cells  with 
1 µg/ml LPS (Sigma, L2755) instead of IFN-γ was also tested. However, compared to 
1000 U/ml IFN-γ, a weaker upregulation of CD64 and a slightly weaker cytotoxicity 
of Gb-H22(scFv) was observed. In both cases, a reduction of the viability to ~50% was 
only seen when the toxicity assay was started 2 h after addition of the stimulating 
agent,  whereas  after  24  h  viability  was  only  decreased  to  ~75% (IFN-γ)  or  even 
unchanged  (100%,  LPS)  (data  not  shown).  This  again  supported  the  fact  that 
expression  level  of  CD64  (which  is  still  unchanged  2  h  after  addition  of  the 
stimulating agent) and sensitivity towards Gb-H22(scFv) do not correlate in a direct 
manner.
Fig.  3.43: Occasionally observed morphological changes upon stimulation of cells with  IFN-γ at a 
concentration of 500 U/ml.
As further alternatives to IFN-γ, PMA, IL-10 and GM-CSF could be tested in a similar 
fashion as in this thesis. In order to test the classical vs. type II activation hypothesis, 
stimulation could be carried out with different combinations of concentrations of LPS 
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and IFN-γ in the presence or absence of Gb-H22(scFv) or full size IgG, and transcript 
levels of IL-10 and IL-12 could be analysed.
Taken together, with all the parameters and variations thereof especially occurring 
between different types of cells given, the stimulation of primary cells, i.e. cells of 
different patients, cannot be seen other than following a trial-and-error principle. In 
the long term, the search for a model cell line not requiring stimulation is highly 
preferable. As long as such a system has not been established, ideally in the future 
every new obtained lot of IFN-γ should be internally characterised in terms of its 
activating potential towards the target cells and, if necessary, checked for presence of 
LPS before use.
Furthermore, detection of stimulation could routinely be focussed on other markers 
in addition to CD64, e.g. MHC class II, which is upregulated in response to IFN-γ, at 
least in mice even more than 100-fold (Ehrt et al., 2001).
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5 Outlook
On the basis of the positive results of the in vitro and ex vivo characterisation of Gb-
H22(scFv) obtained during this thesis, further ex vivo and also in vivo experiments are 
planned to be conducted, both in an inflammation and a tumour model. 
Using transgenic  mice expressing human CD64 (hCD64),  cutaneous inflammation 
can be induced by SDS treatment of the skin. The macrophages, which in general 
play a central role in initiation and maintenance of inflammatory reactions, hopefully 
can  be  eliminated  by  intracutaneous  administration  of  Gb-H22(scFv).  Previous 
experiments using H22(scFv)-ETA' in this model have been promising.
Furthermore, lung lavage fluids of human patients suffering from chronic lesions in 
the lung, e.g. due to asthma or chronic obstructive pulmonary disease (COPD), could 
be treated with Gb-H22(scFv) and/or H22(scFv)-ETA' with the aim to deplete  the 
dysregulated, highly CD64-positive alveolar macrophages.
Finally,  evaluation  of  Gb-H22(scFv)  in  a  disseminated  tumour  model  awaits  its 
realisation as soon as a sensitive model cell line has been established again.
With the aim to enhance internalisation and cytotoxic potential and concomitantly 
minimise  unspecific  interactions,  further  optimisations  of  Gb-H22(scFv)  might  be 
carried out. Apart from the cytotoxic evaluation of the minimal adapter constructs 
produced  during  this  thesis,  multivalent  binding  units,  deleted  heparan  sulfate-
binding structures of Granzyme B, modified or deleted glycosylation either through 
a change in the expression system or through deglycosylation, might be valuable to 
reach  this  goal.  In  order  to  corroborate  the  obtained  results,  a  control  protein 
mutated in the active center of Granzyme B from serine to another amino acid might 
come to use.
Concerning the production of the immunotoxin, an optimisation in terms of yield 
would be desirable. This could be accomplished by an optimisation of the producing 
cells, the vector system, and the culture process. In microcarrier-based fermentation, 
a fine-tuning of the culture parameters  is  certainly promising. A simplification in 
downstream processing would be reached if protein variants without requirement 
for enterokinase cleavage would be used.
Regarding its final application in the clinic, Gb-H22(scFv) could be useful for both 
induction  and  postremission  therapy.  When  used  in  combination  therapy  with 
conventional  chemotherapeutics,  it  might  be  possible  to  reduce  the  dose  of  the 
chemotherapeutic or its frequency of administration, thus limiting side effects and 
promoting long-term remission.
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6 Summary
Acute Myeloid Leukaemia (AML) is a heterogeneous group of malignancies of the 
haematopoietic system. Its subtypes M4 and M5 are characterised by an enhanced 
expression of CD64 (FcγRI), the high affinity receptor for IgG. Whereas conventional 
therapies  such as chemo- and radiotherapy unspecifically  affect  cells  with a high 
proliferation rate,  and thus  elicit  undesired side effects  due to  the elimination of 
healthy  cells,  immunotoxins  can  specifically  bind  and  kill  malignant  cells.  The 
utilisation  of  human  protein  components,  e.g.  the  human  serine  protease 
Granzyme B as a toxin, contributes to the absence of side effects and hence safety of 
an immunotoxin.
In this thesis, the first humanised Granzyme B-based immunotoxin directed against 
CD64-positive cells was developed, evaluated and modified. Prior to these studies, 
the sensitivity of the AML-related CD64-positive cell line U937 towards Granzyme B 
was  tested  by  transfection  with  a  plasmid  allowing  cytosolic  expression  of 
Granzyme B. As the target cells were successfully killed by Granzyme B, and thus the 
effectivity of the transfection-based test system for toxin sensitivity was proven, the 
Granzyme B-based CD64-targeting immunotoxin (E)Gb-H22(scFv) was constructed. 
Different  expression  systems  (E. coli,  HEK293T  cells,  CHO  cells,  FlpIn  293  cells, 
apoplast/chloroplasts/ER  of  N.  tabacum) were  evaluated,  among  which  HEK293T 
cells  were  finally  used  for  production.  Different  cell  culture  formats  including 
microcarrier-based  fermentation  were  established.  Downstream  processing  was 
intensely  optimised  in  terms  of  handling  convenience,  required  time  and  in 
particular purity and integrity of the end product.
In  order  to  clarify  the  role  of  a  free  NH2 terminus  for  a  Granzyme  B-based 
immunotoxin,  enterokinase-cleaved  Gb-H22(scFv)  was  compared  with  uncleaved 
EGb-H22(scFv) in a proteolysis assay with a synthetic Granzyme B substrate. Only 
the activated Gb-H22(scFv) showed the same proteolytic activity as free Granzyme B, 
whereas  the  uncleaved  EGb-H22(scFv)  failed  to  cleave  the  synthetic  substrate. 
Therefore,  further  experiments  were  focused  on  Gb-H22(scFv),  although  EGb-
H22(scFv) was also cytotoxic albeit with about 10-fold lower IC50 values compared to 
Gb-H22(scFv).
For all  cell-based analyses,  the stimulation in particular  of  U937 target  cells  with 
IFN-γ  was optimised with regard to concentration, physiological state of the cells 
(time point for stimulation after passaging), and time frame for cytotoxicity assays.
Concerning its biological activity, Gb-H22(scFv) was shown to bind to CD64+ U937 
cells, but not CD64- Raji cells, and exhibited potent specific cytotoxicity towards U937 
cells  with  IC50 values  in  the  range  of  1.7  to  17  nM.  This  is  in  accordance  with 
published IC50 values of other Granzyme B-based immunotoxins. The induction of 
apoptosis  was  successfully  detected  via  phosphatidylserine  exposure,  caspase-3 
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activation or mitochondrial depolarisation in U937 cells, primary peripheral blood 
mononuclear cells of a healthy donor, and primary acute myeloid leukaemia blasts.
Based on these  in vitro studies, optimised structural variants of Gb-H22(scFv) were 
constructed, expressed and characterised in terms of binding activity.
In conclusion, the present work laid the basis for subsequent in vivo experiments in 
the characterisation of Gb-H22(scFv) and its derivatives.
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8 Appendix
8.1 List of abbreviations
α anti (used in antibody abbreviations)
A. tumefaciens Agrobacterium tumefaciens
aa amino acids
Ac acetyl group
AML acute myeloid leukaemia
Amp ampicillin
Ang angiogenin
AP alkaline phosphatase
AP-1 activator protein 1 (transcription factor)
ATCC American Type Culture Collection
BCIP 5-bromo-4-chloro-3-indolyl-phosphate, p-toluidine salt
BP band pass
bp base pairs
BSA bovine serum albumin
Carb carbenicillin
CCP cytosolically cleavable peptide
CDR complementarity-determining region
CHAPS 3-[(3-cholamidopropyl)dimethyl ammonio]-1-propane 
sulphonate
CHO chinese hamster ovary (mammalian cell line)
CIP calf intestinal alkaline phosphatase
Con A concanavalin A
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
DNA-PK DNA-dependent protein kinase
dNTP deoxynucleoside triphosphate
dsFv disulfide-stabilised variable fragment
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DSMZ German Collection for Microorganisms and Cell Cultures
DT diphtheria toxin
DTT dithiothreitol
E. coli Escherichia coli
ECP endosomally cleavable peptide
ECS enterokinase cleavage site
EDTA ethylene diamine tetra-acetic acid
EGF epidermal growth factor
eGFP enhanced green fluorescent protein
EGFR epidermal growth factor receptor
ER endoplasmatic reticulum
ERAD ER-associated protein degradation
ETA Pseudomonas aeruginosa exotoxin A
EtOH ethanol
FACS fluorescence activated cell sorting
FCS fetal calf serum
FITC fluorescein isothiocyanate 
FL fluorescence channel
FPLC fast protein liquid chromatography
FRT Flp recombination target
FSC forward scatter
Fv variable fragment
GαM goat anti mouse
GαR goat anti rabbit
Gb Granzyme B
Gly glycine
GM-CSF granulocyte macrophage colony-stimulating factor
GMFI geometric mean fluorescence intensity
HEK human embryonic kidney (mammalian cell line)
HEPES N-2-hydroxyethyl piperazine-N'-2-ethane sulphonic acid
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His histidine/6x histidine tag
HL Hodgkin lymphoma
HPSF high purity salt free
HUVEC human umbilical vein endothelial cells 
ICAD inhibitor of caspase-activated DNAse
IETD oligopeptide  composed  of  isoleucine-glutamic  acid-
threonine-aspartic acid
IFN-γ interferone gamma
Ig immunoglobulin
IL interleukin
IMAC immobilised metal-ion affinity chromatography
IPTG isopropyl-beta-D-thiogalactopyranoside
IRES internal ribosome entry site
IVS synthetic intron
Kan kanamycin
kb kilobases
kDa kilo-Dalton
LB Luria-Bertani
LDL low density lipoprotein
LPS lipopolysaccharide
LRP LDL receptor related protein
MALDI matrix-assisted laser desorption/ionisation 
MOPS 3-(N-morpholino) propane sulphonic acid 
mRNA messenger ribonucleic acid
MS Murashige and Skoog
MTP membrane transfer peptide
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt
MTX methotrexate
MW molecular weight
MWCO molecular weight cut-off
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N. tabacum Nicotiana tabacum
N/A not applicable
NBT nitro-blue tetrazolium chloride
NFκB nuclear factor 'kappa light chain enhancer' of activated B 
cells
Ni-NTA nickel nitrilotriacetic acid
NK natural killer
NuMA nuclear mitotic apparatus protein
OD optical density
PAGE polyacrylamid gel electrophoresis 
PARP poly(ADP-ribose) polymerase
PBS phosphate buffered saline
PCD programmed cell death
PCR polymerase chain reaction
PDTC pyrrolidin dithiocarbamate (NFκB inhibitor)
PE phycoerythrin
PEG polyethylene glycol
PES polyethersulfone
pH pondus hydrogenii
PHA phytohaemagglutinin
PI propidium iodide
pI isoelectric point
PMA phorbol-12-myristate-13-acetate, same as TPA
pNA para-nitroanilin
PTD protein transduction domain
PTGS post-transcriptional gene silencing
rfp red fluorescent protein (DsRed)
Rif rifampicin
RNA ribonucleic acid
rpm rotations per minute
RT room temperature
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RuBisCO ribulose-1,5-bisphosphate carboxylase/oxygenase
scFv single chain variable fragment
SD standard deviation
SDS sodium dodecyl sulfate
SEKDEL oligopeptide  composed  of  serine-glutamic  acid-leucine-
aspartic acid-glutamic acid-lysine (ER retention signal)
Ser serine
siRNA small interfering RNA
SSC sideward scatter
T-DNA transferred DNA (by A. tumefaciens)
Taq Thermus aquaticus
TGF transforming growth factor
TGS transcriptional gene silencing
TGS Tris glycine SDS buffer
TNF-α tumour necrosis factor alpha
TPA 12-O-tetradecanoylphorbol-13-acetate, same as PMA
UTR untranslated region
UV ultraviolet
v/v volume per volume
VEGF vascular endothelial growth factor
w/v weight per volume
XIAP X-linked inhibitor of apoptosis protein
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8.2 Sequences of synthetic genes
All synthetic genes were delivered by GenScript (Piscataway, NJ, USA) in a pUC57 
vector backbone.  Prior to manufacture, the gene sequences coding for protein had 
been codon-optimised by GenScript relating to the respective expression host. The 
5' UTR in the plant expression vectors remained in the original sequence.
8.2.1 Sequences destined for expression in N. tabacum
8.2.1.1 Synthetic DNA sequence for cloning of pTRAkc-GbH22opt-AH and pTRAkc-
GbH22opt-ERH
Base numbers refer to the respective pTRA backbones. Cloning was carried out via 
EcoRI preceding the 5' UTR and NotI preceding a 6x histidine tag. In case of the -ERH 
vector,  the 6x histidine tag is  followed by a SEKDEL tag mediating ER retention 
(Munro & Pelham, 1987). CHS: 5' UTR from chalcone synthase (Voss et al.,  1995), 
LPH: murine signal peptide of mAb24 (Voss et al., 1995).
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8.2.1.2 Synthetic DNA sequence for cloning of pTRAkc-GbH22opt-CTP
Base numbers refer to the pTRA-GbH22opt-AH backbone. Cloning was carried out 
via EcoRI and ApaI. CHS: 5' UTR from chalcone synthase (Voss et al., 1995), rbcs-CTP: 
chloroplast transit peptide from small subunit of RuBisCO from Solanum tuberosum 
(GenBank: X69759).
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8.2.2 Sequences destined for expression in HEK293T cells
8.2.2.1 Synthetic  DNA  sequence  for  cloning  of  pMS-LH22MTPGbII-OPT,  pMS-
LH22MTPMTPGbII-OPT, pMS-LH22MTPCCPGbII-OPT
As  different  parts  of  the  synthetic  sequence  were  employed  for  cloning,  base 
numbers do not refer to the target vector but to the synthetic sequence itself. Cloning 
was carried out via XbaI to yield the constructs pMS-LH22MTPGbII-OPT and pMS-
LH22MTPMTPGbII-OPT, or via  NotI and  BsmBI to yield pMS-LH22MTPCCPGbII-
OPT. MTP: membran transfer peptide, CCP: cytosolically cleavable peptide (Heisler 
et al., 2003).
Appendix 139
8.2.2.2 Synthetic  DNA  sequence  for  cloning  of  pMS-LH22CCPGbII-OPT,  pMS-
LCCPGbH22IV-OPT, pMS-LMTPCCPGbH22IV-OPT 
Cloning  was  carried  out  via  XbaI  and  BsmBI  to  yield  the  constructs  pMS-
LCCPGbH22IV-OPT  and  pMS-LH22CCPGbII-OPT.  For  the  cloning  of  pMS-
LMTPCCPGbH22IV, the MTP sequence depicted in  8.2.2.1 was inserted into pMS-
LCCPGbH22IV via XbaI. CCP: cytosolically cleavable peptide (Heisler et al., 2003).
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